










Analysis of 14-3-3σ methylation and 
associated changes in gene expression and  














Thesis submitted for degree of Doctor  
in Philosophy 
 









I declare that this thesis was composed entirely by myself and that the research 
presented is my own unless otherwise stated. 
 
 














The aims of the work presented in this thesis were: to investigate the role of 
methylation of 14-3-3σ (a key regulator of p53-mediated G2/M arrest and of 
translational control during mitosis) in colorectal cancer using colorectal cancer cell 
lines and fresh colorectal tumours; to investigate any relationship between 14-3-3σ 
methylation status and gene expression; to determine whether aberrant methylation is 
associated with cell cycle defects and other factors known to contribute to colorectal 
carcinogenesis. 
 
PCR bisulphite sequencing showed that 78% (7/9) of colorectal cancer cell lines 
were unmethylated in the 14-3-3σ upstream promoter region (UPR). The 
unmethylated cell lines expressed high levels of 14-3-3σ, while methylated cell lines 
expressed negligible levels of 14-3-3σ protein or mRNA. Methylated colorectal 
cancer cell lines were treated with 5-aza-2’-deoxycytidine and demethylation was 
confirmed by MSP analysis. However, demethylation did not induce 14-3-3σ re-
expression in the methylated cell lines, suggesting that CpG methylation may not be 
the only mechanism of transcriptional control. In contrast to colorectal cancer cell 
lines, 90% (89/99) of fresh colorectal tumours were methylated at CpG dinucleotides 
within the 14-3-3σ UPR. Bisulphite sequencing analysis of individual clones from 
14-3-3σ methylated tumours (n =3) demonstrated that the clones displayed 
methylated CpG levels of approximately 41%. In agreement with previous PCR 
bisulphite sequencing analysis, there were a low percentage of methylated CpG 
dinucleotides (~ 15%) in clones from the 14-3-3σ unmethylated tumours (n =3). 
Unmethylated tumours expressed significantly higher levels of 14-3-3σ in 
comparison to methylated tumours (p =0.03), indicating that 14-3-3σ methylation 
may be associated with expression. PCR bisulphite sequencing analysis of matched 
normal mucosa tissues indicated that the 14-3-3σ UPR was methylated in all 
samples. Preliminary studies therefore suggest that there is tumour-specific loss of 
14-3-3σ methylation in colorectal tumours within the 14-3-3σ UPR and CpG island. 
There were no apparent clinico-pathological correlations with 14-3-3σ methylation 
 
 iii 
status. Whilst 14-3-3σ methylation was associated with expression in fresh colorectal 
tumours, there was no significant difference in expression levels between 
unmethylated colorectal tumours and matched methylated normal tissue. Bisulphite 
sequencing analysis of individual clones from normal tissues (from patients free of 
cancer) revealed that the 14-3-3σ UPR and CpG island was methylated at the 
majority of CpG sites analysed in colonic tissue (422/495, ~85.2%) and 
approximately half (795/1557, 51.1%) of CpG sites in skin samples (n =3). 
Furthermore, higher levels of 14-3-3σ protein were observed in skin tissue samples 
compared to normal colonic tissue, suggesting that 14-3-3σ CpG island methylation 
may be associated with tissue-specific expression.    
 
Experiments to assess the relationship between 14-3-3σ methylation and general 
methylation defects, suggest that methylation differences in 14-3-3σ were not simply 
a consequence of more general methylation phenomena well described in colorectal 
cancer. Nearest Neighbor analysis showed no evidence of generalised 
hypomethylation. Furthermore, MethyLight analysis of the CpG Island Methylator 
Phenotype (CIMP) showed no relationship between 14-3-3σ methylation status and 
CIMP; since, 1/5 (20%) tumours methylated at 14-3-3σ UPR and 1/5 (20%) tumours 
unmethylated at 14-3-3σ  UPR were CIMP positive. 
 
In vitro functional assays showed that overexpression of 14-3-3σ in SW480 cells 
(14-3-3σ methylated) delayed the apoptotic response to UV-C, compared to control 
SW480 cells. This suggests that 14-3-3σ may protect colorectal cancer cells from 
apoptosis. MTT assays showed that overexpression of 14-3-3σ in SW480 cells 
resulted in a trend of increasing proliferation with a significant increase on day 4, 
compared to controls SW480 cells (p <0.01). Furthermore, FACS-sorted SW480 
cells overexpressing 14-3-3σ, showed a significant shift to S-phase from G1 
compared to control SW480 cells (p <0.01). Western blot analysis and 
immunohistochemistry revealed no relationship between p53 status and methylated 
14-3-3σ in fresh tumours, while there was no relationship between published p53 
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status for colorectal cancer cell lines and 14-3-3σ methylation status defined 
experimentally. 
 
I have presented data which shows that methylation status of 14-3-3σ varies between 
colorectal cancer tissue, colorectal cancer cell lines and normal colonic tissue. 
Overexpression of 14-3-3σ appears to contribute to colorectal cancer carcinogenesis, 
raising the hypothesis that 14-3-3σ expression and function may at least in part be 
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Cancer arises due to genetic alterations, which can be acquired somatically or 
inherited through the germline. Somatic mutations in critical genes such as in 
oncogenes or tumour suppressor genes can alter gene function and lead to a growth 
advantage in the host cell. Cancer development involves an additional accumulation 
of these somatic mutations. Within some tumours this can vary and it has been 
demonstrated that the actual rate of mutational accumulation is lower than was first 
expected (DePinho, 2000). Furthermore, it was hypothesised that the accumulation of 
somatic mutations in tissues accounts for the increased incidence of cancer with age, 
while, there has been little definitive evidence of an increase in mutation rate in 
ageing tissue (Bohr & Anson, 1995). This suggests that other molecular mechanisms 
are involved.  
 
One definition of epigenetics is that it is the study of heritable changes in gene 
expression without the requirement for associated changes in DNA sequence. More 
specifically, epigenetics is the study of chemical modifications of DNA or 
chromatin-associated proteins (mainly histones), which can lead to alterations in 
gene expression between different tissues and in diseased states. DNA methylation is 
the main modification of vertebrate DNA and occurs when a methyl group (CH3) is 
attached to the 5-carbon position of a cytosine base. DNA methylation only takes 
place when a guanine residue precedes the cytosine, therefore only the dinucleotide 
Cytosine/Guanine (CpG) is methylated. DNA methylation occurs on both strands and 
is stably transmitted during cell division, through the activity of DNA 
methyltransferase (DNMT) enzymes. In 1975, it was first proposed that DNA 
methylation regulates gene expression (Holliday & Pugh, 1975; Riggs, 1975). 
Subsequent research provided further evidence of a role for DNA methylation in 
transcriptional repression (Bird et al, 1985; Jones & Taylor, 1980) and the underlying 
 
 2 
mechanistic pathways that were involved (Jones et al, 1998; Nan et al, 1998). 
Aberrant methylation at the promoter region of tumour suppressor genes is 
associated with changes in gene expression and loss of function in human cancers 
(Herman et al, 1996b; Kane et al, 1997). This phenomenon was first identified by 
Feinberg and Vogelstein, reporting that a substantial proportion of CpG dinucleotides 
were differently methylated in normal tissues compared to cancer cells (Feinberg & 
Vogelstein, 1983a). Building on this, it was shown that cancer cells often exhibit 
global loss of methylation, mainly occurring at repeat sequences, and gains of 
methylation at normally methylation-free promoters (Paz et al, 2003). A number of 
tumour suppressor genes found to be hypermethylated at their respective promoter 
regions include: p16INK4A in colorectal cancer (Herman et al, 1995); the 
retinoblastoma 1 gene (Rb1) in retinoblastoma (Greger et al, 1989); and the von 
Hippel-Lindau gene (VHL) in renal cell cancers (Herman et al, 1994). There has been 
a recent surge in genome-wide methylation analysis in cancer and a number of 
different technologies have been developed to analyse DNA methylation patterns and 
screen for novel disease markers (epimarkers). Alterations in methylation patterns 
can be detected with a high degree of sensitivity and there is real prospect for its 
clinical use in prognostic and diagnostic applications. With greater understanding, 
there also lies the potential for therapeutic intervention to reverse aberrant DNA 
methylation, and this currently is the focus of intense research.   
 
 
1.2 DNA Methylation in normal cells 
1.2.1 DNA Methylation in physiological circumstances  
Methylation is an enzymatically catalysed chemical reaction, which adds a methyl 
group to selected sites on proteins, DNA and RNA. A DNMT enzyme is required to 
methylate the cytosine of the CpG dinucleotide to form 5-methylcytosine; and S-
Adenosyl-methionine (SAM) is used as a methyl donor (Figure 1.1). In mammalian 
cells, DNA methylation is the major modification of DNA. It has been proposed that 
the role of methylation is to control gene expression or act as a form of genomic 
protection by repressing the large number of the retro(transposon) families that are 
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present in vertebrate genomes (Bird, 1995). Transposable sequences are known to be 
heavily methylated and therefore this may contribute to active repression of 
transposition.  
 
DNA methylation has also been viewed as a primary mechanism for the control of 
gene transcription (Jones et al, 1998; Nan et al, 1998). When present at promoters 
and regulatory sequences, it is associated with gene repression (Bird & Wolffe, 
1999). DNA methylation may have evolved a role in reducing transcriptional noise 
through reducing background gene transcription that is unnecessary for the cell to 
function. From this perspective, DNA methylation could have enabled the increase in 
gene number and complexity that characterise vertebrates (Bird, 1995). Support for 
the idea that DNA methylation may be important in regulating gene expression 
during development comes from experiments in which the maintenance DNMT 
enzyme (DNMT1) is inactivated. This results in an embryonically lethal phenotype, 
although stem cells survive without the enzyme (Lei et al, 1996; Li et al, 1992). This 
suggests that DNA methylation or the DNMT enzyme itself is essential for 













Figure 1.1: DNA methylation mechanism 
Cytosine residue is methylated to form 5-methylcytosine by a DNA methyltransferase 
(Mtase) which catalyses the transfer of a methyl group (CH3) from the methyl donor S-




In the very early stages of mammalian development, cells are initially pluripotent 
with the potential to differentiate into many cells types. Cell and embryo 
specification is primarily governed by gene regulatory elements (GRN) during 
development; however, epigenetic regulation also has a role in initiating and 
maintaining developmental gene expression. Epigenetic regulation is mediated 
through the following modifications: changes in DNA methylation; histone 
modifications; and chromatin re-modelling (Figure 1.2). These epigenetic 
modifications will be discussed in more mechanistic detail in section 1.3. It has been 
reported that pluripotent stem cells express genes mainly encoding transcription 
factors and genes required later in development are flexibly suppressed by the 
polycomb group (PcG) proteins and histone methylation (Boyer et al, 2006). In 
contrast, in fully differentiated somatic cells, some pluripotency-associated genes 
(such as Oct-3/4), transposons, and imprinted genes are silenced long-term through 
DNA methylation and histone modifications inactivate repressed developmental 
genes (Feldman et al, 2006). In the germline, many of these epigenetic marks are 
erased. Development is geared so that silenced pluripotent-associated genes are re-
expressed and imprinted genes are already epigenetically re-programmed  in the next 



















Figure 1.2: Mammalian development and epigenetic gene regulation 
Both global epigenetic modifications and gene expression patterns are shown alongside key 
developmental events. DNA methylation is erased and pluripotent genes begin to be 
expressed very early in development. At the same time, developmental genes are repressed 
by both the PcG protein system and H3K27 methylation (respectively). When pluripotent 
cells (such as ES cells) differentiate, pluripotent-associated genes are potentially 
permanently repressed by DNA methylation. During this time, there is also an increase in 
H3K4 methylation, and developmental genes begin to be expressed. The early development 
of primordial germ cells (PGCs) involves the erasure of DNA methylation and repressive 
histone marks such as H3K9 methylation. As a result, pluripotent- associated genes are re-
expressed and imprinted genes are re-programmed in the next generation. Developmental 
genes are expressed afterwards. 




Genetic imprinting is the process by which epigenetic changes in a specific parental 
chromosome (in the gamete or zygote) results in differential expression of two alleles 
of a gene in somatic cells of the offspring. A recent study identified over 150 
imprinted genes in the human genome, using both a computational and experimental 
approach (Luedi et al, 2007). It should be noted however, that only two out of the 
150 genes were verified experimentally to be imprinted, therefore further analysis is 
required to validate this study. The most widely recognised imprinted clusters are in 
a 1Mb region at 11p15 (encompassing the Beckwith Wiedemann region) (Brown et 
al, 1992) and a 2.3Mb region at 15q11-q13 (encompassing the Prader Willi and 
Angelman syndrome loci) (Driscoll et al, 1992). The silencing of imprinted genes 
occurs when differentially methylated regions (DMRs) that overlap a gene promoter 
region become heavily methylated (Birger et al, 1999). Methylation at a single DMR 
can also regulate expression of a whole cluster of imprinted genes (Sullivan et al, 
1999). It is not fully understood how these regions are selected for de novo 
methylation following fertilisation. However, an exciting novel finding this year has 
suggested that transcription may play an important role in the methylation of 
germline DMRs (Chotalia et al, 2009). Using a mouse model, it was shown that 
disruption of a transcript upstream from the Gnas locus prevented the normal 
methylation of germline DMRs. Transcription across DMRs in germ cells could be 
essential for the re-modelling of histone modifications or to form chromatin domains 
which are required for de novo methylation (Chotalia et al, 2009). 
 
X-chromosome inactivation is a stable silencing event, which is also associated with 
epigenetic modifications. X-inactivation involves the silencing of large areas of the 
X-chromosome instead of individual genes; and in humans is the random process by 
which one of the two copies of X-chromosome becomes inactivated in females. The 
X- inactivation centre (XIC) on the inactive X-chromosome encodes two RNA 
transcripts: Xist and Tsix, which are thought to initiate X-inactivation during 
embryonic development. Xist RNA coats the chromosome, spreading out from the 
XIC and subsequently causing gene silencing. Tsix also encodes RNA and is 
transcribed antisense to Xist; it overlaps the Xist RNA on the inactive X-
chromosome (Brown et al, 1991; Lee et al, 1999) (Figure 1.3). The X-chromosome is 
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enriched 2-fold for Long Interspersed Element (LINE) repeat sequences compared to 
other human autosomes (Bailey et al, 2000), and it is thought that these repeat 
sequences have a functional role in the spreading of inactivation (the Lyon Repeat 
Hypothesis) (Lyon, 1998). It was initially believed that compared to the active X-
chromosome, the inactive X-chromosome had higher levels of DNA methylation and 
histone marks in CpG islands. These epigenetic changes are thought to play a role in 
maintaining the inactive state as opposed to  the initiation of X-inactivation (Bartlett 
et al, 1991; Heard et al, 2001; Kohlmaier et al, 2004; Sado et al, 2000). Unlike 
genomic imprinting, methylated CpG islands on the X-chromosome are not re-
programmed during the normal life cycle. For example, the inactivated X-















The overall global methylation state along the inactive X-chromosome was unknown 
until recently. Interestingly, the inactive X-chromosome has lower overall levels of 
methylation compared to the active X-chromosome (Hellman & Chess, 2007; Weber 
et al, 2005). Methylation on the active X-chromosome occurs mainly at 
transcribable, gene-rich regions (gene bodies), rather than at specific promoter 
regions. This suggests that on the active chromosome there is DNA hypomethylation 
at gene promoters and DNA hypermethylation at gene bodies and on the inactive X-
Figure 1.3: Structure of human X-inactivation centre (XIC) and associated epigenetic 
modifications involved in maintaining the inactive state 
X-inactivation is initiated by the transcription of the Xist gene (green arrow) together with the 
overlapping antisense transcript Tsix (green dotted arrow). Transcription of Xist in cis coats 
the entire length of the X-chromosome resulting in its inactivation. Maintenance of the inactive 
state involves epigenetic modifications such as CpG methylation and histone marks. 
 
Source: adapted from Heard et al., 2001 
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chromosome, there is DNA hypomethylation in gene bodies and hypermethylation at 
gene promoters (Hellman & Chess, 2007). The exact function of global 
hypermethylation at the gene bodies of active X-chromosomes is unclear. However, 
it may be involved in chromosome-wide epigenetic control.  
 
It was initially hypothesised by Holliday and Pugh that specific modifying enzymes 
existed in eukaryotes which methylate and demethylate DNA and thereby control 
tissue-specific gene expression during mammalian development (Holliday & Pugh, 
1975). Several investigators found no link between DNA methylation and tissue-
specific expression during development (Hsiao et al, 1984; Walsh & Bestor, 1999), 
suggesting that methylation had no role in tissue-specific expression. Methylation 
was believed to only be involved in specialised biological functions, such as 
imprinting and X-inactivation. Although, recent studies have contradicted this belief, 
revealing a number of CpG islands which are methylated in normal tissues 
independent of imprinting and X-inactivation, many of which have been associated 
with tissue-specific methylation (Illingworth et al, 2008; Shen et al, 2007). Some of 
these non- X-linked novel promoter CpG islands were discovered to be densely 
methylated in normal somatic tissues and escape methylation in the germline cells. 
The CpG island hypermethylation occurring at these gene promoters appears to be an 
important mechanism for tissue-specific gene silencing (Shen et al, 2007). These 
studies identified approximately 4-8% of CpG islands with tissue-specific 
methylation. Similar to this, a separate report identified tissue-differential 
methylation regions (T-DMRs) with the majority of T-DMRs (76%) residing in 
regions located within 2kb of islands known as ‘CpG island shores’ rather than in 
CpG islands (6%) (Irizarry et al, 2009). The relationship between shore methylation 
and gene expression was confirmed using pharmaceutical inhibition of methylation 
and DNMT knock-out experiments. This suggests that the CpG island shores may 
play an important role in tissue-specific regulation (Irizarry et al, 2009).  
 
1.2.2 CpG Islands 
The likelihood of any dinucleotide pairing occurring in a DNA sequence is 1 in 16. 
However, the mammalian genome has disproportionately few CpG dinucleotides 
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(~1%, ~1 in 80 dinucleotides) a phenomenon known as CG suppression. This 
suppression was thought to have occurred over long periods of time as a result of 
DNA methylation deaminating CpG to Thymine/Guanine (TpG) (Coulondre et al, 
1978). Even though the frequency of CpG dinucleotides is low in the mammalian 
genome, there are stretches of DNA that have CpG-rich regions and extend over 
hundreds of nucleotides. These regions are known as CpG islands (Bird et al, 1985; 
Cooper et al, 1983). Around half of the CpG islands in the human genome are 
associated with gene transcriptional start sites and half are associated with intra- or 
intergenic regions (Illingworth et al, 2008). Genes with widespread expression, such 
as housekeeping genes, often have CpG islands at the 5’ end of genes, usually in the 
promoter region and surrounding transcriptional start site and rarely have 
downstream CpG islands (Illingworth et al, 2008). Downstream CpG islands occur in 
49% of genes with limited expression (Larsen et al, 1992). Their function is 
unknown, but it is thought they may represent tissue or developmental specific 
promoters, or they may not act as functional promoters at all and have essential 
coding functions that have not been lost by mutation (Jones, 1999). The most widely 
accepted method of identifying a CpG island uses two sets of criteria: ‘NCBI strict’ 
and ‘NCBI relaxed,’ and these are described below (Takai & Jones, 2002). To 
introduce less bias, the algorithm (and cut-offs) to set these criteria were designed 
using the complete genomic sequences of human chromosomes 21 and 22 rather than 
using gene exon databases previously used to define a CpG island (Gardiner-Garden 
& Frommer, 1987). This new definition excludes many intragenic CpG-rich areas 
such as Alu sequences (Schmid, 1998), which are highly repetitive short interspersed 
elements and also excludes CpG dinucleotides not associated with the promoters of 





- 200 base pair (bp) min length 
- 50% or higher GC content 
- 0.60 or higher observed CpG/ expected CpG 
 
• Strict 
- 500bp min length 
- 50% or higher GC content 
- 0.60 or higher observed CpG/ expected CpG 
 
The vast majority of CpG islands are unmethylated. However, it has been shown that 
CpG island promoter methylation is physiologically variable and is associated with 
transcriptional silencing of genes (Figure 1.4), which can be passed between cellular 









Figure 1.4: Effect of DNA methylation within CpG island promoter regions on 
gene transcription 
Normal unmethylated CpG island at the promoter region (as depicted by unfilled 
lollipop sticks) where gene is transcribed. Methylated promoter region (as depicted by 
filled lollipop sticks) is associated with gene silencing. 
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1.2.3 DNA methyltransferases 
CpG methylation is catalysed by a number of different DNMT enzymes. In 
eukaryotes there are three families of DNMTs (1, 2 & 3), which are likely to have 
diverged early in eukaryotic evolution. The enzymes are distantly related to each 
other and the genes are conserved between species in genomes that are methylated, 
such as in Arabidopsis thaliana and Xenopus laevis (Siedlecki & Zielenkiewicz, 
2006). Studies have shown that these enzymes cooperate, some having distinct but 
also overlapping functions. DNMT1, DNMT3a and DNMT3b are the key players 
involved in establishing global methylation patterns in mammals, whereas DNMT2 
and DNMT3L have not been shown to be directly involved (Brenner & Fuks, 2006). 
 
DNMT1, the first mammalian DNMT to be cloned and purified, was initially 
described as having de novo methylation function (Bestor et al, 1988). However, it 
was later found that DNMT1 had a 5-30 fold preference for hemimethylated DNA 
(Yoder et al, 1997a) and therefore this enzyme was termed a ‘maintenance 
methyltransferase’. This term refers to a system that reproduces parental DNA 
methylation on the daughter strand DNA, providing heritability, with genomic 
methylation patterns being copied during DNA replication and passed onto the next 
cell generation. DNMT1 is closely associated with the DNA replication machinery 
and has a preference for new unmethylated CpG sequences whose opposite strand 
has a methyl group attached (Leonhardt et al, 1992). Inactivation of DNMT1 in mice 
results in embryonic lethality and widespread demethylation in all sequences 
analysed (Li et al, 1992). ES cells lacking DNMT1 can no longer maintain 
differentiation (Damelin & Bestor, 2007; Lei et al, 1996; Panning & Jaenisch, 1996). 
However, they are viable and contain low but stable levels of de novo DNA 
methyltransferase activity (Lei et al, 1996; Li et al, 1992). This finding led to the 
hypothesis that an independent de novo methyltransferase may exist. DNMT3a and 
DNMT3b were subsequently cloned and characterised as de novo methyltransferase 
enzymes (Okano et al, 1998). Although both DNMT3 enzymes are regarded as de 
novo methyltransferases, they are also involved in maintaining methylation by 
restoring methylation sites missed by DNMT1 (Liang et al, 2002). Evidence has 
suggested that there is a cooperative function between the two DNMTs a model in 
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which: DNMT3a initiates de novo methylation by transferring methyl groups to one 
region of DNA; and then DNMT1 is recruited, which then methylates the entire 
region of the DNA (Fatemi et al, 2002). DNMT3a and DNMT3b are both highly 
expressed during development and are necessary for proper development in 
mammalian embryos. DNMT3a-/- mice develop to term, however they die at 
approximately four weeks of age. DNMT3b-/- mice are embryonically lethal (Okano 
et al, 1999). The DNMT3 enzymes are essential for establishing new methylation 
patterns and DNMT3b in particular is required for methylation of genome-specific 
regions, such as pericentromeric repetitive sequences and CpG islands on the 
inactive X-chromosome (Okano et al, 1999). Table 1.1 summarises the phenotypes 
of the DNMT knock-out mice and the DNA methyltransferase activity for each 
DNMT discussed in this section (DNMT1, DNMT3a & DNMT3b) and others not 
discussed (DNMT2 and DNMT3L).  
 
Mutational events causing the deletion of DNMT3b function are associated with the 
disease Immunodeficiency, centromeric instability and facial anomalies (ICF) 
syndrome (Hansen et al, 1999; Xu et al, 1999). ICF patients display marked 
hypomethylation and decondensation of pericentromeric heterochromatin on certain 
chromosomes (Franceschini et al, 1995; Tuck-Muller et al, 2000) and is the only 





DNMT Class Dnmt knock-out in mice DNA methyltransferase 
activity 
DNMT1 - Embryonic Lethality (E8.5) 
- Global hypomethylation 
- Lack of imprinting 
- Yes 
- Maintenance DNMT 
de novo activity: possible but low  
DNMT2 - Viable, fertile with only minor 
defects 
- Yes (low) 
- Preferences for centromeric 
structures 
- Methylates a tRNA* 
DNMT3a - Postnatal lethality (4 weeks) 
- Loss of de novo methylation 
- Severe intestinal defects 
- Impaired spermatogenesis 
- Yes 
- de novo activity; probably some 
maintenance activity 
  
DNMT3b - Embryonic lethality (E14.5-E18.5) 
- Loss of de novo methylation 
- Mild neural tube defects 
- Demethylation of centromeric 
repeat sequences 
- Yes 
- de novo activity; probably some 
maintenance activity 
- Preference for minor satellite 
repeats 
DNMT3L - Viable; males are sterile 
- Females have no viable progenitor 
- Loss of maternal and paternal 
imprinting in gametes 
- No 
- Cofactor of DNMT3a (enhances 
its de novo activity) 
Table 1.1: Summary of phenotypes of the DNMT knock-out mice and methyltransferase 
activity for each DNMT enzyme 
*function for DNMT2 published: (Goll et al, 2006).  
 
                                                                     Source: adapted from Brenner and Fuks, 2006 
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1.3 DNA Methylation and mechanisms of gene silencing 
Mutational inactivation of tumour suppressor genes has long been known to be 
associated with tumour progression. However, cancer development is also associated 
with transcriptional silencing of tumour suppressor genes by DNA methylation 
(Herman et al, 1996b; Kane et al, 1997). It is currently unknown whether 
methylation of tumour suppressor genes directly causes the silencing of genes or if 
methylation occurs subsequent to gene silencing by another mechanism. There is an 
association between cancerous cells and aberrant methylation (Gama-Sosa et al, 
1983; Herman et al, 1996b), however, there are likely to be other factors such as 
histone modifications and chromatin re-modelling events, in addition to DNA 
methylation, that contribute to gene silencing. 
 
1.3.1 Direct mechanism of gene silencing by DNA methylation 
DNA methylation may act independently from other epigenetic modifications and 
repress transcription by the direct interference of the methyl group in the binding of 
proteins, (such as transcription factors) to its DNA sequence (Jones & Wolffe, 1999). 
Most of the evidence for this is based on reports on c-Myc and the CCCTC-binding 
factor (CTCF). c-Myc is a transcription factor which is involved in regulating both 
differentiation and cell growth, and studies have demonstrated that a heavily 
methylated sequence inhibits c-Myc from binding to its consensus sequence 
(Prendergast et al, 1991). In addition, CTCF a transcriptional regulator protein best 
known for its role in the imprinting of the H19/Igf2 locus, is prevented from binding 
to a regulatory site on the paternal allele as it is methylated (Bell & Felsenfeld, 
2000). In contrast, a recent study found that p53, a transcription factor involved in 
the response to carcinogenic stress, binds at similar affinities to methylated CpG 
sequences and unmethylated CpG sequences. Furthermore, for some sequences, 
methylation in the binding sites actually increases the binding of p53 four- to six-fold 
(Petrovich & Veprintsev, 2008). Very few other transcription factors, whose binding 
is affected by methylation, have been reported. In addition, it seems very improbable 
that in the entire genome, the function of DNA methylation is only restricted to 
recognition sites for individual transcription factors. Other indirect mechanisms 
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involving DNA methylation and chromatin re-modelling are more likely to have a 
prominent role in gene silencing.   
 
1.3.2 Indirect mechanisms of gene silencing by DNA methylation 
Chromatin undergoes varying degrees of organisation and comprises of subunits 
known as nucleosomes, where approximately 200bp of DNA sequence is organised, 
by an octamer of structural proteins called histones, into a bead-like structure. The 
core histones (H2A, H2B, H3 and H4) are susceptible to post-translational 
modifications, some of which include: acetylation, methylation, phosphorylation, 
ubiquitination and adenosine diphosphate (ADP) ribosylation (Spotswood & Turner, 
2002; Strahl & Allis, 2000). These modifications function in the regulation of 
chromosome condensation, DNA repair, DNA synthesis and transcription 
(Kouzarides, 2007). Deacetlyation and methylation of histone H3 at both lysine 
residue 9 (H3K9) and histone H3 lysine 27 (H3K27) for example, are the best 
characterised histone modifications associated with gene silencing (Margueron et al, 
2005). It is generally considered that transcriptionally-active chromatin has an open, 
extended structure with unmethylated promoter regions and core histones are 
acetylated by histone acetlytransferases (HATs) (Tazi & Bird, 1990). 
Transcriptionally inactive chromatin has a highly condensed structure, high levels of 
methylation at promoter regions, and core histone proteins are deacetlyated by 
histone deacetlyases (HDACs). Studies have however shown a correlation between 
open chromatin structures and areas of high gene density, but not necessarily with 
high levels of gene expression due to the fact that inactive genes can be found in 
open chromatin and active genes can be found in regions of compact chromatin 
(Gilbert et al, 2004). From using mouse embryonic cells completely lacking both 
DNMT3a and DNMT3b, it was recently found that DNA methylation affects 
chromatin structure at the level of the nucleosome and at the level of nuclear 
organisation, but not at secondary levels of bulk chromatin and heterochromatin 
(Gilbert et al, 2007). This suggests that DNA methylation modifies both primary 
chromatin structure and nuclear organisation, and therefore adds more complexity to 




DNA methylation and histone deacetylation function can act together, using a 
common mechanistic pathway, to silence gene expression (Nan et al, 1998). A family 
of Methyl-CpG binding proteins, which have been cloned and fully characterised, 
mediates this. Some of these proteins have a homologous methylcytosine-binding 
domain (MBD). MBD1, MBD2, MBD4 and MeCP2 are known to be involved in 
transcriptional repression by binding 5-methylcytosine through their methyl-binding 
domain (Cross et al, 1997; Kondo et al, 2005; Nan et al, 1997; Ng et al, 1999). 
MeCP2 is a protein that specifically binds to methylated DNA and in vitro can 
invade chromatin and displace the histone H1 (Lewis et al, 1992; Nan et al, 1997; 
Nan et al, 1993) In 1998, MeCP2 was demonstrated to repress transcription by 
associating with HDAC proteins (Jones et al, 1998; Nan et al, 1998) (Figure 1.5). 
Both MeCP2 and the MBD proteins are thought to associate with HDACs, which 
deacetylate histones and in turn repress transcription (Ballestar & Esteller, 2002; 
Jones et al, 1998; Nan et al, 1998).  
 
Kaiso is another methyl-CpG binding protein, which is involved in transcriptional 
repression. Kaiso is different to other MBD proteins, in that it binds methylated DNA 
through its zinc-finger motif (Prokhortchouk et al, 2001). The protein plays an 
essential role in maintaining transcriptional silencing during early Xenopus laevis 
development as the absence of kaiso results in early zygotic gene expression and 
subsequent developmental arrest and apoptosis (Ruzov et al, 2004). In comparison, 
Kaiso-null mice have no obvious phenotype but do show a resistance to intestinal 
tumours when bred onto an ApcMin/+ genetic background (Prokhortchouk et al, 2006). 
This suggests that Kaiso may be involved in epigenetic mechanisms which occur in 
tumorigenesis. Indeed, a recent report demonstrated that Kaiso represses the tumour 
suppressor gene p16INK4A in a methylation dependent manner. Kaiso depletion 
resulted in induced expression of p16INK4A without reversing aberrant 




























Figure 1.5: Gene silencing by histone deacetylation may be mediated through CpG 
promoter methylation 
Nucleosome ‘beads on a string’ are shown (blue blocks) with DNA (thick black line), 
acetylated histone tails are protruding from the nucleosome (red lines) and methylated CpG 
dinucleotides are also indicated (CH3). Transcriptional repressor MeCP2 recruits co-




In human neoplasia, MBD2 is selectively recruited at the hypermethylated promoter 
regions of p14ARF/p16INK4a but not at acetylated histones H3 and H4 (Magdinier & 
Wolffe, 2001). Recently, it was also shown that: MeCP2, MBD1 and MBD2 
specifically bind to methylated hMLH1 promoters in endometrial cancer; and 
hyperacetylated H3 and H4 histones were associated with unmethylated and actively 
transcribing hMLH1 promoters (Xiong et al, 2006). This data suggests that DNA 
methylation and histone deacetylation work in synergy for gene silencing in cancer. 
It is unknown whether DNA hypermethylation has a dominant effect in the 
maintenance of gene silencing. Although, experiments have demonstrated that 
hypermethylated genes cannot be transcriptionally activated with treatment of a 
HDAC inhibitor alone (Trichostatin A -TSA) (Cameron et al, 1999). 
 
It is unclear how histone deacetylation produces a transcriptionally inactive state, 
however, two models have been proposed. One theory is that 
acetylation/deacetylation modifications of the lysine residues directly alter 
electrostatic charges. This then subsequently changes the interaction between the 
histone tails and DNA and therefore decreases the accessibility to transcription 
factors (Lee et al, 1993). Another model proposes that histone 
acetylation/deacetylation combinations are interpreted as a ‘histone code’, which 
results in the interaction with trans-acting factors such as chromatin re-modelling 
factors (Strahl & Allis, 2000). Therefore, the action of the histone-modifying 
enzymes may be targeted by chromatin re-modelling events. Finally, it has been 
shown that DNMTs directly interact with HDACs. DNMT3a is known to be targeted 
to promoter regions through its association with a transcription factor, and then acts 
to repress transcription by recruiting HDAC activity (Fuks et al, 2001). This suggests 
that DNMT3a may have important functions other than de novo methylation, and 
further provides a link between DNA methylation and transcriptional activity. 
 
In contrast to histone acetylation, histone methylation at lysine and arginine residues 
are thought to be relatively stable and represent ‘marks’ that are transmissible 
through cell divisions. Methylation of histones is catalysed by histone 
methyltransferases (HMTs), which use the methyl-donor SAM (Rice & Allis, 2001). 
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The monomethylations of H3K27, H3K9, H4K20, H3K79 and H2BK5 are related to 
gene activation, whereas trimethylations of H3K27, H3K9 and H3K79 are related to 
gene repression (Barski et al, 2007). It is unknown how histone methylation precisely 
affects gene transcription. Unlike histone acetylation, histone methylation does not 
alter the overall charge of the histone tails. Methylation does however increase the 
affinity of the histone tails for anionic molecules such as DNA (Baxter & Byvoet, 
1975). Thus, it is believed that histone methylation may have an effect on the 
interaction of histone tails with DNA and/or chromatin re-modelling proteins (Rice 
& Allis, 2001). There is much speculation as to how DNA methylation affects 
histone methylation or vice versa. One model is that H3K9 methylation by a HMT 
leads to the recruitment of an adaptor molecule known as heterochromatin protein 1 
(HP1) (Lachner et al, 2001). HP1 then recruits DNMT enzymes, which catalyse CpG 
methylation in the region of the methylated histone tails (Fuks et al, 2003). Methyl-
CpG binding proteins could then bind methylated DNA, which subsequently leads to 
the recruitment of HDAC proteins. Therefore, it may be that DNA methylation, 
histone acetylation and H3K9 methylation cooperate to regulate gene transcription.  
 
In the sections above, the role of DNA methylation in normal physiological 
processes has been described. In cancer, these processes can be disrupted due to 






1.4 Aberrant methylation and cancer 
It is well established that neoplastic cells have a methylation imbalance and that this 
imbalance may fundamentally contribute to tumour progression (Esteller, 2008). 
Neoplastic cells can simultaneously display widespread genomic hypomethylation, 
regional areas of hypermethylation often involving the promoters of selected tumour 
suppressor genes, and increased total DNMT activity (Baylin et al, 1998). It is 
unknown whether global hypomethylation and region-specific hypermethylation are 
linked in tumorigenesis. However, it has been shown that these changes in 
methylation occur at specific but distinct sites, suggesting that they may have 
different effects within the neoplastic cell. Overall, the methylation status in cancer 
cells is complex and unravelling causality between general non-specific effects and 
specific methylation events requires extensive and painstaking research. 
 
1.4.1 Global Hypomethylation 
The first report of global loss of 5-methylcytosine in cancer cells was by Gama-Sosa 
et al (1983). Using high-performance liquid chromatography, loss of methylation 
was identified in both benign and malignant tumours and also in pre-malignant 
adenomas when compared with normal tissues, suggesting that demethylation of 
DNA may be involved in tumour progression (Gama-Sosa et al, 1983). Since then, 
various studies have shown that global hypomethylation occurs in a number of 
different tumour types and is highly specific with regard to tumour type and tumour 
stage. For example, hypomethylation is identified more commonly in solid tumour 
types such as hepatocellular cancer, cervical cancer and prostate tumours (Bedford & 
van Helden, 1987). Loss of genomic methylation in some tumours is a frequent and 
early event, relative to other epigenetic changes during tumorigenesis, and can 
correlate with disease severity and metastatic potential. For instance, extensive 
hypomethylation of chromosome 1 is a marker for poor prognosis in ovarian cancer 
and was found to be more informative than tumour grade or stage (Widschwendter et 
al, 2004). However, more recently it was demonstrated that global DNA 
hypomethylation occurs in later stages of prostate cancer progression, appearing to a 
significant extent only in metastatic disease stages (Yegnasubramanian et al, 2008). 
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Therefore, in prostate cancer, changes in DNA hypomethylation may occur 
following CpG island hypermethylation. 
 
It is estimated that more than one third of DNA methylation is found at repetitive 
elements (Kochanek et al, 1993) and in tumour cells,  DNA methylation at these 
regions is often lost (Yoder et al, 1997b) (Figure 1.6). In fact, one method for 
measuring global DNA methylation is based on measuring the methylation status of 
DNA repetitive elements, such as Alu elements and LINE sequences (Yang et al, 
2004). Hypomethylation has also been observed at pericentromeric satellite 
sequences on chromosome 1 and chromosome 16 in a high percentage of Wilms 
tumours. Furthermore, there was a significant relationship between chromosomal 
rearrangements of 1q and 16q, and hypomethylation of satellite DNA in the 
pericentromeric regions of these chromosomes (Qu et al, 1999). Therefore, loss of 
methylation at pericentromeric satellite sequences in these cancers may predispose 
them to breakage or recombination. This is supported by in vivo studies, which have 
shown that mice with reduced levels of DNMT1 develop T cell lymphomas with a 
high frequency of chromosome 15 trisomy (Gaudet et al, 2003). This implies that 
there may be an association between global hypomethylation, chromosome 
aberrations, and tumorigenesis. Another theory is that re-activation of transposon 
promoters following demethylation may contribute to aberrant gene regulation in 
tumorigenesis by transcriptional interference or the generation of antisense 
transcripts. Double-stranded RNA homologues (to the gene or its promoter) could be 
generated and the recruitment of the RNA interference (RNAi) machinery would 
then lead to the epigenetic marks, including DNA methylation (Robertson, 2005).  
 
The underlying mechanism responsible for global DNA hypomethylation is not fully 
understood. One hypothesis is that hypomethylation is due to dysfunction of 
chromatin-remodelling proteins or maintenance DNMTs. Knock-out studies on Lsh, 
a SNF-2 family member, chromatin-remodelling protein, leads to a global defect in 
genomic methylation as well as chromosome instability (Fan et al, 2003). This is 
interesting, as Lsh is primarily known for its role in chromatin remodelling. Lsh may 
regulate methylation directly or indirectly. However, it has been shown to not affect 
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DNMT activity, which suggests that it may have a more direct role (Dennis et al, 
2001). MBD proteins mediate histone deacetylase-dependent gene silencing at 
methylated CpG islands, and mouse studies have shown that deficiencies in methyl-
CpG binding proteins such as MBD1, MBD2 and MeCP2 results in phenotypic 
changes, but there have been no reports of associated alterations in global 
methylation levels (Guy et al, 2001; Hendrich et al, 2001; Zhao et al, 2003). This is 
not surprising as these proteins are involved in machinery that binds and interprets 
methylation marks rather than actually producing them. Furthermore, they are not 
directly involved in chromatin re-modelling unlike Lsh.  
 
DNMT proteins are more likely to have a role in DNA hypomethylation as they are 
directly involved, unlike the other proteins mentioned previously. DNMT1 null mice 
are embryonically lethal (section 1.2.3). Although, mutations of DNMT1 in 
homozygous murine embryonic stem cells results in a 3-fold decrease in global 
levels of methylated CpG compared to wild-type cells (Li et al, 1992). In addition, 
the splice variant of DNMT3b (DNMT3b4), which has been found in patients with 
liver cancer, is associated with hypomethylation of pericentromeric satellite 
sequences when transfected into human epithelial cells (Saito et al, 2002). The 
specific functions of the DNMT3b splice variants are not fully understood. Whilst 
DNMT3b4 is a negative regulator of methylation, DNMT3b3 is involved in 
methylating satellite repeat sequences but is dependent on other unknown factors that 
affect its activity (Weisenberger et al, 2004). Currently, no studies have identified a 
direct link between DNMT mutations and global levels of demethylation in tumours. 
Furthermore, whether the global epigenetic change manifests as hypomethylation is a 
cause or consequence of tumorigenesis is still under much debate, however, as 
mentioned previously, some studies propose that DNA hypomethylation plays a 
causal role by promoting chromosomal instability (Gaudet et al, 2003; Qu et al, 





















1.4.2 Hypomethylation of CpG Islands 
Hypomethylation was the first epigenetic abnormality to be identified in cancer cells 
when a loss of DNA methylation at CpG dinucleotides in the c-Ha-ras and c-Ki-ras 
genes was observed in primary small cell lung carcinomas (Feinberg & Vogelstein, 
1983b). Following on from this initial finding, the primary focus moved towards the 
search for hypermethylated genes, and studies involving hypomethylation of specific 
CpG islands were overlooked. High-throughput genomic methylation analysis in 
various different cancers has suggested that the number of hypomethylated sites in 
the human genome may be quite high (Adorjan et al, 2002; Iacobuzio-Donahue et al, 
2003). In one study, using cDNA microarrays, 149 genes were found to be 
differentially expressed in pancreatic cancer tissues, compared to the normal 
pancreas. The majority of these genes tended to be overexpressed and one gene, 14-
Figure 1.6: Aberrant DNA methylation and cancer.  
The diagram shows a region of genomic DNA in a normal cell, consisting of a repeat-rich, 
hypermethylated pericentromeric heterochromatin and an actively transcribed tumour 
suppressor gene (TSG), hypomethylated at the CpG island (indicated in red). In tumour 
cells, the repeat-rich heterochromatin is hypomethylated and is associated with genomic 
instability, most likely through increased mitotic recombination. Hypermethylation of CpG 
islands can also occur in tumour cells, which results in transcriptional silencing.  
Source: Robertson, 2005. 
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3-3σ was associated with aberrant hypomethylation (Iacobuzio-Donahue et al, 2003). 
CpG-island-specific hypomethylation, followed by increased expression has been 
reported for many genes, including: the S100 calcium-binding protein A4 gene 
(S100A4) in colorectal cancer (Nakamura & Takenaga, 1998); the normally silenced 
long control region (LCR) and E6 genes of human papillomavirus 16 (HPV16) in 
cervical cancer (Badal et al, 2003; de Capoa et al, 2003); and the serpin peptidase 
inhibitor, clade B (ovalbumin) member 5 gene (SERPINB5) in gastric cancer 
(Akiyama et al, 2003). Little is known regarding the mechanisms responsible for 
gene-specific hypomethylation and as with global DNA hypomethylation, it is still 
unclear whether gene-specific hypomethylation is a cause or consequence of 
tumorigenesis.  
 
1.4.3 Hypermethylation of CpG Islands 
Abnormal methylation of promoter regions can result in transcriptional silencing and 
increased mutagenicity by the deamination of 5-methylcytosine to thymidine, both of 
which can contribute to carcinogenesis. Methylation is at least as common a 
mechanism as mutation for gene silencing in currently identified tumour suppressor 
genes (Jones & Baylin, 2002). Approximately half of genes mutated in the germline 
that cause familial forms of cancer are also known to undergo methylation-associated 
silencing in different sporadic cancers (Jones & Baylin, 2002). In addition, there are 
a growing number of tumour suppressor genes, which are inactivated by promoter 
hypermethylation, but not frequently mutated in different cancers. The first gene 
shown to have abnormal hypermethylation in its promoter region was Calictonin 
(Baylin et al, 1986). The functional significance of this epigenetic event was unclear, 
as Calcitonin is not ubiquitously expressed in adult tissues and does not function as a 
tumour suppressor gene. This finding did however lead on to the possibility that 
tumour suppressor genes may be inactivated in cancer as a result of promoter 
hypermethylation. A number of tumour-suppressor genes have been found to be 
methylated at their CpG islands in different cancer types (Table 1.2). Genes that are 
affected include those involved in cell cycle regulation, DNA repair, apoptosis, cell-
to-cell interaction and angiogenesis, all of which have a role in cancer development 
(Esteller, 2008). Demethylation of some of these genes using the DNMT inhibitor 5-
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Azacytidine is associated with re-expression at the mRNA and protein level. This 
suggests that methylation may play a role in silencing affected genes and thereby 


















(Kane et al, 1997) 
(Herman et al, 1995; Merlo et al, 1995) 
(Robertson & Jones, 1998) 
(Caldwell et al, 2004) 
(Agrelo et al, 2006) 
Breast cancer BRCA1 
E-cadherin 
TMS1 
(Dobrovic & Simpfendorfer, 1997) 
(Graff et al, 1995) 
(Conway et al, 2000) 
Lung cancer p16INK4A 
DAPK 
RASSF1A 
(Merlo et al, 1995) 
(Zochbauer-Muller et al, 2001) 




(Costello et al, 1994) 
(Alaminos et al, 2005) 




(Herman et al, 1996b) 
(Ropero et al, 2004) 




(Herman et al, 1997) 
(Corn et al, 1999) 
(Esteller et al, 1999b) 
Bladder cancer p16INK4A 
TMEFF2/HPP1 
(Gonzalez-Zulueta et al, 1995) 
(Suzuki et al, 2005) 
Kidney cancer VHL (Herman et al, 1994) 





(Maesawa et al, 1996) 
(Nie et al, 2002) 
Stomach cancer hMLH1 
p14ARF 
(Leung et al, 1999) 
(Iida et al, 2000) 
Liver cancer SOCS1 
GSTP1 
(Yoshikawa et al, 2001) 
(Tchou et al, 2000) 
Ovarian cancer BRCA1 (Catteau et al, 1999) 
Table 1.2: Tumour suppressor genes associated with CpG island hypermethylation in 
different cancer types.  
BRCA1 (breast-cancer susceptibility gene 1), DAPK (death-associated protein kinase), 
EMP3 (epithelial membrane protein 3), EXT1 (exostosin 1), GSTP1 (glutathione 
S-transferase 1), hMLH1 (homologue of MutL Escherichia coli), ID4 (inhibitor of DNA binding 
4), MGMT (O6-methylguanine–DNA methyltransferase), RASSF1A (ras association domain 
family protein 1), SFRP1 (secreted frizzled-related protein 1), SOCS1 (suppressor of 
cytokine signaling 1), THBS1 (thrombospondin 1), TMEFF2/HPP1 (hyperplastic polyposis 
gene 1), TMS1 (target of methylation-induced silencing), VHL (von Hippel–Lindau disease), 
and WRN (Werner’s Syndrome). Note: this is not a definitive list. 




Figure 1.7: The revised Knudson two-hit model hypothesis.  
Methylation of the promoter region can occur as a ‘second hit’ in addition to the ‘first hit’ of 
either intragenic mutations or deletions.  
Source: Jones and Laird, 1999. 
  
 
Aberrant methylation can be detected in the earliest precursor lesions in tumours 
with well-defined progression, such as in colon cancer. Aberrant crypt foci (34%) 
displayed hypermethylation of six genes frequently found to be methylated in 
established colorectal cancer (Chan et al, 2002). This suggests that methylation could 
directly contribute to transformation, and may not occur as a late event because of 
genetic alterations. Excluding haploinsufficiency, the phenotypic consequence of a 
loss of a tumour suppressor gene is usually only seen when both alleles of the gene 
are inactivated in a tumour (‘two hit hypothesis’) (Knudson, 2000). In addition to 
intragenic mutations and chromosomal loss (by loss of heterozygosity (LOH) or 
homozygous deletion), methylation of CpG islands within the promoter region of 
tumour suppressor genes represents a third pathway in which tumour suppressor 
genes are inactivated (Figure 1.7) (Jones & Laird, 1999). Promoter hypermethylation 
has been shown to play a significant role in the inactivation of tumour suppressor 
genes, either as a first or second hit in both sporadic and familial forms of different 


















Following on from the initial studies carried out on CpG island hypermethylation in 
neoplastic cells, methylation analysis using a restriction enzyme approach found a 
small degree of methylation in the estrogen receptor 1 (ESR1) gene in normal colonic 
tissue adjacent to colorectal tumours. Furthermore, the degree of methylation 
positively correlated with the age of patient (R2 = 0.71, p <0.000001) (Issa et al, 
1994). Subsequent studies in colorectal cancer and in other cancers revealed that 
there were many more genes methylated in normal tissues and that methylation 
increased with age (Ahuja et al, 1998; Issa et al, 1996; Kwabi-Addo et al, 2007). 
These will be discussed in more detail in section 1.5.2. It was observed however, that 
not all genes hypermethylated in cancer display age-related methylation and with 
these cases, hypermethylation may be a tumour-related event. It has therefore been 
suggested that there are in fact two types of methylation in cancer: age-related in 
which methylation precedes neoplasia; and cancer-related in which methylation 
occurs primarily and is a fundamental process in the formation of neoplasia. These 
two types of methylation were termed Type A (for Age-related) and Type C (for 
Cancer-related) (Toyota & Issa, 1999). 
 
1.4.4 DNA methylation - Cause or consequence  
There has been much debate as to whether methylation is the initial cause for gene 
silencing or methylation is a consequence of prior gene silencing. De novo 
methylation may be the result of loss of expression due to upstream mutational 
events in signal transduction cascades or transcription factor networks. It is also 
thought that aberrant histone modification may cause gene silencing in cancer cells, 
which consequently catalyses DNA methylation by recruiting DNMT enzymes. In 
one study, H3K9 deacetylation and H3K9 methylation preceded re-silencing and re-
DNA methylation of p16INK4A in cancer cells, which occurs after DNA demethylation 
(drug-induced) and re-expression (Bachman et al, 2003). Another hypothesis is that 
polycomb-induced H3K27 methylation, which is normally involved in gene silencing 
during development, brings about tumour-specific targeting of de novo methylation 




The most generally held view is that DNA methylation results in repressive 
chromatin by recruiting chromatin modifying proteins, and this then leads to 
inactivation of genes early in carcinogenesis. However, if aberrant DNA 
hypermethylation is the initial event, it is still unclear what triggers it. The three main 
hypotheses are:  
 
1. CpG island methylation occurs randomly and results from errors during DNA 
replication and these cells are then selected for because they lead to an 
enhanced growth phenotype (Herman et al, 1998). 
 
2. Tumour-specific methylated genes belong to distinct functional categories, 
have common sequence motifs in their promoter regions, and are found in 
clusters on chromosomes, indicating that cancer-related de novo 
hypermethylation may be a pre-programmed event (Keshet et al, 2006).   
 
3. CpG island hypermethylation arises from a defect in the methylation 
machinery that results in aberrant methylation. 
 
It is speculated that a combination of the hypotheses above may be the actual answer 
to the aberrant CpG island hypermethylation phenomena and it is likely that age-
related methylation has different etiological factors to that of cancer-related 
methylation. Type A methylation is so common and tissue-specific that it is more 
likely to be caused by a physiological process rather than a mutation in gene 
involved in the methylation machinery. Type C methylation, however, is less 
frequent and shows clustering in some tumours, suggesting that it may be a 
secondary event to an acquired defect in the CpG island methylation or 
demethylation processes (http://mdanderson.org/departments/methylation). There has 
only been one report of somatic mutations in a DNMT gene in colorectal cancer and 
this will discussed further (in section 1.4.5). Therefore, there is currently a lack of 





1.4.5 DNA Methyltransferase activity in cancer   
Many studies examining the expression of DNMTs at the RNA level in tumour tissue 
have reported variable levels of overexpression (el-Deiry et al, 1991; Lee et al, 1996; 
Robertson et al, 1999). Lee et al found a 1.8 - 2.5-fold increase in DNMT RNA 
levels in colonic carcinoma compared to matching normal mucosa, whereas el-Deiry 
et al found a 15-fold increase in DNMT1 overexpression in colonic carcinoma (el-
Deiry et al, 1991; Lee et al, 1996). The extent to which DNMT1 overexpression 
contributes to cancer remains controversial, but it is likely that low level 
overexpression (2 - 4-fold) is relatively common (Robertson, 2001). Contradicting 
these studies, there are also reports of tumours which do not overexpress DNMTs 
(Eads et al, 1999; Ehrlich et al, 2006). Using MethyLight technology, Ehrlich et al 
concluded that there was no significant association between gene hypermethylation 
and altered DNMT RNA levels in ovarian cancer (Ehrlich et al, 2006). It has also 
been proposed that changes in DNMT activity in cancer may be due to improper 
DNMT expression during the cell cycle. DNMT1, DNMT3a and DNMT3b are all 
differentially expressed during the cell cycle (Robertson et al, 2000; Szyf et al, 1991; 
Tatematsu et al, 2000). DNMT levels are higher in G0/G1 in cancer cell lines 
compared to normal cell strains (Robertson et al, 2000). Thus, these studies 
demonstrate another level of control of the DNA machinery during the cell cycle, 
and disruption of this this may be another mechanism by which aberrant methylation 
is observed in tumour cells. Finally, microRNAs (miRNAs) may play a role in 
regulating DNMT levels in cancer cells. miRNAs are small non-coding RNAs that 
regulate the expression of different genes, and studies have shown the expression 
levels of miRNAs are downregulated in cancer compared to normal tissues (Volinia 
et al, 2006). The miRNA29 family has a complementary sequence to both DNMT3a 
and DNMT3b, and downregulated miRNA29 levels were inversely correlated to 
DNMT3a and DNMT3b RNA levels in lung cancer tissues. Furthermore, induced 
expression of miRNA29  in lung cancer cell lines restored normal patterns of DNA 
methylation, induced the re-expression of silenced tumour suppressor genes, and 





The disruption of DNA methyltransferase activity and subsequent genome-wide 
changes in DNA methylation may contribute to carcinogenesis, through promoting 
genomic instability. As mentioned previously, DNMT1 and DNMT3b knock-out mice 
are embryonically lethal (Li et al, 1992) and DNMT3a knock-out mice are peri-lethal 
(Okano et al, 1999). Therefore, it is unlikely that a germline mutation of any of the 
DNMT genes contributes to carcinogenesis.  However, there has been one report in 
which a loss-of-function mutation in a DNMT protein has been described (Kanai et 
al, 2003). This study identified mutations in the coding region of DNMT1 in 7% 
(2/29) of colorectal carcinomas. One of these mutations was a one-base deletion 
which consequently led to the deletion of the whole catalytic domain of DNMT1, 
and the other was a point mutation resulting in a single amino acid substitution. No 
stomach or hepatocellular carcinomas displayed mutations in the coding regions of 
DNMT1. Mutational screening was also carried out in the 5’ region of DNMT1, 
although no mutations were detected in any of the colorectal carcinomas, stomach 
cancers or hepatocellular carcinomas (Kanai et al, 2003). This demonstrates that 
mutational inactivation of DNMT1 does occur in colorectal cancer, however, further 
studies are required to determine whether these mutations are associated with human 
carcinogenesis. 
 
Interestingly, it was initially demonstrated that the disruption of DNMT1 activity in 
HCT116 colorectal cancer cells does not result in a significant alteration in global 
DNA methylation levels or associated gene silencing (Rhee et al, 2000). It was 
believed that DNMT1 functions in a cooperative manner with DNMT3b, since 
genetic disruption of both DNMT1 and DNMT3b is required to significantly reduce 
genomic methylation levels and demethylate repeat sequences, imprinted genes and 
aberrantly silenced tumour suppressor genes (Rhee et al, 2002). However, recently it 
was reported that the ‘double knock-out methyltransferase’ (DKO) cells used in the 
earlier studies actually express an alternatively spliced variant, which bypasses the 
knock-out cassette and results in an active DNMT1 protein lacking a proliferating 
cell nuclear antigen (PCNA) binding domain (Spada et al, 2007). RNAi-mediated 
knock-down of the truncated DNMT1 in the DKO cells results in significantly 
reduced global genomic DNA methylation levels and cell death (Spada et al, 2007). 
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To lend further support to these results, another report also demonstrated that 
HCT116 cells which lack DNMT1 methyltransferase activity undergo mitotic 
catastrophe and cell death (Chen et al, 2007). Thus, it appears from these studies that 
DNMT1 is required for maintaining DNA methylation levels in human cancer cells 
and plays a crucial role in their growth and survival.   
  
1.5 DNA methylation and Colorectal Cancer 
1.5.1 Introduction 
Colorectal cancer accounts for 14.5% (males) and 11.3% (females) of all cancers in 
Scotland (Information Services Division Scotland, 2005). Colorectal cancer is 
associated with a relatively poor survival rate remaining around 40%, which resulted 
in 16,100 deaths in 2002 despite improved understanding of cellular and molecular 
events involved in the development of colorectal cancer and progresses in surgery, 
radiotherapy, and chemotherapy (CancerResearch UK, 2006). Hence, further 
understanding of initiation, progression, and metastasis of colorectal cancer at a 
mechanistic level will improve the development of new drugs and therapies to treat 
and potentially prevent colorectal cancer.  
 
A series of morphological changes occur in the epithelium during colorectal cancer 
development. Vogelstein proposed a Darwinian model of adenoma to carcinoma 
progression in which an accumulation of genetic alterations can lead to the 
morphological changes seen in tumorigenesis (Fearon & Vogelstein, 1990; 
Vogelstein et al, 1988) (Figure 1.8). Recent studies have acquired a vast amount of 
molecular data on the ‘adenoma to carcinoma sequence’, which has been utilised to 
examine the genetic basis of human cancer as a whole (Quirke, 1997). The proposed 
model (Figure 1.8), illustrates the development of the histological stages in the 
majority of colorectal cancers, however, often the underlying genetic alterations are 
less predictable. As will be discussed in this section, the amalgamation of epigenetic 
and genetic research more than likely holds the key to providing a complete 
molecular understanding of colorectal cancer and this may be significant for the 
















1.5.2 Age-related methylation in colorectal cancer 
Aberrant CpG methylation is a frequent event resulting in gene silencing in 
neoplastic cells (Jones & Baylin, 2002). Research has suggested that the majority of 
aberrant methylation is associated with age-related changes in normal cells and 
tissues and is a generic effect that occurs over the lifetime of normal tissue. 
Neoplasia is then thought to occur through continuous selection (Ahuja et al, 1998). 
As mentioned previously, the first report of Age-related methylation (or Type A 
methylation) involving a promoter-associated CpG island was the ESR1 gene in 
human colorectal tissue (Issa et al, 1994). The ESR1 CpG island was methylated in 
all cell lines, adenomas, carcinomas, and in a small amount of normal colonic tissues 
adjacent to tumours. Experimental introduction of the ESR1 gene into colorectal 
cancer cells resulted in growth inhibition, suggesting that ESR1 functions to regulate 
cell growth, and its silencing through CpG hypermethylation leads to de-regulated 
growth of colonic cells (Issa et al, 1994). Other genes that have been found to be 
aberrantly methylated in the normal colon include the transcription factor myogenic 
differentiation gene (MYOD) and the tumour suppressor gene N33. Restriction 
Figure 1.8: Vogelstein’s proposed model for development of sporadic colorectal 
cancer.  
The linear accumulation of epigenetic changes, gene mutations or chromosomal changes 
leading to tumour progression. 




enzyme analysis showed that these genes displayed hypermethylation in the 
carcinoma, as well as low levels of methylation in normal colonic tissue, which 
increased with age (Ahuja et al, 1998). Another study looked at the methylation 
status of 19 tumour suppressor genes in normal colonic tissue and found that 
methylation of some genes was tightly correlated in adenomas, intermediate normal 
mucosa, and colorectal cancer (Takahashi et al, 2006). In addition, they confirmed 
that groups of genes are frequently methylated in normal appearing cells and tissues, 
and that methylation of these genes may contribute to increased cancer risk with the 
added factor of increased age (Takahashi et al, 2006). Normal colonic mucosa has 
also been reported to have higher levels of methylation in the distal (left side) 
compared to the proximal (right side) of the colon in both the ESR1 and MYOD loci 
(Horii et al, 2008). As higher incidences of colorectal cancer have been reported in 
the distal colon than in the proximal colon (Cancer Research UK, 2008), this 
suggests that methylation changes in the normal mucosa may be at least partially 
responsible for these observed differences.  
 
It has been proposed that Type A methylation is a gene-specific process and is 
modulated by tissue-specific factors such as environmental exposure or gene 
modifiers (Ahuja et al, 1998; Toyota & Issa, 1999). Initial studies have indicated that 
there is directionality in-cis to the process of age-related methylation with the spread 
of methylation emerging from methylation centres. Methylation centres have been 
described in many different systems and consist of highly repeated sequences such as 
alu repeat sequences. One example is the MYOD gene in which its methylation 
centre is in intron 1 and exon 2 of the gene and spreads progressively upstream with 
age (Ahuja et al, 1998). It has also been proposed that Type A methylation is 
responsible for the ‘field defect’ often observed in colorectal cancer (Issa et al, 
1994). A field defect can be described as an area of abnormal tissue, which precedes 
and predisposes to carcinogenesis. One theory suggests that ageing is associated with 
gene-specific hypermethylation, which then alters the physiology of the aged cells, 
and the affects of aberrant hypermethylation are then further modulated through cell 
selection. For example, methylation of ERS1 gene in the colon would promote the 
growth of these cells in the colon, and these cells would then progressively take the 
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place of normal cells, giving rise to an apparent increase in the process of age-related 
methylation (Issa, 1999). The multistep carcinogenesis process in the colon (as 
depicted in Figure 1.8) involves a series of pathways that may be activated or 
inhibited in a population of cells, which are then selected based on growth or survival 
advantages. In addition to the well-characterised pathways that are altered in 
colorectal tumours, aberrant methylation is believed to be another mechanism, which 
exists in aging cells and contributes to neoplastic transformation. Further research in 
this area is required to clarify its exact contribution to colorectal carcinogenesis and 
the etiology of age-related changes in methylation in normal-appearing cells.   
 
It should be recognised that recently there has been some discrepancy to the above 
theories proposed by Jean Pierre Issa; specifically, as to whether Type A and Type C 
methylated genes represents two distinct groups. Several studies have found age-
related increases in methylation for a number of Type C genes including MLH1 and 
p16INK4a (Belshaw et al, 2008; Kawakami et al, 2006). This suggests that the Type A 
and Type C classification first proposed by Toyato et al may not be as distinct as was 
first thought (Toyota & Issa, 1999). Nevertheless, recent quantitative methylation 
profiling has identified and classified field defects in colon cancer to a high degree of 
sensitivity and specificity (Belshaw et al, 2008). Thus, this type of analysis may 
assist in the early detection or determine the relative risk, of colorectal cancer. 
 
1.5.3 CpG Island Methylator Phenotype 
Although Type A methylation is frequent in colorectal cancer and precedes neoplasia 
in apparently normal cells, a number of genes are also thought to be specifically 
methylated in cancer tissues (Type C methylation, for Cancer-specific) (Toyota et al, 
1999a). Various studies have shown clustering of hypermethylation events in a 
number of colorectal tumours, and these tumours are described as having the CpG 
Island Methylator Phenotype (CIMP) (Ahuja et al, 1997; Toyota et al, 1999a). CIMP 
is associated with promoter methylation of multiple tumour suppressor genes in 
colorectal cancers and the choice of promoters to describe CIMP in colorectal cancer 
has been under the focus of much discussion. The most popular list utilised to 
describe CIMP includes p16INK4A; Calcium channel, voltage-dependent T type, alpha 
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1G subunit gene (CACNA1G); Insulin-like growth factor 2 (IGF2); suppressor of 
cytokine signalling 1 (SOCS1); Runt-related transcription factor 3 (RUNX3); 
Neurogenin 1 (NEUROG1); cellular retinoic acid binding protein 1 (CRABP1); 
MLH1 and the MINT1, MINT2 and MINT31 loci (Ahuja et al, 1997; Toyota et al, 
1999a). Recently, a group validated the use of these markers by carrying out 
methylation analysis on a large independent dataset. They found all of these markers 
had high sensitivity and specificity (Ogino et al, 2007). CIMP-high tumours are 
generally diagnosed if ≥3 of the gene promoters from an analysed panel are 
methylated. If <3 of the gene promoters are methylated then they are classed as 
CIMP-low (Weisenberger et al, 2006). CIMP is thought to contribute to colorectal 
cancer formation and progression by inactivating genes involved in cell cycle 
regulation, apoptosis and angiogenesis (Toyota & Issa, 1999). 
  
Microsatellite instability (MSI) in colorectal cancer tissue is a hallmark DNA 
mismatch repair deficiency. Thus, MSI is a characteristic feature of tumours arising 
in the familial colorectal cancer susceptibility syndrome hereditary non-polyposis 
colorectal cancer (HNPCC) or Lynch Syndrome (Liu et al, 1995a). Lynch Syndrome 
is due to germline  mutations of MLH1, MSH2, MSH6 and less frequently PMS2 (Liu 
et al, 1996). MSI can also arise  through somatic mutations and LOH (mainly MLH1 
and MSH2 loci) (Liu et al, 1995b; Lothe et al, 1995). However, the most frequent 
mechanism is through epigenetic silencing of MLH1 by promoter hypermethylation 
(Herman et al, 1998; Kane et al, 1997; Liu et al, 1996; Lothe et al, 1995). MSI is a 
result of defective mismatch-repair, leading to an increase frequency of insertional or 
deletional ‘slippage’ loops in microsatellite sequences during tumour cell DNA 
replication. This subsequently manifests in length variation mutations (MSI). 
Colorectal tumours with MSI are categorised into three groups, based on the number 
of markers showing instability. Markers include two mononucleotide repeat 
sequences Bat25 and Bat26 and three dinucleotide sequences D2S123, D5S346 and 
D17S250 (Bocker et al, 1997; Dietmaier et al, 1997). If more than 30 - 40% of 
markers display genomic instability then they are classed MSI-H(igh). MSI-L(ow) 
tumours display markers with less than 30 - 40% genomic instability. The third 
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group, MSS, are tumours where none of the markers tested exhibit instability 
(Boland et al, 1998). 
 
MSI has been linked to CIMP since multiple-methylated CpG islands have been 
detected in MSI tumours. One frequently methylated promoter as part of the CIMP 
phenotype is that of MLH1 (Ahuja et al, 1997). CIMP is also present in a proportion 
(approximately 45%) of colorectal adenomas in which MSI is rare. This provides 
circumstantial evidence that in mismatch-repair deficient tumours, CIMP precedes 
and may cause the mutator phenotype through silencing of MLH1 (Issa, 2000). 
Population-based studies have suggested that CIMP tumours are pathologically and 
genetically distinct. For example, the behaviour of CIMP tumours can vary 
depending upon their MSI status; CIMP positive, MSS phenotype in tumours is 
associated with poor prognosis (Ward et al, 2003). In addition, CIMP tumours are 
similar to MSI tumours in that they usually occur in older individuals and in females; 
and are right-sided, high grade and mucinous, poorly differentiated type (Hawkins et 
al, 2002; Samowitz et al, 2005; van Rijnsoever et al, 2002). Genetically, CIMP 
tumours, MSS and MSI-L/MSI-H are often associated with p53 mutations and a high 
rate of mutations in KRAS or BRAF (Kambara et al, 2004; Toyota et al, 2000). It is 
unknown why there is an association between BRAF and KRAS mutations and CIMP. 
However, it may be that these mutations are activating and are directly involved in 
causing CIMP. This was proposed by Ordway et al who found fibroblasts 
transformed by fos or ras had increased levels of DNMT expression and global 
hypermethylation (Ordway et al, 2004). 
  
Not all researchers in the field accept CIMP as a distinct phenotype. There have been 
many discussions as to whether CIMP tumours represent a biologically distinct group 
of colorectal cancers, or are an arbitrarily selected group from a continuum of 
tumours displaying different methylation levels at particular loci (Yamashita et al, 
2003). A feature of some of the papers that could not confirm the presence of CIMP 
was the use of unselected genes and/or non-quantitative, very sensitive methylation 
detection methods. All the papers that analysed the methylation profile of the 
originally described genes and methods confirmed CIMP (Issa et al, 2005). A recent 
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study attempted to resolve the controversy, utilising a robust new marker panel that 
classified CIMP positive tumours in colorectal cancer. A screen was performed using 
195 markers to assess the methylation status of 100 different CpG islands on more 
than 100 different tissue samples. The conclusions of this study were that CIMP-
positive tumours do indeed represent a distinct subset and sporadic cases of 
mismatch-repair deficient cancer occur almost exclusively as a consequence of 




1.6 Methods utilised for DNA methylation detection in 
tumours 
In some cases, aberrant methylation has been described as an early occurring event in 
carcinogenesis (Esteller et al, 1999a; Umbricht et al, 2001). Thus, DNA methylation 
detection in clinical samples may be useful for the early detection of cancer 
screening. In addition to early cancer detection, different tumour types in the same 
organ as well as in different tissues have been found to have distinct methylation 
profiles (Costello et al, 2000; Esteller et al, 2001a). Therefore, analysis of DNA 
methylation profiles could be used to identify ‘original sites’ of cancer development. 
Furthermore, since many hypermethylated genes are tumour suppressor genes, drugs 
that reverse the effects of DNA methylation and restore gene expression of these 
genes could be utilised. Indeed, 5-aza-2’deoxycytidine (Decitabine) has been FDA 
approved for the treatment of patients with myelodysplastic syndrome. Thus, the 
main clinical application of DNA methylation research relies heavily on the 
discovery of novel and useful methylation markers. As a result, there has been a 
recent surge in research involving genome-wide approaches for methylation analysis, 
in both tumour material and in normal tissues and cell types. Global approaches are 
high-throughput with regard to the number of loci examined at one time and are 
developed for methylation profiling and screening novel disease markers. Some of 
the methods described include: microarray expression profiling before and after 
DNA methylation inhibition, either by pharmacological intervention or DNMT 
knock-down (Gius et al, 2004; Suzuki et al, 2002); restriction landmark genomic 
scanning (RLGS) (Hatada et al, 1991); and affinity purification or 
immunoprecipitation of methylated DNA combined with microarray analysis or 
high-throughput sequencing (Down et al, 2008; Keshet et al, 2006; Zhang et al, 
2006). In contrast, fine mapping and quantitative analysis of DNA methylation in 
tumours is relatively high-throughput for samples, however, there is often a low 
throughput for individual gene analysis. Several methods are described, including: 
sodium bisulphite conversion and direct sequencing (Frommer et al, 1992); 
methylation-specific polymerase-chain reaction (PCR) (MSP) (Herman et al, 1996a); 
MethyLight, a fluorescence-based real-time PCR (Eads et al, 2000); and 
Pyrosequencing, a sequencing-by-synthesis technology (Uhlmann et al, 2002).  
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Each method, whether it is involving global methylation analysis or higher resolution 
mapping of individual CpG islands, has its advantages and disadvantages. Careful 
consideration of both the technical aspects of DNA methylation analysis and the 
biological material available for use need to be addressed before a study is carried 
out. Different types of materials and indeed the quality of the material may affect 
data interpretation. For example, methylation analysis of cancer cell lines, which 
represent a homogenous population of cells, will differ from the analysis of clinical 
samples, which can consist of a mixture different cell types. Tissue samples can 
contain a combination of tumour cells, normal cells, stroma, lymphocytes, 
leukocytes, and dead cells. Therefore, if the methylation status in the analysed region 
varies in any of these cell types compared to the tumour cells, or there are different 
admixtures of tumour cells in different samples, it may not be clear which 
methylation signal is actually being detected or quantified. A combination of 
microdissection, sufficient sample numbers, and a high level of accuracy and 
attention to detail can usually control for this variation. 
 
1.6.1 Fine mapping and quantitative analysis of DNA methylation   
Many of the high-resolution techniques utilised for DNA methylation detection and 
quantification usually involve the sodium bisulphite conversion of DNA prior to 
analysis. Sodium bisulphite is a mutagen that chemically modifies unmethylated 
cytosine residues to uracil residues. However, methylated cytosines cannot be 
modified in the same way and remain unchanged. Following the bisulphite 
conversion of DNA, methods such as MSP or direct sequencing can be carried out. 
For MSP analysis, PCR primers are designed to be complementary to unmethylated 
or methylated DNA sequences, therefore two PCRs are carried out on the same 
sample (Herman et al, 1996a). This method has a relatively high throughput with 
regard to samples but a low throughput for individual gene analysis. Therefore, MSP 
analysis of tumour samples is often used for the rapid analysis of a large number of 
samples for known markers. MSP analysis is limited by the fact that it is a qualitative 
method and false positive results are often obtained when PCR conditions are not 
optimal. Furthermore, the qualitative data obtained is based on the methylation status 
of only a few, or sometimes even one CpG dinucleotide. Direct sequencing of 
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bisulphite-modified DNA uses PCR primers that are specifically designed to amplify 
a region of interest and can include multiple CpG dinucleotides. All uracil and 
thymine residues are amplified as thymine and only 5-methylcytosine residues are 
amplified as cytosine. PCR products can then be sequenced directly, providing an 
average sequence for a population of molecules, or can be cloned and sequenced 
providing methylation maps of single DNA molecules. (Clark et al, 1994; Frommer 
et al, 1992). Bisulphite sequencing analysis provides a single base resolution and can 
be quantifiable, thus it is a highly informative method. The majority of reports 
involving methylation analysis of tumour DNA using bisulphite sequencing tend to 
be carried out on a small scale. There have however, been a few reports of large-
scale bisulphite sequencing across large regions of the genome (Eckhardt et al, 2006; 
Rollins et al, 2006) but these methods are expensive and labour intensive.  Similar to 
MSP, incomplete bisulphite conversion and PCR bias can prove to be problematic 
when interpreting sequencing data. Therefore, samples in which the methylation 
status is already known are often modified and sequenced alongside tumour samples 
to act as controls for these discrepancies. 
 
Unlike MSP and bisulphite sequence analysis, MethyLight allows for the rapid 
quantitative methylation analysis of many samples at multiple gene loci (Eads et al, 
2000; Eads et al, 1999). MethyLight involves the amplification of sodium bisulphite-
converted DNA by fluorescence based, real-time quantitative PCR (Taqman), using 
gene-specific primers that flank an oligonucleotide probe with 5’ fluorescence 
reported dye and a 3’ quencher dye. Primers and probe sequences are both designed 
to overlap potential methylation sites. Therefore, there is sequence discrimination at 
the level of PCR amplification and the probe, which yields a high level of specificity. 
In addition, MethyLight is a highly quantitative method that determines the relative 
amounts of a particular methylation pattern compared to a control reaction, rather 
than detecting and measuring all methylated CpG dinucleotides in a heterogeneous 
DNA sample. Pyrosequencing is another technology that also involves real-time 
technology and has been combined with sodium bisulphite conversion of DNA to 
quantify methylation (Uhlmann et al, 2002). Pyrosequencing is a sequencing-by-
synthesis technique that relies on luminometric detection of pyrophosphate release 
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upon nucleotide incorporation through a cascade of enzymatic reactions. The data 
that is produced from this technology are actual sequences rather than fluorescent 
data, which are obtained from other PCR-based techniques such as MethyLight. 
Pyrosequencing has recently been used to measure methylation levels across the 
entire CpG island region of the cyclin-dependent kinase inhibitor 2B gene 
(CDKN2B) (p15INK4B) in myeloid malignancies (Brakensiek et al, 2007). Although 
only 15 CpG dinucleotides were measured at a time, 114 samples were analysed 
which meant 7762 individual methylation sites were analysed. This demonstrates that 
pyrosequencing is a high throughput method, which can be utilised for scanning 
large regions of CpG islands unlike MSP and bisulphite sequencing. Pyrosequencing 
is slowly superseding these conventional methods, although the technology does 
require specialist equipment, which is relatively expensive. 
 
1.6.2 Global analysis of DNA methylation 
Genome-wide mapping of DNA methylation is a less direct method of measuring 
and quantifying methylation in tumours, and at present, all methods are relatively 
expensive and labour-intensive. However, as mentioned previously, genome-wide 
mapping provides high-throughput analysis of individual loci and is extremely 
informative for discovering novel DNA methylation markers. RLGS was one of the 
first technologies developed for mapping global DNA methylation patterns (Hatada 
et al, 1991). RLGS uses a two-dimensional electrophoresis system and radiolabelled 
methylation sensitive restriction endonuclease sites to create ‘landmarks’ which can 
be observed on an autoradiograph. Highly reproducible profiles can display over 
2000 radiolabelled restriction landmark sites in a single assay. Paired samples, which 
are ideally matched tumour and normal tissue profiles, are analysed alongside each 
other and methylation is detected from the absence or decrease in signal intensity 
(Rush & Plass, 2002). Distinguishing bands are then verified by subsequent cloning 
and sequencing in order to identify novel methylated sites. The main disadvantage of 
this method is the fact that novel methylation markers can only be detected at a small 
number of restriction sites, and therefore there is limited coverage. Moreover, not all 
restriction sites in the cloned libraries will be associated with gene loci, thus the 




Unlike RLGS, microarray-based methylation analysis can be used to analyse a set of 
specific candidate genes. Several reports have demonstrated that the methylation 
status of CpG islands in multiple and specific genes can be analysed simultaneously 
using microarray profiling (Adorjan et al, 2002). The microarray technology 
commonly utilises a pair of DNA oligonucleotides, one that reflects the methylated 
status of a CpG dinucleotide (CpG) and one reflecting the unmethylated status of a 
dinucleotide (TpG) following sodium bisulphite treatment. The oligonucleotides are 
spotted and immobilised onto an array and hybridised to labelled PCR fragments 
from a sample. This technique was utilised in the analysis of 232 CpG dinucleotides 
located in CpG rich regions of 56 different genes, randomly selected from a panel of 
genes associated with tumorigenesis. From the analysis of over 70 samples from four 
different human tumour types and matched controls, this method was shown to assist 
in predicting known tumour classes and discovering novel ones (Adorjan et al, 
2002). In addition to combining sodium bisulphite pre-treatment with microarray 
analysis, restriction enzyme digestion (Schumacher et al, 2006) and affinity 
purification methods (Rauch et al, 2008) have also been coupled with microarray 
technology to detect global DNA methylation changes. The microarray-based 
profiling approach can also be used to detect novel methylation markers. One study 
screened over 10,000 genes for promoter hypermethylation in the RKO colorectal 
cancer cell line following treatment with the de-methylating agent 5-aza-2’-
deoxycytidine and the HDAC inhibitor TSA, and subsequent cRNA hybridisation to 
a 12,599 oligonucleotide array (Suzuki et al, 2002). They identified a substantial 
number of genes which were upregulated following treatment, and subsequently 
confirmed a novel group of genes that were preferentially hypermethylated in 
colorectal cancer. One of the major disadvantages of using this approach is that 5-
aza-2’-deoxycytidine is highly toxic to cells and affects the expression of many 
genes. Therefore, microarray expression profiling studies may not actually identify 
methylation as such; rather genes that respond to 5-aza-2’-deoxycytidine treatment. 
This can be demonstrated in reports that have shown that nearly half of the genes 
unregulated by 5-aza-2’-deoxycytidine treatment do not actually contain CpG islands 
(Shames et al, 2007; Suzuki et al, 2002). These genes may be regulated by long 
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range control through the methylation of ‘CpG islands shores’ mentioned previously 
(Irizarry et al, 2009). Alternatively, it has been shown recently that DNA methylation 
at some low CpG density promoters is inversely correlated with gene expression 
(Rakyan et al, 2008). Therefore, some of the genes upregulated following 5-aza-2’-
deoxycytidine may include non-CpG island promoter genes.  
 
Finally, recent high-throughput approaches have used protein affinity and 
immunoprecipitation to enrich methylated sequences prior to microarray or large-
scale sequencing analysis. These methods are an improvement on the two methods 
discussed above as they provide a higher level of sensitivity and specificity. DNA 
which has been sonicated or digested is either immunoprecipitated using a 
monoclonal antibody to 5-methylcytosine (methylated DNA immunoprecipitation; 
MeDIP) (Weber et al, 2005) or purified using the DNA-binding domain of a methyl-
CpG-binding protein (methyl-binding domain affinity purification; MAP) (Cross et 
al, 1994). When MeDIP is coupled with whole-genome microarray analysis (MeDIP-
chip, or ChIP on chip), the reference sample is a sample of input DNA and the test 
sample is the immunoprecipitated DNA. Methylated sequences are identified by 
comparing the fluorescent signal from probes corresponding to known sequences in 
the test and reference samples (Keshet et al, 2006). MeDIP has also been combined 
with large-scale genome sequencing (MeDIP-seq) (Pomraning et al, 2009). 
Following MeDIP purification, DNA samples are processed to generate in vitro 
sequencing libraries. These libraries are then sequenced using Solexa/Illumina 
sequencing, which is currently able to produce approximately 1.5 Gb of sequence 
data in around three days (Pomraning et al, 2009). Genome-wide MeDIP-seq 
analysis has been used to map methylation patterns in a number of genomes (Down 
et al, 2008; Pomraning et al, 2009). However, as of yet, it has not been utilised for 
mapping DNA methylation patterns in tumours. The antibody used for the 
enrichment of methylated DNA sequences has been to shown to recognise 
methylation in regions with a CpG density of only around 2-3% (Keshet et al, 2006). 
Therefore, whilst MeDIP may be very useful for detecting aberrantly methylated 
CpG islands, for example in tumours, this method may not be sensitive enough for 
mapping methylation in the majority of the genome where the CpG content is 
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considered to be less than 2% (Keshet et al, 2006). Moreover, as this is the case, 
MeDIP could introduce bias toward certain types of genomic sequences where the 
CpG density is higher in some regions than others. In an attempt to correct for this, 
an algorithm known as Bayesian tool for methylation analysis (Batman) was 
developed (Down et al, 2008). An alternative approach that was recently developed, 
enriches specifically for unmethylated DNA using CXXC affinity purification (CAP; 
X can represent any residue). The cysteine-rich CXXC3 domain was linked to a 
sepharose matrix and the DNA was fractionated over the CXXC column. Eluted 
DNA following CAP is believed to purify genomic DNA based on CpG density and 
methylation status. (Illingworth et al, 2008). As with MeDIP-seq, this method was 
utilised for scanning methylated CpG islands in human tissues and cell types and has 
not yet been used for screening aberrantly methylated CpG islands in tumours (see 
section 1.2.1 for more details on this study).   
 
The recently developed genome-wide methods discussed above have revolutionised 
the analysis of methylated DNA. Although, as with all methylation analysis 
techniques, they have their limitations. Following all screening methods, the 
relationship between methylation and expression needs to be further explored. It 
cannot be assumed that tumour-specific methylation is associated with aberrant 
expression. Furthermore, when carrying out large-scale screening methods, there is 
always a risk of acquiring false positives. Therefore, researchers need to carefully 
consider how stringent the screen will be and apply the relevant statistics to test for 
the likelihood of attaining a false positive result. It is apparent that both global and 
locus-specific changes in methylation are involved in cellular transformation, and 
although there has been a recent increase in research carried out to investigate global 
epigenetic changes in cancer, studies involving a single candidate gene approach are 
still under investigation. The focus of the work presented in this thesis is on one such 
candidate gene; 14-3-3σ, for which there is evidence of aberrant methylation in 






There has been a great interest in the 14-3-3σ gene as it is a transcriptional target of 
p53, promoting stable cell cycle arrest upon its activation and is involved in 
regulating translational control during mitosis (Hermeking et al, 1997; Wilker et al, 
2007). Furthermore, data has shown that it is frequently deregulated in primary 
human tumours suggesting that 14-3-3σ may be an important mediator of p53’s 
tumour suppressive function in vivo.  
 
14-3-3σ belongs to a large family of 14-3-3 encoded proteins which are highly 
conserved, acidic, small polypeptides ranging from 28-33 kDa, and are found in all 
eukaryotic species (Aitken et al, 1992; Ferl et al, 2002; Wang & Shakes, 1996). 14-3-
3 proteins work as adaptor molecules and are able to move freely from the cytoplasm 
to the nucleus and vice-versa (Mhawech, 2005). The proteins can form heterodimers 
or homodimers and function by binding to phosphorylated protein ligands on 
serine/threonine residues in the consensus binding motif RSXpSXP (Muslin et al, 
1996). A small number of proteins can also associate with 14-3-3 proteins 
independently of this motif such as the protein Bax (Pozuelo Rubio et al, 2004; 
Seimiya et al, 2000). 14-3-3 proteins regulate a number of different proteins by 
cytoplasmic sequestration, activation/repression of enzymatic activity, prevention of 
degradation, transactivation, promotion/inhibition of protein interactions, and 
assisting in protein modifications. As a result, 14-3-3 protein products have many 
diverse functions including key roles in cell cycle regulation and cellular signalling. 
In humans there are seven different expressed 14-3-3 isoforms: β,γ, ε, η, σ, τ (also 
called θ), and ζ (Hermeking, 2003). 14-3-3σ, also known as human epithelial 
marker-1 (HEM-1), or stratifin (SFN), was originally identified as a human 
mammary epithelial marker and interestingly, its expression was significantly 
reduced in human breast cancer cells (Prasad et al, 1992). 14-3-3σ is unique in that it 
has tissue-specific expression restricted to epithelial cells and keratinocytes, 
however, most other 14-3-3 isoforms are expressed ubiquitously (Hermeking, 2003). 
Phylogenetic analysis shows that 14-3-3σ is the most divergent isoform and lacks 
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introns which is a unique feature of the gene (Wilker et al, 2005). In addition, and 
more importantly, 14-3-3σ is structurally different compared to other 14-3-3 
isoforms. 14-3-3σ has a unique amino acid patch in its second ligand-binding site, 
which consists of amino acids Met202, Asp204, and His206. This site may be 
responsible for the binding of certain ligands that are not recognized by the other 14-
3-3 proteins and may account for 14-3-3σ-specific function (Benzinger et al, 2005; 
Wilker et al, 2005). 
 
1.7.2 Regulation and function of 14-3-3σ  
It has been reported that 14-3-3σ is regulated by different mechanisms, the major 
regulator being the tumour suppressor gene, p53. Upon DNA damage, p53 is 
activated and this subsequently leads to cell cycle arrest or apoptosis in order to 
maintain genetic stability. Cell cycle arrest can occur at the G1/S checkpoint, which 
is mediated by the interaction of the p53-inducible p21WAF1/CIP1 gene with the cyclin-
dependent kinase 2 (cdk2)/cyclin E complex (el-Deiry et al, 1993; Xiong et al, 1993).  
Alternatively, cell cycle arrest in G2 is induced by p53-activated 14-3-3σ. The 
combination of both p21WAF1/CIP1 and 14-3-3σ results in a coordinated arrest in which 
cells are blocked in either G1 or G2, prolonging the lifetime of the cell and thus 
mediating a significant part of the cell-cycle regulatory effects of p53 because of 
DNA damage. 14-3-3σ induction following DNA damage was first determined from 
a serial analysis of gene expression (SAGE) screen (Hermeking et al, 1997). SAGE 
is a method used for the comprehensive analysis of gene expression patterns. SAGE 
involves the sequencing and quantification of tags, which are representative of the 
RNA species present in a given sample. p53-mediated G2 arrest was not fully 
understood, therefore SAGE was utilised to measure gene expression changes in the 
colorectal cancer cell line HCT116 (wild-type for p53) following irradiation. SAGE 
determined that a tag representing 14-3-3σ was expressed at higher levels in the 
irradiated G2 arrested cells compared to exponentially growing non-irradiated cells. 
To confirm the SAGE results and determine whether 14-3-3σ is regulated by p53, 
Hermeking et al first investigated the induction of 14-3-3σ following DNA damage 
in a series of colorectal cell lines using Northern blot analysis. p53 wild type 
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colorectal cancer cell lines expressed high levels of 14-3-3σ upon DNA damage. 
However, colorectal cancer cell lines with mutated p53 were unable to induce 14-3-
3σ. Subsequent investigation found that p53 can directly transactivate 14-3-3σ 
expression by binding to a p53 responsive element 1.8kb upstream from the 
transcriptional site of 14-3-3σ. Mutated p53 cannot bind the responsive element of 
14-3-3σ and is therefore unable to induce 14-3-3σ expression. Thus, it was 
concluded 14-3-3σ expression is induced following DNA damage and induction of 
14-3-3σ is mediated by p53 (Hermeking et al, 1997).  
 
DNA damage can also activate BRCA1 which acts synergistically with p53 to 
activate 14-3-3σ expression (Aprelikova et al, 2001; Yarden et al, 2002). BRCA1 
itself, is activated by upstream DNA damage response proteins such as ataxia 
telangiectasia and Rad 3-related (ATR)/ataxia telangiectasia mutated homolog 
(ATM) and cell cycle checkpoint kinase (Chk2) protein kinases (Yarden et al, 2002). 
Irradiation of BRCA1-/- cells results in an unsustainable G2/M growth arrest, which is 
similar to the phenotype observed in irradiated 14-3-3σ-/- cells (Chan et al, 1999). 
This further emphasises the functional affects of reduced 14-3-3σ expression in 
BRCA1 deficient cells following DNA damage (Aprelikova et al, 2001).  
 
A positive feedback loop exists in the 14-3-3σ pathway since the protein has been 
shown to regulate p53 (Yang et al, 2003). In vitro experiments demonstrated that 14-
3-3σ stabilises p53 by inhibiting Mdm2-mediated p53 degradation. 14-3-3σ affects 
Mdm2 activity by inhibiting Mdm2 ubiquitin ligase function and interfering with 
nuclear export of Mdm2 (Yang et al, 2003). Furthermore, 14-3-3σ was shown to 
increase p53 transcriptional activity and facilitate cooperative p53 dimer-dimer 
formation, stabilising p53 DNA binding and thus potentiating its transcriptional 
activity toward target genes (Yang et al, 2003). As mentioned previously, the 
downstream effect of 14-3-3σ transactivation by p53 results in G2/M arrest. 14-3-3σ 
protein causes G2/M arrest by sequestering the cell division cycle 2 (CDC2)-cyclin 
B1 in the cytoplasm. This blocks the interaction of CDC2-cyclin B1 with substrates 
which have to be phophorylated to achieve a G2/M transition, thus providing time for 
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sufficient DNA repair (Chan et al, 1999; Hermeking et al, 1997; Peng et al, 1997). 
14-3-3σ also binds to G1-specific Cdks such as Cdk2 and Cdk4. Therefore, 14-3-3σ 
may additionally be involved in G1 arrest in cells (Laronga et al, 2000). Figure 1.9 
illustrates 14-3-3σ function downstream and upstream of p53 upon DNA damage. 
 
Figure 1.9: 14-3-3σ causes stable G2/M cell-cycle arrest mediated through 
p53 or BRCA1 after induction of DNA damage.  
DNA damage leads to dephosphorylation of Ser376 producing a 14-3-3 binding 
site in p53. 14-3-3σ is transactivated by p53 and induced 14-3-3σ may contribute 
to further p53 activation in a positive feedback loop. 14-3-3σ sequesters Cdks in 
the cytoplasm causing cell cycle arrest in G2 (CDC2) as well as G1 (Cdk2). DNA 
damage activates BRCA1 which can also induce 14-3-3σ expression.  
Source: Hermeking et al, 2003. 
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In addition to the p53 and BRCA1 pathways, 14-3-3σ is regulated by the p53 
homologues p63 and p73, which have both been reported to be involved in 
controlling cell cycle and/or apoptosis (el-Deiry et al, 1993; Jost et al, 1997; Yang et 
al, 1998). The p63 gene encodes two major isoforms; transcriptionally active p63 
(TAp63) and the dominant negative p63 (∆Np63) (Yang et al, 1998). 14-3-3σ 
expression in keratinocytes within the epidermis of the skin varies depending upon 
the level of differentiation of the cell (Pellegrini et al, 2001). The suppression of 14-
3-3σ in the basal epidermal layer of skin is mediated by ∆Np63 binding to p53 
responsive elements in the 14-3-3σ promoter. 14-3-3σ is highly expressed in 
terminal differentiated (stratifying) keratinocytes as ∆Np63 is absent and suppression 
of 14-3-3σ is lifted (Ghahary et al, 2005). The other p53 homologue, p73, activates 
14-3-3σ suggesting that the G2/M signalling pathway is conserved between p53 and 
p73 (Zhu et al, 1998). It has even been proposed that 14-3-3σ may be the primary 
cellular target of p73 as activation of 14-3-3σ by p73 is 3-6 times higher than by p53 
(Zhu et al, 1998). 14-3-3σ is also regulated post-transcriptionally by the estrogen-
induced zinc finger protein (EFP) (Urano et al, 2002). EFP is a RING-finger-
dependent ubiquitin ligase (E3) and targets the proteolysis of 14-3-3σ. Moreover, 
overexpression of EFP in vivo, generates tumours thought to be due to the loss of 14-
3-3σ and the induction of genomic instability (Urano et al, 2002). Finally, in various 
cancers, aberrant expression and associated CpG methylation of 14-3-3σ has been 
observed (Ferguson et al, 2000; Mhawech et al, 2005). Figure 1.10 shows the 




Figure 1.10: Regulation of 14-3-3σ in normal and cancer cells.  
DNA damage leads to increased expression of 14-3-3σ mediated by p53 and BRCA1. p73 
and ∆Np63 suppress 14-3-3σ expression. In addition, CpG methylation at the promoter 
region has been shown in cancer cells to silence 14-3-3σ expression. At the protein level, 
14-3-3σ levels are downregulated by proteolysis. This is regulated by an oestrogen 
dependent increase in expression of EFP, an E3 ubiquitin (Ub) ligase. 
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As well as its role in inducing cell cycle arrest following DNA damage, a recent 
report by Wilker et al demonstrated that 14-3-3σ is involved in regulating translation 
during mitosis and is required for normal mitotic progression (Wilker et al, 2007). 
Throughout mitosis and directly afterwards, translation in mammals changes with a 
suppression of cap-dependent translation and a corresponding increase in cap-
independent translation (Pyronnet et al, 2001). This is because mRNAs for cell cycle 
proteins, such as c-myc, contain an internal ribosome entry site (IRES) domain that 
allows for their rapid translation during mitosis (Pyronnet et al, 2000). The majority 
of ligands bound to 14-3-3σ during mitosis and immediately following mitosis, are 
proteins involved in translation, including a number of initiation factors involved in 
mediating cap-dependent translation such as the eukaryotic initiation factor 4B 
(eIF4B) (Wilker et al, 2007). eIF4B is required for the translation of mRNAs with a 
5’ cap structure and recruits ribosomes to this site. Cells in which 14-3-3σ is knocked 
down are unable to suppress cap-dependent translation or stimulate cap-independent 
translation throughout or immediately after mitosis (Figure 1.11). Thus suggesting 
that 14-3-3σ is involved in the switch from cap-dependent to cap-independent 
translation, and consequentially plays an important role in regulating cell cycle 
progression (Wilker et al, 2007). More specifically, expression of a cell cycle protein 
cyclin-dependent kinase cdk11, which contains an IRES domain, is reduced in 14-3-
3σ depleted cells which results in impaired mitosis (Wilker et al, 2007). It is very 
likely that other cell cycle cap-independent mRNAs are also affected by the defective 
switch in 14-3-3σ regulated translation, some of which may also contribute to the 
aberrant mitotic phenotype observed in 14-3-3σ depleted cells. Wilker et al went on 
to investigate the cellular defects in the 14-3-3σ knock-down cells and proposed how 
downregulation of 14-3-3σ may contribute to cancer progression. This will be 
discussed in more detail in the following section. 
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Figure 1.11: 14-3-3σ plays a critical role in cap-dependent and cap-independent 
mRNA translation during mitosis.  
(a) When 14-3-3σ is bound to eIF4B, it cannot bind to the 5’ cap. Therefore, cap-
dependent translation is suppressed and only mRNA sequences containing an IRES 
domain undergo translation through a cap-independent mechanism. (b) When 14-3-3σ is 
absent, eIF4B can bind the 5’ cap initiating cap-dependent translation and cap-
independent translation is not induced.  
Source: (Wynshaw-Boris, 2007)  
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1.7.3 The role of 14-3-3σ in cancer 
The first study to examine 14-3-3σ expression demonstrated that 14-3-3σ mRNA 
was downregulated in a number of breast cancer cell lines (Prasad et al, 1992). 
Similarly, complete loss of 14-3-3σ protein expression was detected in 46% of 
keratinocytes that had undergone transformation to basal cell carcinomas (Lodygin et 
al, 2003). In contrast, 14-3-3σ overexpression at both the mRNA and protein level 
has been detected in hematological malignancies (Motokura et al, 2007), and two 
studies have reported increased levels of 14-3-3σ protein in colorectal cancer 
(Perathoner et al, 2005; Tanaka et al, 2004). The loss of 14-3-3σ expression in cancer 
may be due to mutational inactivation of 14-3-3σ since the 14-3-3σ gene is localised 
on chromosome 1p35, a region frequently deleted in cancer. However, in a number 
of studies, mutational inactivation of 14-3-3σ has not been observed (Gasco et al, 
2002a; Lodygin et al, 2003). 
 
As mentioned in the previous section, 14-3-3σ plays an important role in p53 
mediated G2/M arrest following DNA damage and in regulating protein synthesis 
during mitosis. In an experimental system using cancer cells, both 14-3-3σ alleles 
have been inactivated in the colorectal cancer cell line HCT116 (wild-type for p53) 
to generate somatic 14-3-3σ knock-outs. Irradiated HCT116 14-3-3σ-/- cells initially 
arrest in the G2 phase but are unable to maintain an arrested state. The CDC2-
cyclinB1 complexes migrate to the nucleus, which results in mitotic catastrophe and 
cell death (Chan et al, 1999). Mitotic catastrophe is likely to occur due to the extent 
of DNA damage. Indeed, this theory is consistent with a study which showed that 14-
3-3σ-/- cells have frequent loss of telomeric repeat sequences, increased frequency of 
chromosome end-end associations and terminal non-reciprocal translocations (Dhar 
et al, 2000). Therefore, even without radiation induced DNA damage, 14-3-3σ-/- cells 
have a greater frequency of chromosomal aberrations. A similar phenotype was 
observed in studies carried out by Wilker et al in which 14-3-3σ was stably knocked 
down in various cancer cell lines. Due to the defective switch in the mechanism of 
translation, the mitotic expression of a cap-independent cyclin-dependent kinase 
cdk11 was reduced, which resulted in impaired cytokinesis, loss of Polo-like kinase-
 
 55 
1 (Plk1) at the midbody, and an increase in the number of binucleated and fused cells 
(Wilker et al, 2007). Interestingly, the affects observed from 14-3-3σ  knock-down 
could be reversed using the drug rapamycin, which suppresses cap-dependent 
translation and increases cap-independent translation during mitosis. Re-introduction 
of the cyclin-dependent kinase cdk11 into the  knock-down cells however, only 
resulted in partial rescue of the defective mitosis phenotype (Wilker et al, 2007). This 
suggests that the expression of other cell cycle proteins via a cap-independent 
mechanism may also be affected by reduced 14-3-3σ levels, which subsequently 
contributes to the observed aberrant mitotic phenotype. The formation of binucleate 
cells as a result of impaired cytokinesis is associated with tumorigenesis and may 
underlie genomic instability (Fujiwara et al, 2005). Therefore, it is hypothesised that 
loss of 14-3-3σ contributes to tumorigenesis through aberrant mitotic translation and 
consequential impaired mitotic exit (Wilker et al, 2007). It should also be noted that 
primary keratinocytes from the normal human epidermis evade senescence because 
of 14-3-3σ downregulation. It is still unclear how loss of 14-3-3σ leads to this 
evasion, however, downregulation of 14-3-3σ is associated with the maintenance of 
telomerase activity and a strong reduction in p16INK4A expression (Dellambra et al, 
2000). These genetic alterations have been shown to contribute to the 
immortalisation of keratinocytes in vitro (Dickson et al, 2000; Kiyono et al, 1998). 
Thus, downregulation of 14-3-3σ in keratinocytes may promote immortalisation, a 
key feature that can lead to cell transformation. 
 
Conversely, knock-in studies in cycling cancer cells using adenoviral infection have 
demonstrated that 14-3-3σ overexpression leads to an increase in cell size, with cells 
arresting at G2/M. Further infection results in cells re-entering a synthetic phase with 
a number of cells displaying a DNA content of 4N and more. This suggests that the 
cells undergo an uncoordinated arrest in which cycles of synthesis occur without 
mitosis (Hermeking et al, 1997). In separate studies focusing purely on the tumour 
suppressive function of 14-3-3σ, it was shown that induced 14-3-3σ expression 
inhibited the tumorigenicity of HER2 transformed NIH-3T3 cells. Moreover, 14-3-
3σ expression reduced the tumorigenicity of these oncogene expressing cells in a 
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xenograft mouse model, further reinforcing its role in inhibiting tumour growth 
(Yang et al, 2003). 
 
Adding even more complexity to the exact role 14-3-3σ plays in tumorigenesis, one 
report has shown that 14-3-3σ is also implicated in the protection of cancer cells 
from apoptosis (Samuel et al, 2001). 14-3-3σ -/- colorectal cancer cell lines are 
sensitised to chemotherapy-induced apoptosis. Furthermore, it was shown that the 
reintroduction of 14-3-3σ into these cells delays the apoptotic signal by sequestering 
the pro-apoptotic protein Bax into the cytoplasm. The authors proposed that p53-
induced G2/M arrest is accompanied by a separate mechanism that delays apoptosis 
(Samuel et al, 2001).  
 
Collectively, aberrant 14-3-3σ expression and function are common features of 
cancer (Prasad et al, 1992; Tanaka et al, 2004). Although, research involving 14-3-
3σ has created a paradox. 14-3-3σ is silenced in a number of different cancers whilst 
overexpressed in others (Ferguson et al, 2000; Tanaka et al, 2004). In addition, 14-3-
3σ appears to act as a tumour suppressor as it is a negative regulator of the cell cycle 
and is involved in regulating translation during cell division (Hermeking et al, 1997; 
Wilker et al, 2007). The tumorigenicity experiments carried out by Yang et al further 
support this notion (Yang et al, 2003). However, 14-3-3σ has also been implicated in 
protecting cancer cells from apoptosis and overexpression of 14-3-3σ can also lead 
to an impaired cell cycle arrest and cycling of DNA synthesis occur without mitosis 
(Hermeking et al, 1997; Samuel et al, 2001). Therefore, it might be proposed that 14-
3-3σ expression has to be exquisitely controlled within the cell in order for it to 
function appropriately. Epigenetic changes at the promoter region of 14-3-3σ could 
hold the key to this type of regulation. 
 
1.7.4 Methylation of 14-3-3σ in normal tissue 
14-3-3σ expression is restricted to different cell types, with the majority of epithelial 
cells expressing 14-3-3σ (Nakajima et al, 2003). However, fibroblasts (Ghahary et al, 
2005), lymphocytes (Bhatia et al, 2003), and brain tissues (Nakajima et al, 2003) do 
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not express 14-3-3σ. A recent report by Oshiro et al demonstrated that the normal 
cell type-specific expression of 14-3-3σ is regulated by epigenetic mechanisms 
(Oshiro et al, 2005). In normal 14-3-3σ positive cells, (these included epithelial cells 
from the airway, prostate, breast, skin and mouth) the 14-3-3σ promoter region was 
completely unmethylated; the associated histones hyperacetylated; unmethylated at 
histone H3K9; and an accessible chromatin structure was exhibited. In non-
cancerous 14-3-3σ negative cells, (these included skin fibroblasts, lymphocytes, 
chondrocytes, bone marrow, heart and kidney) the 14-3-3σ promoter region was 
fully methylated; the associated H3 and H4 histones were hypoacetylated, 
methylated at histone H3K9; and an inaccessible chromatin structure was found 
(Oshiro et al, 2005). This study demonstrated that 14-3-3σ belongs to a large 
spectrum of cell type-specific genes that are regulated by epigenetic mechanisms. 
Given the important role of 14-3-3σ in regulating cell cycle arrest and protein 
translation during mitosis, it is surprising to find that the protein is not expressed in 
some cell types. It must however be considered that 14-3-3σ could be expressed at 
extremely low levels in these cell types and the sensitivity of current transcriptional 
assays may be limited. 
 
1.7.5 Aberrant methylation of 14-3-3σ in cancer 
As mentioned previously, an early study found that 14-3-3σ expression was 
dramatically reduced in a number of transformed breast cancer cell lines compared to 
non transformed human mammary epithelial cells (Prasad et al, 1992). Eight years 
later, the mechanism underlying the observed decrease of 14-3-3σ expression in 
breast cancers was deduced. LOH and intragenic mutations of 14-3-3σ were not 
found and instead epigenetic silencing was demonstrated to be the primary 
mechanism for reduced 14-3-3σ expression (Ferguson et al, 2000).  
Hypermethylation of 14-3-3σ was detected in 91% (75/82) of breast tumours and this 
was associated with very low levels of 14-3-3σ expression (Ferguson et al, 2000). 
Furthermore, an impaired G2/M cell cycle checkpoint was identified in the 14-3-3σ 
silenced breast cancer cell lines, consistent with previous 14-3-3σ knock-out studies 
in colorectal cancer (Chan et al, 1999). Inactivation of 14-3-3σ by epigenetic 
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silencing has also been observed in other tumour types, some of which include 
prostate (Lodygin et al, 2004), gastric (Suzuki et al, 2000), hepatocellular (Iwata et 
al, 2000) and small-cell lung carcinomas (Osada et al, 2002) (Table 1.3 provides a 
more comprehensive list). In colorectal cancer, 14-3-3σ hypermethylation is a rare 
event (Ide et al, 2004; Suzuki et al, 2000). Suzuki et al showed 14-3-3σ 
hypermethylation in only one out of eight colorectal cancer cell lines. Ide et al 
demonstrated that all seven colorectal cancer cell lines studied were unmethylated 
and 70% (7/10) microdissected fresh tumour tissues were unmethylated.  
 
Reversal of epigenetic effects by 5’-aza-2’-deoxycytidine treatment has 
demonstrated that 14-3-3σ can be re-expressed in breast (Ferguson et al, 2000) or 
gastric (Suzuki et al, 2000) cell-lines. This suggests that reduced 14-3-3σ expression 
is due to methylation of CpG sites within the 14-3-3σ gene. It is believed that 14-3-
3σ hypermethylation is an early event during breast cancer formation and may be the 
case in the progression of other cancers (Umbricht et al, 2001). 14-3-3σ 
hypermethylation frequency increases during breast cancer progression and has been 
found in adjacent normal breast epithelial cells but not in individuals without 
evidence of breast cancer (Umbricht et al, 2001). 14-3-3σ hypermethylation and 
associated inactivation in mammary epithelial tissue can be classed as a field defect; 
occurring in pre-dysplastic tissue preceding carcinogenesis indicating that 14-3-3σ 












86% (43/50) primary tumours 
100% (32/32) microdissected 
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Liver 
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89% (17/19) primary HCC 
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(Lee et al, 2002) 
Lung  33% (8/24) microdissected primary 
SCLC 
69% (9/13) SCLC cell lines 
57% (4/7) large-cell NSCLC cell lines 




(Osada et al, 2002) 
Skin 68% (28/41) microdissected primary 
basal cell carcinoma 




35% (32/92) primary oral SSC 
50% (3/6) oral dysplasia 
 
56% (20/36) vulval SCC 




(Gasco et al, 2002a) 
 
 
(Gasco et al, 2002b) 
Ovarian 
cancer 
79% (11/14) clear cell adenocarcinoma 
26% (5/19) serous adenocarcinoma 
36% (4/11) mucinous adenocarcinoma 
20% (2/10) endometioid 
adenocarcinoma 
 
58% (7/12) ovarian cancer cell lines 
30% (3/10) IHC positive 















(Akahira et al, 2004) 
Prostate 
cancer 
100% (41/41) microdissected primary 
prostate adenocarcinomas 
 





(Lodygin et al, 2004) 
 
 
(Urano et al, 2004) 
Table 1.3: Frequency of 14-3-3σ CpG methylation in different types of epithelial tumours 
and techniques utilised for methylation detection.  
CRC = colorectal carcinoma; HCC = hepatocellular carcinoma; IHC = immunohistochemistry; 
NSCLC = non- small cell lung cancer; SCLC = small cell lung carcinoma; SSC = squamous 
cell carcinoma; VIN = vulval intraepithelial hyperplasia; MSP = Methylation-specific PCR; 
SSCP = Single-strand conformation polymorphism.  




Very few studies have investigated the relationship between 14-3-3σ methylation 
and p53 status in human cancers. Given that p53-induced 14-3-3σ expression is 
critical in maintaining G2/M arrest following DNA damage (Chan et al, 1999; 
Hermeking et al, 1997), it might be hypothesised that inactivation of 14-3-3σ and 
p53 mutations are mutually exclusive occurring events. p53 plays a crucial role in 
preserving genomic stability and 14-3-3-/- cells are defective in maintaining G2/M 
arrest following DNA damage, exhibiting chromosomal anomalies even in cancer 
cells with wild-type p53 (Chan et al, 1999). Therefore, it could be proposed that 
methylation and subsequent inactivation of 14-3-3σ may be determined by p53 
status. Suzuki et al found that there was no difference in the frequency of p53 
mutations between 14-3-3σ methylated and unmethylated cell lines. Although in 
gastric cancers, p53 mutations were at a lower frequency in 14-3-3σ methylated 
cases compared to unmethylated cases (p =0.03, n =16) (Suzuki et al, 2000). 
Similarly methylation of 14-3-3σ is detected more frequently in squamous cell 
carcinomas with wild-type p53 than cancers with mutant p53, although the difference 
just fails to reach significance (p = 0.074, n = 92) (Gasco et al, 2002a). These reports 
are inconclusive, however, they do suggest that there is no causal relationship 
between p53 status and 14-3-3σ methylation in cancer cells.  
 
A number of reports suggest that 14-3-3σ functions as a tumour suppressor gene. 
Therefore, it would seem counter-intuitive that 14-3-3σ expression is elevated in a 
small number of human cancers compared to normal cells or tissues. As well as 
having increased expression in hematological malignances and colorectal cancer 
(Motokura et al, 2007; Perathoner et al, 2005; Tanaka et al, 2004), 14-3-3σ is 
overexpressed in pancreatic cancer. 14-3-3σ was identified as one of a 149 genes 
overexpressed in pancreatic cancer using cDNA microarray screening. This was 
subsequently confirmed by reverse transcription-polymerase chain reaction (RT-
PCR) and immunohistochemistry. In the majority of pancreatic cancers, 
overexpression was associated with hypomethylation of CpG sites within 14-3-3σ 
(Iacobuzio-Donahue et al, 2003). Elevated levels of 14-3-3σ expression and 
associated hypomethylation have also been observed in high grade histological type 
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endometrial carcinomas (Nakayama et al, 2005). Furthermore, several studies have 
described overexpression of 14-3-3σ in lung cancer tissues (Qi et al, 2005) and head 
and neck cancer (Villaret et al, 2000). As with the reports of increased 14-3-3σ 
expression in hematological malignances and colorectal cancer, it is unknown 
whether the observed overexpression is associated with demethylation at CpG sites 
within 14-3-3σ as no methylation analysis was performed. 
 
The exact role (if any) that 14-3-3σ plays in tumorigenesis appears to be complex. 
Firstly, in cancer, aberrant methylation at CpG sites within 14-3-3σ and associated 
changes in expression compared to normal tissue or cells varies in different tumour 
types. It is very likely that in cancer, other epigenetic modifications are involved in 
regulating 14-3-3σ expression as was shown in the study which examined 14-3-3σ in 
normal cell types (Oshiro et al, 2005). Secondly, the majority of published data 
supports the notion that 14-3-3σ functions as tumour suppressor gene (Hermeking et 
al, 1997; Wilker et al, 2007). However, one report has shown that 14-3-3σ may be 
tumour promoting as it delays apoptosis in cancer cells (Samuel et al, 2001). 
Furthermore, another study showed that not only loss of 14-3-3σ expression, but also 
overexpression of the gene can result in impaired cell cycle regulation (Hermeking et 
al, 1997). The common occurrence of 14-3-3σ methylation in cancer suggests that it 
may have diagnostic or prognostic benefits. It is likely that this may need to be 
tailored to individual cancer types due to the reason discussed above. It is believed 
that 14-3-3σ hypermethylation detection could in time assist in the diagnosis of 
cancer type. For example, one report demonstrated that inactivation of 14-3-3σ by 
methylation was restricted to a specific sub-type of lung cancer (Osada et al, 2002). 
14-3-3σ hypermethylation could also be used as an early marker for detection of 
cancer in humans. 14-3-3σ methylation would be an attractive marker for breast 
cancer, since it is an early event in neoplastic transformation (Umbricht et al, 2001). 
Alternatively, 14-3-3σ could be a new target for anti-cancer therapy. As 14-3-3σ is 
overexpressed in some cancers, its activity could be inhibited and subsequent 




Taking all of the background literature reviewed above into consideration, it is 
hypothesised that 14-3-3σ is aberrantly methylated in colorectal cancer cell lines and 
in colorectal tumours. Despite the two previous studies on 14-3-3σ methylation 
analysis in colorectal cancer in which it was reported that 14-3-3σ methylation is a 
rare event in colorectal cancer, no corresponding normal colonic tissue was 
examined in either studies and hence the specificity of 14-3-3σ methylation in the 
colorectal tumours is still unknown (Ide et al, 2004; Suzuki et al, 2000). Therefore, 
from investigating the methylation status of 14-3-3σ in normal colonic mucosa tissue 
in addition to colorectal cancer cell lines and colorectal tumours it is proposed that 
aberrant 14-3-3σ methylation in colorectal cancer may be in contrast to what was 
previously thought. In addition, it is hypothesised that 14-3-3σ methylation in 
colorectal cancer will determine its expression as it has been previously shown to 
tightly associated in other cancers resulting in either overexpression or gene silencing 
of 14-3-3σ. Finally, it has been demonstrated that 14-3-3σ methylation occurs in a 
number of different cancers, in some cases at a high percentage and at different 
stages of tumorigenesis, and is associated with the tumour suppressor gene p53. 
Therefore, it is hypothesised that 14-3-3σ methylation and consequential aberrant 
expression in colorectal cancer will have a contributory effect on carcinogenesis or 




1.9 Research Aim 
The overall aim of the work presented in this thesis was to investigate the 
methylation status of the gene 14-3-3σ in colorectal carcinoma and to determine if 
methylation at the promoter region of 14-3-3σ determines expression and function of 
the gene in colorectal cancer and contributes to carcinogenesis or tumour 
progression. 
 
Previously published data has demonstrated that 14-3-3σ hypermethylation and 
associated gene inactivation occurs at a high percentage in a number of different 
epithelial cancers (Ferguson et al, 2000; Lodygin et al, 2004). However, only a few 
studies have been carried out in colorectal cancer tissue and in these reports 
hypermethylation of 14-3-3σ was a rare event as it was detected in a low percentage 
of colorectal cancer cell lines and colorectal tumours (Ide et al, 2004; Suzuki et al, 
2000). Interestingly, in both studies, methylation of 14-3-3σ in the normal colon 
tissue was not examined. Furthermore, several reports have shown 14-3-3σ 
overexpression in colorectal tumour tissue when compared against expression in 
adjacent normal mucosal tissue from the colon (Perathoner et al, 2005; Tanaka et al, 
2004). I set out to investigate the methylation status of 14-3-3σ in more detail to 
resolve the previously conflicting data from various studies.  
 
14-3-3σ plays a pivotal role in arresting cells at G2/M upon DNA damage and 
various knock-out studies further support its function as a tumour suppressor (Chan 
et al, 1999; Hermeking et al, 1997). In addition, certain findings have raised a 14-3-
3σ paradox as the protein has been shown to suppress cell death by sequestering the 
pro-apoptotic Bax protein (Samuel et al, 2001). Therefore, I set out to examine the 
role of 14-3-3σ in colorectal cancer cells and determine if the protein can contribute 
to colorectal cancer carcinogenesis or tumour progression. 
 




1. Determine the methylation status in the upstream promoter region and CpG 
island of 14-3-3σ in colorectal cancer cell lines, colonic normal mucosa 
tissue and in colorectal tumours to determine any changes occurring in 
colorectal cancer carcinogenesis.  
 
2. Measure expression of 14-3-3σ at both the mRNA and protein level in vitro 
and in vivo to establish whether expression is related to methylation status.  
 
3. Assess the specificity of methylation of 14-3-3σ by examining global levels 
of DNA methylation and CIMP phenotype in a small number of colorectal 
tumours.  
 
4. Investigate whether altered 14-3-3σ expression influences apoptosis, 
proliferation, and the cell cycle in an in vitro system. 
 
5. Analyse the expression and status of p53 in colorectal cancer cell lines and in 
vivo to examine whether there is a relationship between p53 status and 14-3-








Materials and Methods 
 
 
The following chapter provides an overview of the methods used during the course 
of this thesis. Where appropriate, specific details are included in the relevant results 
chapters. Stock solutions and media marked with an asterisk (*) were prepared by the 
MRC Human Genetics Unit technical services department and sterilised by 
autoclaving. Standard operating procedures covered by risk assessments (including 
COSHH regulations) were adhered to throughout and in accordance with the MRC 
health and safety policies. 
 
2.1 Biological Material  
2.1.1 Summary of cell lines 
A number of colorectal cancer cell lines examined throughout the duration of this 
PhD and are outlined in Table 2.1. Some colorectal cell lines were maintained as 
laboratory stocks and were originally purchased from the European Type Culture 
Collections (ECACC). For the interest of this PhD, information regarding p53 status 
and chromosomal instability are listed for each cell line. p53 status was obtained 
from the International Agency for Research on Cancer (IARC) TP53 mutation 












2.1.2 Maintenance of cell lines 
The following methods were used to grow and maintain all cell lines for DNA, RNA 
and protein extraction, transfection, proliferation assays, apoptosis assays and 
fluorescence activated cell sorting (FACS) analysis: 
 
L-15 (SW480), RPMI (Colo320DM, HCT116) or DMEM (HT29) (Gibco BRL) 
Tissue Culture Medium 
10% w/v Foetal calf serum* 
1% w/v Penicillin and streptomycin* 





8% w/v Dimethysulfoxide (DMSO) in FCS* 
Freezing Media 


















Mutated (Din et al, 2004) 
Unknown 
Mutated 
Positive (Lengauer et al, 1997) 
Positive (Lengauer et al, 1997) 
Negative (Lengauer et al, 1997) 
Positive (Prof Ian Tomlinson, 
personal communication) 
Unknown 
Positive (Lengauer et al, 1997) 
Unknown 
Negative (Lengauer et al, 1997) 
Unknown 
Table 2.1: Summary of colorectal cell lines.  
* Colorectal cancer cell lines maintained as laboratory stocks. SW480 cell line was originally 
purchased from the ECACC in 2000; HT29: ECACC, 1998; HCT116: ECACC, 1998; and 
Colo320DM cells were a kind gift from Professor Ian Tomlinson (Wellcome Trust Centre for 
Human Genetics, University of Oxford) in 2007.  
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50% w/v Trypsin* 
Trypsin Versene (TV) 
50% w/v Versin* 
 
Maintenance of all cell-lines was carried out under sterile conditions in a category 1 
containment hood. Cell lines were stored long-term in the liquid nitrogen storage 
facility at the MRC Human Genetics Unit. Cell lines were raised from liquid nitrogen 
rapidly by thawing in warm water then placed into the appropriate media as soon as 
possible, and washed twice with media, by centrifugation (1500rpm in an Eppendorf 
5702 centrifuge). Cells were fed with media as required and split by a PBS wash, and 
incubating with TV (5 mins) for adherent cells, and then, as for all cell lines 
aliquoting 1/2 to 1/10 of cell suspension into fresh media. To maintain a renewable 
stock of the cell lines, at least 3 x 106 cells were split from the main culture, 
centrifuged at 1500rpm in an Eppendorf 5702 centrifuge and re-suspended in 1.5ml 
of freezing media. The cells were then subsequently frozen at -700C before being 
transferred to liquid nitrogen (-140°C). 
    
2.1.3 Tissue sample collection 
Tissue collection was covered by ethical approval held by Prof M. Dunlop or 
covered by generic informed consent for anonymous samples. 
 
2.1.4 Colorectal tissue samples 
A panel of colorectal carcinomas and corresponding colonic normal mucosa tissue 
samples from patients with colorectal cancer treated in the Colorectal Surgery Unit, 
Western General Hospital, Edinburgh were collected. These samples were prefixed 
with KR and represent a selection of tissue samples analysed throughout this PhD. 
Colonic normal mucosa biopsies from individuals who were shown to be cancer and 
disease free during examination for a rectal bleed, were collected and used as control 
samples.    
 
2.1.5 Skin Samples 




2.1.6 Tissue Lysate samples 
Cytoplasmic protein extract from healthy human adult colonic mucosa tissue were 
supplied by Zyagen Laboratories, San Diego, California.  
 
2.1.7 Tumour sections 
Tumour samples from a Scottish cohort were available as laboratory stocks and were 
previously collected by Prof M. Dunlop and Dr S. Farrington (MRC Human Genetics 
Unit, Edinburgh). Paraffin embedding and sectioning of tumours was carried out by 
Aberdeen General Hospital, Pathology department. 
 
2.2 DNA and RNA Purification protocols 
 
2.2.1 Purification of DNA from cell lines, skin, tumour and normal 
mucosa colorectal tissue 
Isolation of genomic DNA from cell cultures, skin samples, colorectal tumour and 
normal mucosa tissue was carried out using a QIAamp DNA mini kit (QIAGEN Ltd, 
Crawley, UK) according to the manufacturer’s instructions.  
 
2.2.2 RNA Extraction 
Purification of RNA from cell cultures and human tissue was carried out using 
TRIzol reagent (Invitrogen, Paisley, UK) according to the manufacturer’s 
instructions. 
  
2.2.3 Estimation of DNA and RNA concentration 
 To estimate the concentration of DNA and RNA purified from the protocols listed 
above, optical densitometry on a GeneQuant Pro RNA/DNA calculator UV 
spectrophotometer (Amersham Pharmacia biotech, Cambridge, UK) was used. DNA 
samples were diluted 1 in 20 and the absorbency measured at 260nm and 280nm. A 




2.3 DNA Samples 
The following were acquired directly as DNA samples. 
 
2.3.1 Colorectal tumour DNA 
DNA samples from a Scottish cohort were available as laboratory stocks and were 
previously collected by Prof M. Dunlop and Dr S. Farrington (MRC Human Genetics 
Unit, Edinburgh). Prospective patients were recruited from the colorectal clinic at the 
Western General Hospital, Edinburgh, and following consent, a full family history 
was recorded from interviews with patients. Tumours were characterised as to AJCC 
stage, whether they were located proximal to the splenic flexure or distal, mucin 
content and degree of differentiation from pathology reports. Screening for germline 
mutations in MLH1, MSH2, MSH6 & PMS2 were performed and MSI status 
determined by comparison of matched normal and tumour DNA using a panel of 8 
recommended microsatellite markers (Rodriguez-Bigas et al., 1997; Boland et al., 
1998). 
 
2.3.2 Colorectal cancer Cell line DNA 
A number of genomic DNA samples from colorectal cancer cell lines were available 
as laboratory stocks. These included DNA samples from the following colorectal 
cancer cell lines; Caco-2, LoVo, HRT18, SW48 & SW620. 
 
2.3.3 Control Tissue DNA from healthy individuals 
Genomic DNA from colonic mucosa tissue was obtained from Zyagen Laboratories, 
San Diego, California. 
 
2.4 Techniques for detection of DNA Methylation employing 
sodium bisulphite modification of DNA 
 
Two methods were utilised throughout this PhD for detecting DNA methylation, 




Bisulphite conversion kits have recently been developed which combine the 
denaturation and bisulphite treatment of DNA, subsequent desulphonation and then 
clean-up of the converted DNA for methylation analysis. During this PhD, two kits 
were used depending on the number of DNA samples that were to be treated at one 
time. These are listed below. 
 
2.4.1 Large-scale bisulphite treatment: 96-well format 
The 96-well format EZ-96 DNA Methylation-Gold Kit (Zymo Research, CA, US) 
was used to bisulphite treat the majority of DNA samples according to the 
manufacturer’s instructions. Approximately 500ng of DNA was bisulphite converted 
if sufficient material was available otherwise the maximum volume allowable by the 
kit (20µl) was converted. A universal methylated DNA standard and control primers 
(Zymo Research) were utilised in conjunction with the EZ-96 DNA methylation kit 
to assess the efficiency of bisulphite conversion of DNA.     
 
2.4.2 Small-scale bisulphite treatment 
For the bisulphite conversion of a small number of DNA samples, the EpiTect 
Bisulfite Kit (Qiagen Ltd) was carried out according to the manufacturer’s 
instructions. Approximately 500ng of DNA was bisulphite converted using the 
standard protocol. DNA samples with low concentrations of DNA were bisulphite 
converted using a protocol modified for low concentrations of DNA, which employs 
a larger volume of DNA for processing and the addition of carrier RNA to enhance 
binding of DNA to the EpiTect spin column membrane. In the first instances, the 
universal methylated DNA standard and control primers (Zymo Research) were used 
to test the efficiency of bisulphite conversion. For subsequent conversions, DNA 
from the 14-3-3σ methylated colorectal cancer cell-line SW480 and the 14-3-3σ 
unmethylated colorectal cancer cell line HCT116, were used alongside other DNA 
samples to assess the efficiency of bisulphite modification.         
 
2.4.3 PCR reactions 
PCR amplification was carried out on bisulphite converted DNA and amplified 
products were sequenced directly from PCR products or from clones (see section 2.5) 
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to identify methylated cytosine residues (bisulphite sequencing). Nested PCR 
primers were required to sufficiently amplify DNA due to the low concentration of 
DNA following bisulphite treatment.  MSP uses PCR primers which are designed to 
distinguish unconverted (methylated) cytosines from converted (unmethylated) 
cytosines using bisulphite treated DNA as a template. Hence, two PCR reactions are 
performed and methylated sequences or unmethylated sequences are amplified 
depending on the methylation status of the sample. Densitometric analysis of 
captured image was performed following MSP reactions using a BioRad Chemi Doc 
system, QuantityOne (version 4.4.1) software (BioRad Laboratories, Hercules, CA, 
US). 
 
All PCR reactions were performed in a final volume of 30µl using the Platinum Taq 
Polymerase kit (Invitrogen). Final reaction concentrations for the Platinum Taq 
system were 1 X PCR buffer, 3mM MgCl2, 0.1 units of Platinum Taq, 300µM 
dNTPs, 0.5µM of each oligonucleotide and 21µl dH2O. A Peltier PCT225 thermal 
cycler (MJ Research, Waltham, US) was used for PCR amplification under the 
following conditions, unless otherwise stated: 94°C – 5min, (95°C – 30secs, 60°C – 
30secs, 72°C – 30secs) x 30, final extension 72°C – 5min. 
 
2.4.4 Oligonucleotides for PCR reactions 
Primers were supplied from Sigma-Aldrich (Dorset, UK) as precipitates and were re-
suspended in dH2O to a stock concentration of 100µM. The primers were further 
diluted with dH2O to a working concentration of 20µM. Bisulphite sequencing 
primers were designed by eye or using the MethPrimer program (Li & Dahiya, 2002) 
at http://www.urogene.org/methprimer/index.html unless otherwise referenced. Table 
2.2 lists all oligonucleotides utilised throughout this PhD. Bisulphite sequencing 
primers (BS) and MSP primers are specified. ‘Nest’ refers to nested (inner) primers 
used in bisulphite sequencing PCR reactions. M and U refer to methylated and 
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Table 2.2: Oligonucleotides used throughout this PhD. R denotes any purine nucleotide and Y 




2.4.5 Gel Electrophoresis 
Solutions: 
2M Tris 
10 X Tris-Acetate EDTA (TAE)* 
5.7% w/v Glacial acetic acid 
50nM Na2EDTA (pH 8.0) 
 
To resolve PCR products ranging in size from 100 – 1000 base pairs, 2% agarose 
gels were prepared using routine grade agarose (Biogene, Kimbolton, UK) and 1 X 
TAE solution. Ethidium bromide (BDH, Electran, Poole, England) was added at a 
final concentration of 0.3 mg/ml to the dissolved gel prior to pouring. 10µl of PCR 
product was loaded into the gel with 2µl 1 X loading buffer (Promega). A 100bp 
ladder (Promega) was additionally loaded into the gel to determine the size of PCR 
products. DNA was electrophoresed at 40-60V for approximately 40min. The 
BioRad Chemi Doc system using QuantityOne (version 4.4.1) software was used to 
visualise PCR products. 
 
2.4.6 PCR product purification 
For sequencing analysis, PCR products were purified using exonuclease I (USB, 
Ohio, US) and shrimp alkaline phosphatase (SAP; USB). 5µl of PCR product was 
added to a combination of 1µl exonuclease I (10U/µl) and 2µl SAP (1U/µl). The 
mixture was incubated for 15min at 37°C in a Peltier PCT225 thermal cycler (MJ 
Research) and then heated to 80°C to inactivate the exonuclease and phosphatase. 
 
2.4.7 DNA Sequencing 
All DNA sequencing reactions were carried out using ABI PRISM Ready Big Dye 
Terminator cycle sequencing kit with Amplitaq DNA polymerase FS (Applied 
Biosystems, Chesire, UK). 
 
Sequencing of PCR products was performed in 10µl reactions using approximately 
10ng of purified DNA, 3µM primer (forward and reverse separate reactions) and 2µl 
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Big Dye Version 3.1 (Applied Biosystems). Amplification was carried out using the 
following reaction conditions (96°C – 30secs, 50°C – 15secs, 60°C – 4min) 25 
cycles in a Peltier PCT225 thermal cycler (MJ Research). 
 
2.4.8 Precipitation of DNA from sequencing reactions 
Sequenced DNA was precipitated by adding 55µl of 95% ethanol and 2µl of NaOAC 
(pH4.0) to the sequencing reaction mix and incubated at room temperature for 
30min. Samples were then spun at 1500rpm in a Micromax IEC centrifuge for 
30min, the DNA pellet washed with 70% ethanol, and then allowed to completely 
evaporate at room temperature before storing the DNA pellet at -20°C for analysis. 
 
The same procedure above was carried out for DNA in a 96-well format, except a 
Sorvell Multifuge 3 S-R Heraeus centrifuge was used to spin plates at 2000rpm for 
30min and the supernatant removed by flicking the plates and then pulse spinning 
them upturned on paper towels at 800rpm. Pellets were washed with 70% ethanol 
and rapidly removed by flicking the plate and further pulse spinning. 
 
Precipitated DNA from the reaction products were re-suspended in Hi-DiTM (Applied 
Biosystems) and heated to 90°C for 2min by Agnes Gallacher (MRC, Human 
Genetics Unit, Edinburgh). Samples were resolved on an ABI PRISM® 3100 or a 
3700 genetic analyser machine according to the manufacturer’s instructions. 
 
2.4.9 Characterisation of methylated CpG islands 
Sequence data was analysed using Sequencing analysis software Version 3.7 or 5.2 
(for 3100 and 3730 respectively) (Applied Biosystems). Multiple sequences of the 
same fragment were aligned using the Consed program by importing all sequence 
data. Sequencing traces were viewed and aligned using the Phred/Phrap/Consed 
packages (www.phrap.org/phredphrapconsed.html). Methylated CpG dinucleotides 






2.5 Cloning and Bacterial Culture 
Media: 
0.1% w/v Tryptone (Difco) 
Luria Broth (L-Broth)* 
0.05% w/v Yeast extract (Difco) 
171mM NaCl 
0.1% w/v Tryptone 
Luria Agar (L-agar) * 
0.05% w/v Yeast Extract 
171mM NaCl 
0.15% w/v Agar (Oxoid Ltd) 
 
Additives: 
20mg/ml ampicillin (Sigma-Aldrich) 
Ampicillin Stock solution 
40mg/ml X-Gal (Sigma-Aldrich) in Dimethylformamide (DMF) 
5-Bromo-4-Chloro-3-Indolyl-β-D-galactosidase (X-Gal) 
 
2.5.1 TA cloning and transformation 
Individual alleles were cloned using a Dual Promoter TA Cloning Kit (Invitrogen). 
Bisulphite treated DNA was PCR amplified as described in section 2.4.3 and 
products were cloned into pCR  II vector (Invitrogen) according to the 
manufacturer’s instructions. Clones were then transformed into One Shot® TOP10 
Chemically Competent E. coli (Invitrogen) according to the manufacturer’s 
instructions. 30 - 80µl of each transformant was spread onto selective L-agar plates 
containing ampicillin (50µg/ml) and X-gal (40µg/ml). Plates were incubated 
overnight at 37°C, upside down.  
 
2.5.2 Colony selection and storage 
White bacterial colonies, indicative of positive transformants, were picked and PCR 
amplified directly from colonies using M13 specific primers. Approximately 288 
white colonies were picked to carry out PCR reactions in 3 X 96-well plates as 
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described in section 2.4.3. Positive transformants containing the correct size insert 
were identified using gel electrophoresis as described in section 2.4.5 and clones 
with the correct length insert were then sequenced directly from the PCR reaction as 
described in section 2.4.7. For long-term storage, selected white colonies were 
cultured in 96-well plates containing 1.2ml/well L-Broth with 100µg/ml ampicillin 
overnight at 37°C, shaking at 160rpm. 25µl of glycerol was added to each well the 
next day and plates were stored at -70°C.      
 
2.6 Expression Analysis 
2.6.1 DNase I Treatment 
Prior to quantitative RT-PCR (qRT-PCR) analysis, RNA was treated with DNase I 
RNase-Free (Ambion, Cambridgeshire, UK) according to the manufacturer’s 
instructions.  
 
2.6.2 cDNA synthesis 
For cDNA synthesis, 1µg of total RNA was transcribed using the 1st Strand cDNA 
Synthesis kit for RT-PCR (AMV) (Roche Diagnostics, Mannheim, Germany) 
according to the manufacturer’s instructions. Negative reverse transcribed reactions 
(AMV Reverse Transcriptase omitted) were amplified by PCR using actin primers 
listed in Table 2.2 and carried out as described in section 2.5 to test all gDNA 
contamination had been removed from the RNA sample. This was carried out in 
addition to testing cDNA contamination by analysing negative reverse transcriptase 
reactions using Taqman analysis.       
 
2.6.3 Quantitative RT-PCR: Taqman analysis 
qRT-PCR was performed to quantify relative levels of 14-3-3σ mRNA expression 
using a Taqman® Gene Expression Assay (Applied Biosystems) on an ABI PRISM® 
HT7900 Sequence Detection System thermal cycler. The assay chosen from a list of 
available TaqMan® Gene Expression Assays was Hs00602835_s1. As 14-3-3σ only 
contains one exon, the primers and probe were designed within the exon. Expression 
of beta actin (Human ACTB endogenous control probe, Applied Biosystems) was 
used as endogenous reference control. The 14-3-3σ probe was labelled with the 
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reporter dye FAM and the beta actin probe labelled with the reporter dye VIC at the 
5’end of the oligonucleotide. A quencher dye (TAMRA) was used to label the 3’ 
ends of both probes.  
 
For each cDNA sample, triplicate amplifications were carried out in 384 well PCR 
plates (ABgene, Surrey, UK) and sealed using Absolute QPCR optically clear 
adhesive sheets (ABgene). Negative reverse transcriptase reactions and non-template 
controls were run on each plate. PCR reactions were performed in a final volume of 
5µl using 0.5µl of cDNA, 1.75µl of sterile H2O, 2.5µl Taqman® Universal Master 
Mix No AmpErase® UNG (2 X; PE Biosystems, New Jersey, USA) and 0.25µl probe 
mix (20 X). PCR conditions were as follows: 50°C – 2min, 95°C – 10min, (95°C – 
15secs, 60°C – 1min) x 40. 
 
Data analysis was carried out using SDS Version 2.1 program (Applied Biosystems). 
The standard curve method was used to quantify relative levels of 14-3-3σ mRNA. 
Standard curves for 14-3-3σ and β-actin amplifications were constructed by plotting 
threshold cycle values (Ct) against logged quantity of a calibrator, which was serially 
diluted cDNA prepared from the HT29 colorectal cancer cell line. Only standard 
curves with an R2 value close to 1 were subsequently used to calculate relative 
expression values. For each sample, the relative expression was calculated using 
linear regression analysis from the corresponding standard curves. To obtain a 14-3-
3σ expression value normalised for initial cDNA quantity variations, 14-3-3σ values 
were divided by β-actin values.  
 











0.2% w/v Triton X-100 
20% w/v Glycerol 
6 x Sample Buffer 
2% w/v SDS 
0.25% w/v Bromophenol blue 
1 x Stacking buffer 
5% w/v β-mercaptoethanol 
1.5M Tris 
4 x Resolving Buffer 
0.4% w/v SDS 
pH 8.8 
500mM Tris  
4 x Stacking Buffer 
0.4% w/v SDS 
pH 6.8 
250mM Tris 
10 x Running Buffer 
2M Glycine 
1% w/v SDS 
47mM Tris 
Semi-Dry Transfer Buffer 
40mM Glycine 
0.037% w/v SDS 
100mM Methanol 
1 x Resolving buffer 
10% Resolving Gel 
10% w/v Acrylaminde 
0.15% w/v Ammonium persulphate (APS) 
0.01% w/v N, N, N’, N’, tetramethyl-1-2-diaminomethane (TEMED) 
5% Stacking Gel




5% w/v acrylamide 
0.15% w/v APS 
0.01% TEMED 
 
2.6.4.1 Preparation of cytoplasmic cell extracts 
Cells were scraped in PBS* from confluent T25 flasks. Cells were pulsed at 6000rpm 
in an Eppendorf 5415R centrifuge to pellet the cells and re-suspended in 3 x volumes 
(~ 300µl) of Buffer A containing Complete protease inhibitor cocktail at 1:1250 
dilution (Roche Diagnostics), 1mM pepstatin A (Sigma), 100mM PEFA block 
(Roche Diagnostics) and 1mM Dithiothreitol (DTT). Nuclei were then pelleted by 
centrifugation (Eppendorf 5415R centrifuge) at 6000rpm for 20 minutes at 4°C. The 
supernatant containing the cytoplasmic fraction was collected and immediately 
frozen on dry ice. 
 
2.6.4.2 Preparation of cytoplasmic extracts from tissue 
Approximately 20mg of tissue was dissected from frozen ‘stock’ tissue, transferred 
into an eppendorf tube and re-frozen by placing on dry-ice. Samples were then 
thawed on a Dri Block® DB-2A hot block (Techne, New Jersey, USA). 3 x volumes 
of Buffer A (~300µl) containing Complete protease inhibitor cocktail at 1:1250 
dilution (Roche Diagnostics), 1mM pepstatin A (Sigma), 100mM PEFA block 
(Roche Diagnostics) and 1mM Dithiothreitol (DTT) was added to the tissue and 
ground using a pestle. The freeze-thawing with subsequent grinding of the tissue was 
repeated a further 3 times and samples were then centrifuged in an Eppendorf 5415R 
centrifuge at 1000rpm for 2 minutes to remove tissue debris. Nuclei were then 
pelleted by centrifugation (Eppendorf 5415R centrifuge) at 6000rpm for 20 minutes 
at 4°C. The supernatant containing the cytoplasmic fraction was collected and 




Total concentrations of protein was verified by Bradford assays (Biorad, Hercules, 
USA), read on a Multiskan MS plate reader (Labsystems), and extracts adjusted for 
Western Blot analysis by adding PBS*. 
2.6.4.3 Western Blot Analysis 
Approximately 30µg of protein extract was added to a 1:6 dilution of sample buffer, 
boiled on a hot block for 5 minutes and then placed on ice. Samples were resolved by 
denaturing SDS-PAGE on a 10% polyacrylamide gel in 1 x running buffer at 160 
volts for approximately 1 hour. Kaleidoscope prestained molecular weight markers 
(BioRad) were run on each gel. Gels were pre-soaked in semi-dry transfer buffer 
prior to transfer and the nitrocellulose membrane (Amersham Biosciences) prepared 
by soaking first in 100% methanol and then also in semi-dry transfer buffer. Proteins 
were transferred to the nitrocellulose buffer using a mini Trans-blot semi-dry transfer 
cell (BioRad) for 30 minutes at 10 volts. 
 
Nitrocellulose membranes were blocked overnight at 4°C in 5% milk (Marvel) 
dissolved in PBS* 0.05% Tween-20 (Sigma). The membranes were incubated with 
primary monoclonal antibodies (see table 2.3) for 1 hour, washed in 0.05% Tween 
(Sigma) in PBS* for 3 x 15 minutes and then incubated for 1 hour with horseradish 
peroxidase conjugated sheep antimouse IgG secondary antibody 1 in 1000 (for both 
primary antibodies) (GE Healthcare Ltd, Buckinghamshire UK), and washed as 
described before. β-actin was employed as a loading control on each membrane. A 
goat anti-mouse IgM horseradish peroxidase secondary antibody (Calbiochem, San 
Diego USA), 1 in 4000 dilution was used for actin detection.   
 
ECL western blotting protocol (Santa Cruz Biotechnology, Buckinghamshire, UK) 
was used to detect protein bands and carried out according to the manufacturers 
instructions. Densitometric analysis of protein bands was performed using the 







2.7 Cell Biology 
 
2.7.1 5-Aza-2’-deoxycytidine treatment 
Cell lines were treated with 0.5µM to 10µM of 5-aza-2’-deoxycytidine (Sigma) 
dissolved in 50% acetic acid for the desired time points (1-4 days). Fresh 5-aza-2’-
deoxycytidine was added every 24hrs following PBS* wash and addition of fresh 
media. Control cells were untreated with and without vehicle, 50% acetic acid, for 4 
days. 
 
2.7.2 Transfection of cell lines 
Cell lines were transfected with the overexpressing 14-3-3σGFP-C1 construct 
(kindly donated by Tomoshige Kino, National Institute of Child Health and Human 
Development, MD USA) or the empty vector control pEGFP-C1 (BD Biosciences 
Clontech, MD USA) using Lipofectamine™ 2000 or Lipofectin™ (both Invitrogen) in 
Antibody Manufacturer Dilution Used 
14-3-3 sigma 
Ab-1 (Clone 1433S01) 
Mouse mAb 





Mouse mAb (DO-1) 
Merck, Calbiochem, 














Santa Cruz Biotechnology, 
Buckinghamshire, UK 
 






Table 2.3: Primary antibodies utilised in Western Blot analysis in this thesis, details 




6-well plates according to the manufacturer’s instructions. Lipofectamine™ 2000 was 
used for transfections preceding apoptosis assays and FACS cell cycle analysis. 
Lipofectin™ was used preceding proliferation assays. In both cases, approximately 
4µg of vector DNA was employed for transfections. Transfection efficiencies were 
calculated using fluorescence light microscopy. 
 
2.7.3 Annexin V Apoptosis Assay 
The Annexin V-Biotin kit (Calbiochem) was used according to the manufacturer’s 
instructions to determine the total percentage of apoptotic cells in the transfected cell 
lines.  
 
Briefly, triplicate wells of cell lines were transfected with both 14-3-3σGFP-C1 
construct and empty vector control pEGFP-C1 and then either UV-C treated (UV-C 
exposed) or not UV-C treated (UV-C unexposed) using a UV Stratalinker 1800 
(Stratagene, Texas USA) at 50J/M2 to induce apoptosis. Apoptosis levels were 
determined 24 hours following UV-C treatment. Cell concentrations were adjusted to 
1 x 106 cells/ml, 0.5ml cell suspension was removed to an eppendorf, pelleted by 
centrifugation using an Eppendorf 5415R centrifuge, and re-suspended in 0.5ml of 
cold 1 x binding buffer (Calbiochem). 2.5µl of Annexin V-biotin (Calbiochem) was 
added to the appropriate tubes and incubated for 30 minutes in the dark at room 
temperature. Cells were pelleted using an Eppendorf 5415R centrifuge, re-suspended 
in 0.5ml of 1 x cold binding buffer (Calbiochem), and 15µl of fluorescent 
streptavidin texas-red conjugate (Calbiochem) added to each tube. Each sample was 
then stored at 4°C overnight to allow cells to settle to the bottom of the tubes. 20µl of 
cells were placed on SUPERFROST PLUS slides and apoptotic cells were counted 
using fluorescent light microscopy. 200 GFP transfected cells were counted for each 
sample and the number of apoptotic cells calculated as a percentage from these cells. 
 
2.7.4 Proliferation Assays 
Cell growth in overexpressing 14-3-3σGFP-C1 SW480 cells and empty vector 
control GFP-C1 SW480 cells was measured. Cell proliferation assays were 
performed over a period of 4 days of growth in 96-well plates, in triplicate, using the 
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CellTiter 96 One Solution Cell Proliferation Assay (Promega). 5000 cells were 
seeded per well prior to transfection; this number was decided by performing a cell 
titration assay to ensure the signal measured at the end of the assay did not exceed 
the linear range. Absorbance at 490 nm was recorded using a Multiskan Spectrum 
Plate Reader (Thermo electron corporation, Waltham, MA USA) 24 hours post 
transfection and then every 24 hours for 4 days total following 2 hours of incubation 
of the cells with CellTiter 96 One Solution reagent. Absorbance readings were 
corrected for transfection efficiency, which was measured separately for each 
experiment. 
 
2.7.5 FACS analysis of GFP transfected cells 
Assistance with FACS analysis was given by Shonna Johnston (QMRI, Edinburgh 
New Royal Infirmary) using a FACS Vantage SE with DIVA option (BD 
Biosciences). GFP cells were sorted using a 100µm nozzle and a 4 way 0240 
precision sort, with an efficiency of 70%, and approximately 4000 events sorted per 
second. 
 
1 x 107 cells/ml of each GFP cell sample were harvested using TV*, centrifuged at 
1500rpm in an Eppendorf 5702 centrifuge and re-suspended in 1ml of the 
appropriate media with 2% FCS*. Approximately 3 x 106 GFP cells for each sample 
were collected following sorting and placed in the appropriate media with 10% FCS*. 
 
GFP cells were spun down at 1500rpm in an Eppendorf 5702 centrifuge for 5 
minutes and fixed by adding ice-cold 70% ethanol in a drop-wise manner whilst 
vortexing. Fixed GFP cells were stored at -20°C until day of cell cycle analysis.  
  
2.7.6 Flow Cytometry Cell Cycle Analysis 
Fixed GFP cells were spun down at 1500rpm for 5 minutes in a Micromax IEC 
centrifuge and washed twice in PBS*. GFP cells were then re-suspended in 500µl of 
Propidium Iodide (PI) solution containing 500µl PBS* with 0.1% Triton X-100, 10µg 
PI (Sigma) and 100µg RNase A (Sigma) and incubated at room temperature for 30 
minutes in the dark until analysis. 
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Assistance with Flow Cytometry was given by Shonna Johnston (QMRI, Edinburgh 
New Royal Infirmary) using a FACSCaliber cytometer with CellQuest software (BD 
Biosciences). The PI signal was quantified at emission spectra/bandpass 585/42nm. 
Output data obtained for 5000 cells in each GFP sample group and data analysed 
using Flowjo Version 7.0 (Tree Star, OR USA). 
 
 
2.8 Analysis of Global Methylation status 
 
2.8.1 Methylight analysis 
The presence of the CIMP phenotype in colorectal carcinomas was determined using 
MethyLight analysis (Eads et al, 2000). A four marker panel comprising of hMLH1, 
CDKN2A, MINT1 & MINT2 was measured for methylation. 
 
Bisulphite treated tumour DNA samples were subjected to real time PCR reaction on 
an ABI PRISM® HT7900 Sequence Detection System thermal cycler. Two types of 
MethyLight reactions were set-up: 1) A MethyLight reaction using bisulphite 
converted DNA, with forward and reverse primers and probes specific for 
methylated DNA and bisulphite converted DNA. 2) A bisulphite specific control 
reaction using β-ACTIN specific primers and probes to measure the loading of 
bisulphite converted DNA. The β-ACTIN reactions are not methylation specific but 
are specific for bisulphite converted DNA. Primer and probe sequences for the 4 
marker panel and β-ACTIN are listed in Table 2.4. The four marker probes were 
labelled with the reporter dye FAM and the beta actin probe labelled with the 
reporter dye VIC at the 5’end of the oligonucleotide. A quencher dye (TAMRA) was 




Duplicate PCR amplifications were carried out in 96 well optical MicroAmp 
reaction plates (Applied Biosystems) and sealed using Absolute QPCR optically 
clear adhesive sheets (ABgene). PCR reactions were performed in a final volume of 
25µl using 5µl of bisulphite treated DNA sample, 4.5µl of sterile H2O, 12.5µl 
Taqman® Universal Master Mix No AmpErase® UNG (2 X; PE Biosystems, New 
Jersey, USA) 200nM probe (Applied Biosystems) and 600nM of each primer 
(Applied Biosystems). PCR conditions were as follows: 50°C – 2min, (95°C – 
10min, 95°C – 15secs, 60°C – 1min) x 40. 
 
Data analysis was carried out using SDS Version 2.1 program (Applied Biosystems). 
Ct values were used to create relative values for each sample by generating standard 
curves. These were created by plotting the threshold cycle (Ct) against logged 



























β-ACTIN VIC- ACCACCACCCAACACACAATAACAAACACA 
5’ TGGTGATGGAGGAGGTTTAGTAAGT 
3’ AACCAATAAAACCTACTCCTCCCTTAA 
(Eads et al, 2000) 




methylated CpGenome ™ Universal Methylated DNA (Chemicon International Inc, 
Dundee Scotland). The coefficient of linear regression (r) was calculated for each 
standard curve and curves with values close to 1 were further utilised. Samples were 
normalised for initial bisulphite treated DNA quantity variations by dividing relative 
values by β-actin values. Percentage methylation ratio (PMR) values were calculated 
by dividing normalised values with fully methylated CpGenome DNA relative values 
and multiplying by 100. 
 
2.8.2 Nearest Neighbor Analysis 
Nearest Neighbor analysis (Ramsahoye, 2002) is a modification of a technique first 
published by Gruenbaum et al, 1981 (Gruenbaum et al, 1981). Assistance with 
Nearest Neighbor analysis was given by Dr Bernard Ramsahoye (Cancer Research 
UK, University of Edinburgh).  
 
Approximately 1µg of DNA was RNaseA (Sigma-Aldrich) treated according to the 
manufacturer’s instructions and then ethanol precipitated. DNA was digested with 
10U of MboI (New England Biolabs, MA US) overnight at 37°C and heat inactivated 
at 70°C for 20 minutes. The digested DNA was again precipitated in ethanol and 
resuspended in 10µl H2O. 3µl of [α-32p]dGTP at 30µCi (Amersham Pharmacia 
Biotech), 1.5µl 10X labelling buffer and 0.5µl Klenow (Amersham Pharmacia 
Biotech) was then added to the DNA and incubated at 15°C for 15 minutes. 2µl of 
0.2M EDTA (Sigma-Aldrich) was added to terminate the reaction before transferring 
the labelling mixture to Sephadex G50 spin columns (Roche). The spin columns 
were spun at 1100g for 4 minutes in a Micromax IEC centrifuge and the flow 
through collected. The labelled DNA was dried down using a Savant DN120 DNA 
speed vac (ThermoFisher Scientific, Surrey UK) and digested in a volume of 7µl, 
(5µl micrococcal nuclease digestion buffer: 15mM CaCl2, 100mM Tris-HCL, 0.2U 
micrococcal nuclease and 2µg of spleen phosphodiesterase (Worthington 




0.3µl of digest was spotted onto a 20 x 20 cm glass-backed cellulose TLC plate 
(Sigma-Aldrich) 1.5cm from the bottom right corner. 44ml of solution A (66 
volumes isobutyric acid: 18 volumes H2O: 3 volumes 30 ammonia solution) was 
poured into a TLC developing tank and the TLC plate placed into the tank at an 
angle. The plate was left for approximately 12 hours to develop and then removed 
from the tank and dried thoroughly for 4 hours. The dried plate was turned 90° and 
the sample subjected to the second dimension of chromatography using solution B 
(80 volumes saturated ammonium sulphate: 18 volumes 1M acetic acid: 2 volumes 
isopropanol). After approximately 12 hours of developing, the plate was dried 
thoroughly for 4 hours and then analysed using a FLA5100 phosphorimager (Fuji, 
Bedfordshire, UK) 635 nm laser and a 665 nm bandpass filter. 
 
 
2.9 Histology techniques 
 
2.9.1 Processing of colon tissue for paraffin wax sectioning 
Tumour KR tissue samples were embedded using the Tissue Tek VIP processing 
machine (Miles Scientific, Glasgow, UK) with the assistance of Allyson Ross and 
Naila Haq. The following program was run and left overnight: 
 
 
Stage 1: 3 hours PBS, 38°C 
Stage 2: 6 hours 70% ethanol, 38°C 
Stage 3: 3 hours 100% ethanol 38°C 
Stage 4: 3 hours xylene 38°C 
Stage 5: 4 hours wax 58°C. 
  
A Leica microtome and ACCU-Edge low profile blades were used to cut 3µm 
sections of paraffin wax embedded tissue material. Sections were floated onto a 
waterbath set at 42°C. The sections were immediately attached to SUPERFROST 





Assistance with immunohistochemistry was given by Naila Haq (University of 
Edinburgh, MRC Human Genetics Unit). Tumour sections were deparaffinised and 
re-hydrated by immersing three times for 5 minutes in xylene, two times for 5 
minutes in 100% ethanol, two times for 5 minutes in 95% ethanol, and once for 5 
minutes in 80% ethanol. Sections were boiled in 10mM citrate buffer (pH 6.0) two 
times for 5 minutes each in a microwave and then cooled for 1 hour at room 
temperature. Sections were rinsed in deionised water two times for 5 minutes and 
endogenous peroxidase activity was blocked with 3% hydrogen peroxide in water for 
20 minutes followed by washing for 5 minutes with PBS* 0.1% Tween. The tissue 
sections were blocked with 2.5% swine serum (Dako Cytomation, Dako Denmark) 
for 30 minutes and then washed in PBS* 0.1% Tween before incubating with the 
primary antibody p53 D-01 (Merk Calbiochem) diluted 1 in 200 at room temperature 
for 1 hour. Sections were washed twice for 5 minutes in PBS* 0.1% Tween and 
incubated for 30 minutes at room temperature in ImmPRESS Peroxidase 
UNIVERSAL anti mouse/rabbit Ig reagent, 100µl (Vector, California USA). 
Sections were rinsed twice in PBS* 0.1% Tween, developed with diaminobenzidine 
tetrahydrochloride (DAB) tablet, 10mg (Sigma) for 2 minutes and lightly 
counterstained with Harris haematoxylin. The slides were then rinsed in deionised 
water and immersed in saturated lithium bicarbonate diluted 1 in 5. The slides were 
rinsed three times for 5 minutes in deionised water and dehydrated by carrying out 
the reverse immersions as described before for re-hydration. Slides were mounted 
using non-aqueous Histomount mounting media (National Diagnostics, Georgia 
USA) and analysed using light microscopy. p53 staining was scored 1-3 according to 




2.10 Calculations and Statistics 
2.10.1  Statistical Analysis 
Fishers exact tests, non-parametric Mann Whitney tests and paired Wilcoxon signed 
rank test, unpaired T-tests, Two-way ANOVA tests and Chi-Squared analysis were 
performed using GraphPad Prism 4 (GraphPad software, CA, USA). Associations 














Methylation analysis of 14-3-3σ in colorectal 





Gene silencing of 14-3-3σ by hypermethylation has been reported in several tumour 
types but data on colorectal cancer are limited, despite aberrant gene methylation 
being well recognised in colorectal carcinogenesis. My main aim in this chapter was 
to establish the methylation status of 14-3-3σ in the region encompassing the 5’ 
region of the CpG island and upstream promoter region in colorectal cancer cell 
lines, colorectal tumours and normal mucosa samples. The 14-3-3σ CpG island was 
delineated using a number of algorithms available as online tools. In order to 
effectively analyse the methylation status of 14-3-3σ, bisulphite sequencing of the 
upstream promoter region and 5’ region of the CpG island was divided into separate 
regions and sequenced accordingly. Methylation-specific PCR was also used 
alongside bisulphite sequencing to determine the methylation status of 14-3-3σ in 
colorectal cancer cell lines. A total of 9 colorectal cancer cell lines, 99 colorectal 
tumours and 10 matched normal mucosa samples were examined for 14-3-3σ 
methylation by bisulphite sequencing. The relationship between 14-3-3σ methylation 
status in tumour DNA and clinicopathological variables was also subsequently 
examined. The colorectal tumour material and corresponding normal mucosa 
samples from patients have been extensively screened for mismatch-repair defects 
and none have been found (Prof Dunlop and Dr Susan Farrington, personal 
communication). Mismatch-repair defects were excluded by screening for mutations 
in MLH1, MSH2 and MSH6 in germline DNA and tumour microsatellite instability 
testing.  
 
The majority of the sequencing analysis was carried out directly on PCR products to 
provide the average level of 14-3-3σ methylation in a given sample. However, in 
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conjunction with this, bisulphite sequencing of individual clones was performed on 6 
colorectal tumour samples and normal tissue samples from individuals free from 
cancer; including one colonic mucosa tissue sample and three skin tissue samples, in 
order to further verify the bisulphite PCR sequencing and the tumour-specificity of 
14-3-3σ methylation in colorectal cancer. Keratinocytes, a cell-type which is present 
in the skin, are known to be unmethylated for 14-3-3σ and express high levels of the 
gene (Leffers et al, 1993; Oshiro et al, 2005). Therefore, 14-3-3σ methylation 
analysis in skin tissue was performed alongside methylation analysis in normal 
colonic mucosa for comparison.  
 
My overall aim of this chapter was thus to investigate the qualitative and quantitative 
status of 14-3-3σ methylation and determine whether there are any relationships to 
suggest differential methylation plays a role in colorectal carcinogenesis. 
 
3.2 Methodology 
3.2.1 14-3-3σ CpG island in silico analysis 
In order to determine the exact region of the 14-3-3σ CpG island, bioinformatics 
analysis using algorithms previously tested; NCBI “relaxed” 
(http://www.ncbi.nlm.nih.gov/mapview/static/humansearch.html#cpg) (% GC ≥50, 
obs/exp ≥0.6, > 200bp in length) (Gardiner-Garden & Frommer, 1987) and the 
newer, more stringent algorithm NCBI “strict” 
(http://www.ncbi.nlm.nih.gov/mapview/static/humansearch.html#cpg) (% GC ≥50, 
obs/exp ≥0.6, > 500bp in length) (Takai & Jones, 2002) was carried out. An online 
program called ‘The CpG island searcher’ (http://www.cpgislands.com), based on 
the study carried out by Takai and Jones, 2002 was employed to determine the 14-3-
3σ CpG island using the different algorithms (Figure 3.1 (A) & (B)). MethPrimer, 
(http://www.urogene.org/methprimer/index1.html) another online program was used 
alongside CpG Island searcher for comparison and to assist in designing bisulphite 
sequencing primers (Figure 3.1 (C)). The 14-3-3σ transcript sequence was based on 
the Ensembl (release 49) gene ENSG00000175793. To define the position of the 14-
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3-3σ CpG island, the complete 14-3-3σ transcript sequence, including 300 base pair 






Figure 3.1: Bioinformatic analysis of 14-3-3σ CpG island using various 
algorithms.  
Complete 14-3-3σ transcript was analysed and an additional 300 base pairs of 
upstream sequence. Exon 1 of 14-3-3σ is depicted as a thick horizontal black line with 
untranslated region (UTR) shown as a thick horizontal green line. Transcriptional start 
site is indicated by an arrow and start codon also indicated (ATG). CpG island (thick 
horizontal blue line) with individual CpG dinucleotides (fine vertical red lines) are 
additionally shown. The CpG island was defined according to (A) The CpG island 
searcher (Takai & Jones, 2002) using NCBI “relaxed” criteria. (B) The CpG island 
searcher using NCBI “strict” criteria (http://www.ncbi.nlm.nih.gov/mapview/static 
/humansearch.html#cpg) and (C) MethPrimer (http://www.urogene.org/ 








3.2.2 Bisulphite sequencing analysis 
CpG island in silico analysis of the 14-3-3σ gene locus indicated a distinct CpG 
island in which the transcriptional start site is at the 5’ end of the island with the 
majority of the CpG dinucleotides residing in the coding region of the gene. This is 
interesting as CpG islands frequently co-localise with the upstream sequence and 
transcriptional start site of genes (Illingworth et al, 2008; Larsen et al, 1992). This 
finding and the possible implications will be discussed in more detail towards the end 
of this chapter. The CpG island delineated by CpG island searcher with NCBI 
“strict” and “relaxed” criteria spans approximately 800 base pairs. The 14-3-3σ CpG 
island defined by the “relaxed” and “strict” criteria were very similar as there was 
only a 7 base pair difference. According to MethPrimer, the CpG island spans 
approximately 300 base pairs. A study reported by Suzuki et al, analysed two regions 
of 14-3-3σ for aberrant methylation (Suzuki et al, 2000). Region 1, a region 
upstream of the 14-3-3σ CpG island, corresponding to nucleotide (nt) -220 to nt 116 
and region 2 corresponding to nt 93 to nt 350 (assuming transcriptional start site = 
+1). Taking into consideration the previously published data by Suzuki et al and 
results from the in silico analysis, it was decided to analyse a region which spanned 
both the upstream promoter region and the 5’ region of the 14-3-3σ CpG island, 
which contains the highest frequency of CpG dinucleotides. Furthermore, it was 
considered important to examine a region encompassing the transcriptional start site 
and promoter sequence, accepting that the online tools determined that the majority 
of this region resided outside of the 14-3-3σ CpG island, since aberrant methylation 
in this region could have the most direct effect on gene expression. Three sets of 
bisulphite sequencing primers were designed to analyse the methylation status of 14-
3-3σ in an area spanning approximately 700 base pairs (nt -242 to nt 431). Bisulphite 
PCR sequencing of this area in vivo, suggested that there were three regions which 
may be differently methylated (see 3.3.2 for more details). Figure 3.2 illustrates the 
three regions in relation to the transcriptional start site and CpG island of 14-3-3σ as 
determined by bioinformatic analysis. These three regions were denoted Region A, 
Region B and Region C respectively. Nested and hemi-nested primers were designed 
using MethPrimer (Table 2.2 and Appendix A). Inner primer positions are shown in 
Figure 3.2. 14-3-3sRegA5’, 14-3-3RegA3’, 14-3-3RegA3’2 and 14-3-3RegA5’nest 
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primers were used in a hemi-nested PCR to amplify a 376 and a 493 base pair region 
from nt –242 to nt 134 and nt -242 to nt 251 respectively, this allowed analysis of 
methylation in the upstream region of 14-3-3σ (similar to region 1 in Suzuki et al 
study) (2.4.4). Primers 14-3-3sRegB5’, 14-3-3RegB3’ and 14-3-3RegB3’nest (2.4.4) 
were also utilised in a hemi-nested PCR to amplify a 307 base pair region from nt 74 
to nt 381 further downstream in the CpG rich coding region of 14-3-3σ. 14-3-
3sRegC5’, 14-3-3sRegC3’, 14-3-3sRegC5’nest and 14-3-3sRegC3’nest (2.4.4) 
primers were used in a nested PCR to amplify a 204 base pair region from nt 227 to 
nt 431 to analyse methylation further downstream from Region B. Primer sets were 
designed to overlap to ensure that the methylation status of each individual CpG 
dinucleotide could be determined. 
 
For colorectal cancer cell line, colorectal tumour and normal mucosa DNAs, ~500ng 
was bisulphite treated as described in 2.4.1 and then used for amplification with the 
Platinum Taq PCR kit (2.4.3). Direct sequencing of the PCR products was carried 
out as described in 2.4.7 and the sequence data analysed for methylated CpG 
dinucleotides as described in 2.4.9. Each sequencing chromatogram was assessed for 
background noise and full conversion of the DNA following bisulphite treatment by 
analysing relevant controls and verifying the conversion of non-CpG associated 
cytosine residues to thymine residues in each sequence. Bisulphite sequencing was 
also performed in triplicate for some samples in order to unambiguously determine 
the methylation status of individual CpG dinucleotides. The numbers of colorectal 
cancer cell lines, tumours and corresponding normal mucosa samples that were 
investigated for each of the defined regions are outlined in subsequent sections of 
this chapter for clarity. 
 
Six colorectal tumours, and one colonic normal mucosa sample and three skin tissue 
samples from non-colorectal cancer individuals were analysed for 14-3-3σ 
methylation in Regions A and B by bisulphite sequencing individual clones. PCR 
products were cloned into TA vectors as described in 2.5.1. Using the M13F and 
M13R primers each bacterial colony was directly amplified as described (2.4.3). 
PCR products from clones with the correct size inserts were subsequently sequenced 
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and analysed for methylated CpG dinucleotides as described in 2.4.9 and as above. 
Data analysis consisted of plotting CpG dinucleotides for each clone and calculating 













































































































































































































































































































































3.2.3 MSP analysis of colorectal cancer cell lines 
500ng colorectal cancer cell line DNA was bisulphite treated as described (2.4.2) and 
analysed by MSP using primers that covered CpG sites 135, 138, 201 and 210 in the 
5’ region of the 14-3-3σ CpG island (Figure 3.2). MSP reactions were carried out as 
described (2.4.3) to generate 105 base pair and a 107 base pair unmethylated and 
methylated products respectively, which were separated by gel electrophoresis to 
differentiate methylated from unmethylated 14-3-3σ 5’ regions (2.4.5). 
Densitometric analysis was performed as described (2.4.3). 
 
3.2.4 Statistical analysis 
Significant difference in the percentage of methylated CpG dinucleotides between 
14-3-3σ methylated and unmethylated colorectal tumours (previously determined by 
bisulphite PCR sequencing), were examined using non-parametric Mann Whitney 
tests as described in 2.10.1. The cut-off for significance was taken at 5% (p <0.05).  
 
The relationship between 14-3-3σ Region A methylation status in colorectal tumours 
and patient clinicopathological variables (gender, age, site of tumour, AJCC stage 
and presence of synchronous cancer) was assessed to determine any associations. 
Fishers exact test, unpaired t-test and Chi-squared tests were used as appropriate. The 
null hypothesis was rejected at the 5% level (p< 0.05). Correction for multiple testing 
was not appropriate, as none of the variables were statistically significantly 
associated with 14-3-3σ Region A methylation. 
 
3.2.5 Colorectal cancer cell lines 
DNA was purified from the following cell lines: HCT116, HT29, SW480 & 
Colo320DM as described in 2.2.1. Other colorectal cancer cell line DNA samples 
(HRT18, SW48, Caco-2, LoVo & SW620) were available directly from laboratory 
stocks.  
  
3.2.6 Patient samples 
Colonic normal mucosa tissue (NM) and tumour (T) samples from colorectal cancer 
patients, and skin tissues (skin A, skin B and skin C) from non-colorectal cancer 
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patients, were used for analysis and presented in this chapter. DNA was purified 
from fresh samples as described in 2.2.1. Other DNA samples were available directly 
from laboratory stocks, or directly from an external source (normal colonic mucosa 
from a cancer free patient, (Zyagen)). 
 
3.3 Results 
3.3.1 14-3-3σ methylation analysis of colorectal cancer cell lines 
Methylation-specific PCR (MSP) was first carried out on 9 colorectal cancer cell 
lines: SW480, Colo320DM, HT29, HCT116, Caco-2, LoVo, HRT18, SW48 and 
SW620 to determine the methylation status of 14-3-3σ. The MSP primers anneal to 
CpG dinucleotides 135 & 138 and 201 & 210 residing in Region B. MSP analysis 
showed that 78% (7/9) cell lines were unmethylated in this region (Figure 3.3). This 
was observed by the presence of amplified products in unmethylated-specific PCR 
reactions and little or no amplification in the methylated-specific PCR reactions. In 
addition, densitometric analysis showed higher intensity levels for unmethylated-
specific PCR reactions compared to methylated-specific PCR reactions (Table 3.1). 
Conversely, amplification of PCR products in methylated-specific PCR reactions 
(high densitometric intensity) and little or no amplification in the unmethylated-
specific PCR reactions (low densitometric intensity) are shown for two methylated 
colorectal cancer cell lines SW480 and Colo320DM. 
 
14-3-3σ methylation in the colorectal cancer cell lines was investigated further by 
bisulphite PCR sequencing. Bisulphite sequencing demonstrated that 7 of 9 cell lines 
were unmethylated in the upstream promoter region (Region A) of the 14-3-3σ CpG 
island. Figure 3.4 (A) shows sequencing chromatograms for two Region A 
unmethylated cell lines (HCT116 and HT29) and two Region A methylated cell lines 
(Colo320DM and SW480). HCT116 and HT29 cell lines were also completely 
unmethylated further downstream in the 5’ region of the 14-3-3σ CpG island 
(Regions B & C) (Figure 3.4 (B) & (C)) and cell lines Colo320DM and SW480 were 
fully methylated further downstream (Figure 3.4 (B) & (C)). A summary of the 
methylation profile of the three regions in 14-3-3σ for each colorectal cancer cell line 
is illustrated in Figure 3.5. 
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Figure 3.3: MSP analysis of 14-3-3σ methylation in colorectal 
cancer cell lines. 2/9 cell lines (SW480 and Colo320DM) were 
methylated. M = methylated specific reactions, U = unmethylated 
specific reactions, B = blank PCR reactions. 
Table 3.1: Densitometric analysis of MSP products from colorectal 
cancer cell lines. 2/9 cell lines (SW480 and Colo320DM) were 
methylated.  M = methylated specific reactions, U = unmethylated 
specific reactions. 













Figure 3.4: 14-3-3σ methylation analysis of colorectal cancer cell lines in (A) 
upstream promoter region (Region A) (nts 24, 27, & 31) (B) 5’ CpG island (Region 
B) (nts 135, 138 & 150) and (C) further downstream in 5’ CpG island (Region C) 
(385, 391, 394 & 401) using bisulphite sequencing directly from PCR products. 
Chromatograms show universal methylation status across the three regions: SW480 
and Colo320DM 14-3-3σ methylated cell lines, HT29 and HCT116 unmethylated cell 
















































































































































3.3.2 14-3-3σ methylation analysis of colorectal tumour samples 
The upstream region of 14-3-3σ (Region A; nt -242 to nt 134) was first analysed for 
methylation in a small number of colorectal tumour samples (n =12). Contrary to 
expectation, bisulphite PCR sequencing analysis revealed that 83% (10/12) of 
tumour samples were methylated in the upstream promoter region of 14-3-3σ. In 
some tumour samples, both cytosine and thymine peaks were present at the CpG 
sites. However, cytosine peaks were always higher in the chromatograms compared 
to the corresponding thymine peak suggesting that the region is methylated. Figure 
3.6 (A) shows bisulphite sequencing chromatograms from tumour sample (KR2T), 
which is unmethylated in the upstream region of 14-3-3σ and tumour sample 
(KR6T), which is methylated in the upstream region. In the unmethylated 14-3-3σ 
upstream region tumours, cytosine peaks were minimal in height or completely 
absent at CpG sites. In the methylated tumour sample KR6T there appears to be 
some background noise in the sequencing chromatogram, however this is negligible 
compared to the peak heights of the methylated cytosine residues at the individual 
CpG sites. Methylation analysis of a selection of these tumour samples further 
downstream, in the 5’ region of the 14-3-3σ CpG island (Region B; nt 74 to nt 381), 
demonstrated that all tumour samples exhibited both cytosine and thymine peaks of 
equal heights at the majority of CpG dinucleotides (n =6). This is shown in the 
bisulphite sequencing chromatograms for tumour samples KR2T and KR6T (Figure 
3.6 (B)). The occurrence of cytosine and thymine peaks of equal heights at individual 
CpG sites may be due to heterogeneity within the tumour sample. This will be 
discussed in more detail in later sections of the chapter. Bisulphite sequence analysis 
further downstream at a region corresponding to nt 227 to nt 431 (Region C) in a 
number of tumour samples demonstrated that all of the tumour samples (n =10) were 
methylated at CpG sites. Bisulphite sequencing chromatograms from tumour samples 
KR2T and KR4T are shown in Figure 3.6 (C). In this region, a mixture of cytosine 
and thymine peaks at CpG sites are often observed, however the cytosine peaks at the 
CpG sites were always of full height and higher than the corresponding thymine peak 
suggesting that this region of 14-3-3σ is methylated in the tumours examined. 
Overall, these results show that the upstream promoter region of 14-3-3σ is 
differentially methylated in individual tumour samples and regions further 
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downstream in the 5’ region of the CpG island are universally methylated or contain 
a mixture of both methylated and unmethylated CpG sites (hemi-methylated). As 
only the upstream promoter region of 14-3-3σ was found to be differentially 
methylated between individual tumours, it was decided to examine the 14-3-3σ 
methylation status in this region in a larger set of tumour samples. A total of 99 
colorectal tumours were examined by bisulphite sequencing and 90% (89/99) were 
methylated. A summary of the methylation data for each region and each tumour 




       
 
 
Figure 3.6: 14-3-3σ direct PCR bisulphite sequencing analysis of colorectal tumours 
in (A) upstream region: Region A (nt -242 to nt 134) (CpG sites 24, 27, & 31) (B) 5’ 
region of CpG island: Region B (nt 74 to nt 381) (CpG sites 135, 138 & 150) and (C) 
Region further downstream: Region C (nt 227 to nt 431) (CpG sites 385, 391, 394 & 
401). Differential methylation is shown in the upstream region with KR2T unmethylated and 
KR6T methylated. The two regions further downstream were universally methylated or hemi- 
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Methylation analysis from the direct sequencing of PCR products demonstrated that 
90% of colorectal tumours were methylated in the upstream promoter region (Region 
A) of 14-3-3σ. Bisulphite sequencing analysis carried out directly from PCR 
amplified products is useful in that the average level of methylation in the sample 
can be assessed and is good for screening purposes. However, bisulphite sequencing 
from clones provides methylation maps of single DNA strands from individual DNA 
molecules, and thus can be utilised for more detailed methylation analysis. 
Methylation in the upstream promoter region and 5’ region of the 14-3-3σ CpG 
island  (CpG sites -5 to 172; encompassing CpG sites in both Regions A and B) was 
re-analysed in 3 colorectal tumours previously found to be unmethylated in Region A 
(KR2T, KR3T & 7645) and 3 colorectal tumours previously found to be methylated 
in Region A (KR4T, KR11T & KR12T). 288 colonies from each tumour sample 
were picked and inserts checked for size using M13 primers. All colonies containing 
the correct size insert (~700bp) were subsequently PCR amplified and sequenced 
directly. Bisulphite sequencing analysis demonstrated that there were a lower 
percentage of methylated CpG dinucleotides in the 14-3-3σ unmethylated tumours 
KR2T, KR3T and 7645 (3.6%, 17.4% & 24.1% respectively) (Figure 3.8) compared 
to the previously found methylated tumours KR4T, KR11T and KR12T (29.8%, 
45.9% & 46.9% respectively) (Figure 3.9) (p =0.05, Mann Whitney test). Tumour 
samples 7645 and KR12T had similar methylation profiles (7645: 24.1% and 
KR12T: 29.8% methylated CpG sites), despite previous direct bisulphite sequencing 
analysis demonstrating that 7645 was unmethylated and KR12T was methylated in 
the 14-3-3σ upstream promoter region (Region A). Thus, further bisulphite 
sequencing analysis from sequencing individual clones is needed to confirm these 
initial findings. However, overall, the sequencing analysis showed that the 14-3-3σ 
methylated tumours have a clonal pattern of methylation where approximately half of 
the clones were methylated and half were unmethylated at CpG sites within the 
upstream region and 5’ region of the 14-3-3σ CpG island. In contrast, the majority of 
the clones sequenced from the 14-3-3σ unmethylated tumours were unmethylated, 




   
Figure 3.8: 14-3-3σ methylation profile (CpG sites -5 to 172, encompassing CpG 
sites in both Regions A & B) in colorectal tumours (A) KR2T (B) KR3T & (C) 7645 
previously found to be unmethylated by direct sequencing of PCR products. The 
number of clones analysed for each tumour sample are shown vertically and CpG 
dinucleotides ( -5 to 172, 11 total, shown in profile (A) only) across Regions A & B of 14-
3-3σ are shown horizontally. Filled circles represent methylated CpG dinucleotides. 
Unfilled circles represent unmethylated CpG dinucleotides. Number of clones 
sequenced and total percentage of methylated CpG dinucleotides is indicated alongside 




-5      24                      99        135             172 
Clones: 15 
 















Figure 3.9: 14-3-3σ methylation profile (CpG sites -5 to 172, encompassing CpG sites 
in both Regions A & B) in colorectal tumours (A) KR4T (B) KR11T & (C) KR12T 
previously found to be methylated by direct sequencing of PCR products. The number 
of clones analysed for each tumour sample are shown vertically and CpG dinucleotides ( -5 
to 172, 11 total, shown in profile (A) only) across Regions A & B of 14-3-3σ are shown 
horizontally. Filled circles represent methylated CpG dinucleotides. Unfilled circles represent 
unmethylated CpG dinucleotides. Number of clones sequenced and total percentage of 




-5      24                     99        135             172 
Clones: 19 
 















3.3.3 Clinicopathological associations with Region A 14-3-3σ 
methylation status 
Since the upstream promoter region (Region A) was differentially methylated in the 
99 colorectal tumour samples analysed for methylation, associations between 14-3-
3σ methylation status in this region and clinicopathological data was investigated 
using various statistical tests. There was no significant association between gender 
and Region A 14-3-3σ methylation status (Table 3.2, p = 0.11, Fishers Exact test). 
There was no significant difference in age and Region A 14-3-3σ methylation status 
(14-3-3σ methylated Region A mean age = 63.9, 14-3-3σ unmethylated Region A 
mean age = 59.8, p = 0.51, unpaired T-test). There was no significant association 
between the site of tumour and Region A 14-3-3σ methylation status (Table 3.2, p = 
0.67, Fishers Exact test). There was also no significant association with Region A 
14-3-3σ methylation status and the presence of a synchronous cancer (Table 3.2, p = 
1, Fishers Exact test). Finally, there was no significant association between 14-3-3σ 
Region A methylation status and the AJCC stage of cancer (Table 3.3, p = 0.23, Chi 
squared analysis). Overall, these results indicate that there is no significant 
association between Region A 14-3-3σ methylation status and clinicopathological 
data examined in this thesis. However, it must be emphasised that only relatively 
small number of tumours were examined. Hence, the power to detect associations 









Gender    
Male  53 3 56 
Female 36 7 43 
Site of tumour    
Left 40 6 46 
Right 15 1 16 
Synchronous cancers    
Yes 6 0 6 











1 8 2 10 
2 15 4 19 
3 26 1 27 
4 3 0 3 
Table 3.2: There was no significant association between Region A 14-3-3σ 
methylation status and gender, location or cancer multiplicity. 
 
Table 3.3: There was no significant association between Region A 14-3-3σ 




3.3.4 Lack of methylation in Region A is tumour-specific 
To determine the specificity of 14-3-3σ methylation, bisulphite PCR sequencing 
analysis of all three regions was undertaken in corresponding fresh colonic normal 
mucosa samples. CpG dinucleotides were fully methylated in Region A (CpG sites -
213 to 103) in 100% (10/10) normal mucosa samples analysed by bisulphite 
sequencing (Figure 3.10 (A)). Further downstream in Region B (CpG sites 135 to 
210), the chromatograms showed both thymine and cytosine peaks of equal height at 
each CpG dinucleotide suggesting that Region B in normal mucosa is hemi-
methylated (n =3) (Figure 3.10 (B)). Bisulphite sequencing analysis of 14-3-3σ 
further downstream again in Region C (CpG sites 261 to 401) in 10 normal mucosa 
samples demonstrated that all samples were fully methylated (Figure 3.10 (C)). In 
contrast to the minority of tumours (10%) in which there was complete loss of 
methylation at CpG sites -213 to 103 (Region A), tumours that were unmethylated in 
Region A (KR2T and KR3T), both corresponding normal mucosa samples were fully 
methylated in this region. Thus, the observed effect appears tumour-specific. A 
summary of the methylation profile for each normal mucosa sample in the three 
different regions is illustrated in Figure 3.11. 
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Figure 3.10: 14-3-3σ methylation analysis of (A) Region A (nts 24, 27, & 31) which 
was methylated (B) Region B (nts 135, 138  150) which was hemi-methylated and 
(C) Region C (385, 391, 394 & 401) which was methylated in normal mucosal 























































































































































3.3.5 14-3-3σ Region A methylation analysis in normal tissues 
from non-cancer subjects 
14-3-3σ methylation analysis in corresponding normal mucosa tissue showed that all 
CpG dinucleotides within the upstream promoter region (Region A: CpG sites -213 
to 103) were methylated. Bisulphite sequencing analysis was carried out directly 
from PCR amplified products, thus it was decided to analyse the methylation status 
of Region A 14-3-3σ methylation status further by bisulphite sequencing individual 
clones. Normal colonic tissue from a non-colorectal cancer patient was analysed, and 
for comparison three skin tissues were also analysed for Region A 14-3-3σ 
methylation.  
 
288 colonies from normal colon tissue and 288 for each of the three skin samples 
were picked and inserts checked for size using M13 primers and PCR amplification. 
All colonies containing the correct size insert (~700bp) were sequenced directly. 
Figure 3.12 shows the degree of methylation in normal colon across Region A (nt -
213 to nt 103) at individual CpG dinucleotide sites. Figure 3.12 demonstrates that in 
the normal colonic tissue, clones were methylated at most CpG dinucleotides within 
the analysed region (85.2%). In comparison, there were a lower number of 
methylated CpG dinucleotides in the skin tissue samples A, B and C (48.4%, 55.6% 
& 45.9% respectively) (Figure 3.13, 3.14 & 3.15 respectively). These results indicate 
that Region A of 14-3-3σ is methylated in the normal colon, confirming the previous 
bisulphite sequencing analysis (3.3.4), and there were lower levels of methylation in 
the skin tissue compared to normal colonic mucosa, as approximately half of the 
CpG dinucleotides were methylated and half were unmethylated in all three skin 





Figure 3.12: 14-3-3σ methylation profile in normal colonic mucosa from a non-
colorectal cancer patient. The number of clones analysed is shown vertically and 
CpG dinucleotides (Region A; nt -213 to 103, 9 total) are shown horizontally. Filled 
circles represent methylated CpG dinucleotides. Unfilled circles represent 
unmethylated CpG dinucleotides. Red circles represent undetermined methylation 
status due to the end of the run of sequencing. The number of clones sequenced and 
total percentage of methylated CpG dinucleotides is indicated alongside the 
methylation profile. 
-213   -139        -86       -5        24  27 31       99   103 
Clones: 55 
 





Figure 3.13: 14-3-3σ methylation profile in skin tissue sample A from a non-
colorectal cancer patient. The number of clones analysed is shown vertically and 
CpG dinucleotides (Region A; nt -213 to 103, 9 total) are shown horizontally. Filled 
circles represent methylated CpG dinucleotides. Unfilled circles represent 
unmethylated CpG dinucleotides. Number of clones sequenced and total percentage 
of methylated CpG dinucleotides is indicated alongside the methylation profile. 
-213    -139      -86       -5        24  27 31      99   103 
Clones: 25 
 





Figure 3.14: 14-3-3σ methylation profile in skin tissue sample B from a non-
colorectal cancer patient. The number of clones analysed is shown vertically and 
CpG dinucleotides (Region A; nt -213 to 103, 9 total) are shown horizontally. Filled 
circles represent methylated CpG dinucleotides. Unfilled circles represent 
unmethylated CpG dinucleotides. Number of clones sequenced and total percentage 
of methylated CpG dinucleotides is indicated alongside the methylation profile. 
-213   -139       -86       -5       24  27 31       99  103 
Clones: 88 
 





Figure 3.15: 14-3-3σ methylation profile in skin tissue sample C from a non-
colorectal cancer patient. The number of clones analysed is shown vertically and 
CpG dinucleotides (Region A; nt -213 to 103, 9 total) are shown horizontally. Filled 
circles represent methylated CpG dinucleotides. Unfilled circles represent 
unmethylated CpG dinucleotides. Number of clones sequenced and total percentage 
of methylated CpG dinucleotides is indicated alongside the methylation profile. 
-213    -139       -86       -5        24  27 31       99   103 
Clones: 84 
 






Research investigating the role of 14-3-3σ methylation in colorectal cancer has been 
limited and in the few studies carried out, tumour-specificity of aberrant 14-3-3σ 
methylation in colorectal cancer was not fully investigated. Therefore, my aims for 
this chapter were to analyse 14-3-3σ methylation status in a series of colorectal 
cancer cell lines, colorectal tumours and corresponding colonic normal mucosa 
tissues. From using online tools and taking into account previous published results, I 
decided to analyse a region spanning approximately 800 base pairs, which 
encompassed the upstream promoter region of the gene and the 5’ region of the 14-3-
3σ CpG island. This region was mainly analysed by bisulphite sequencing to 
examine region-specific methylation and investigate whether differential methylation 
of 14-3-3σ plays a role in colorectal carcinogenesis. To further examine the 
specificity of 14-3-3σ methylation in colorectal cancer, I also examined methylation 
in the upstream promoter region of the gene and in the 5’ region of the CpG island in 
colonic mucosa tissue and skin tissues from individuals free of cancer.  
 
As discussed in section 3.2.2, the 14-3-3σ CpG island is unusual as almost all of the 
CpG island resides in the exon rather than localised to the upstream promoter region 
of the gene. However, a recent study found that a large proportion of CpG islands are 
either inter- or intragenic and that these particular CpG islands were preferentially 
susceptible to methylation (Illingworth et al, 2008). This is interesting as the 14-3-3σ 
CpG island is methylated in some cell types and tissues (Oshiro et al, 2005). 
Therefore, it may be that the 14-3-3σ CpG island belongs to this subset of 
methylated intragenic CpG islands. 
  
In contrast to colorectal tumour tissue, analysis of colorectal cancer cell lines 
revealed that 78% (7/9) were unmethylated in the upstream promoter region (Region 
A) of 14-3-3σ. Analysis of Regions B and C in colorectal cancer cell lines 
unmethylated in Region A also indicated that CpG dinucleotides are unmethylated 
further downstream in the CpG island. Bisulphite PCR sequencing of 14-3-3σ in 
SW480 and Colo320DM colorectal cancer cell lines showed that all CpG sites were 
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fully methylated in all three regions examined. These results demonstrate that the 
methylation status of 14-3-3σ in the majority of colorectal cancer cell lines is very 
different to the methylation status of the majority of colorectal tumours and normal 
mucosa samples. There is also a difference in the distribution of methylated or 
unmethylated CpG dinucleotides across the upstream region and the 5’ region of the 
14-3-3σ  CpG island. The methylation profile of 14-3-3σ in the cell lines is uniform 
across the upstream promoter region and the 5’ CpG island, unlike in fresh colorectal 
tumours in which the peak heights of methylated CpG sites varied across the regions. 
The differences observed may be due to the heterogeneity of cells in the tumour 
samples compared to the population of cells in the cell lines. The tumour samples 
will consist of an admixture of cell types whereas the cell lines will consist of a 
homogenous cell population. The heterogeneity of the tissues examined in this thesis 
and its implications on the data that I have presented will be discussed in more detail 
throughout this section. It must also be considered that the cell lines may not be 
closely related to their primary tumours from which they originated from. For 
example, the epigenetic changes in the colorectal cancer cell lines may be induced by 
cell culture. Methylation profiling in cancer cell lines has however shown that they 
generally have higher levels of CpG island hypermethylation than primary tumours 
(Paz et al, 2003; Suter et al, 2003). This suggests that in the colorectal cancer cell 
lines, 14-3-3σ may have escaped this “induction”. 
 
Methylation analysis of 14-3-3σ  in colorectal tumours by bisulphite PCR 
sequencing demonstrated that there may be three distinct regions of methylation. It is 
recognised however, that each of these regions were sequenced separately and so 
they cannot be directly linked. Region A (CpG sites -213 to 103) had variable 
methylation status between individual tumour samples. 90% (89/99) of colorectal 
tumours were methylated and 10% were unmethylated in the upstream region. All 
tumours examined for methylation in the two regions further downstream were either 
hemi-methylated (Region B, CpG sites 135 to 210) or fully methylated (Region C, 
CpG sites 261 to 401). As mentioned above, the occurrence of both cytosine and 
thymine peaks at CpG sites in Region B may be due to tumour heterogeneity. 
However, it must also be considered that the observed ‘hemi-methylation’ could be a 
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result of differences in the efficiencies of the PCR or sequencing reactions. This is 
discussed in more detail below. 
 
Following the initial analysis of 14-3-3σ methylation in a small number of tumours, I 
decided it was important to concentrate primarily on the upstream promoter region of 
14-3-3σ, as this was the only region in which the bisulphite PCR sequencing data 
suggested that there could be differential methylation between individual tumour 
samples. However, 14-3-3σ methylation analysis further downstream in the 5’ CpG 
island region (Regions B & C) also in a larger dataset is required in order to fully 
determine the methylation profile across the CpG island and confirm the preliminary 
sequencing data that was carried out. Furthermore, the algorithms calculated that the 
14-3-3σ CpG island is 800 base pairs, therefore it would be interesting to analyse the 
methylation status of CpG sites downstream from Region C, across the entire CpG 
island. The majority of 14-3-3σ methylation analysis was performed by bisulphite 
sequencing directly from PCR products. Direct sequencing is advantageous in that it 
can assess the average level of methylation in a given sequence as a pool of PCR 
products are sequenced rather than single DNA strands. As well as providing the 
overall level of methylation, direct sequencing can introduce less bias compared to 
sequencing individual clones and is a useful method for rapid screening. Conversely, 
bisulphite sequencing of single clones is utilised for more detailed analysis and to 
determine methylation maps of CpG islands. This was carried out for a subset of 
colorectal tumours for the analysis of methylation in the upstream promoter region of 
14-3-3σ and the 5’ region of the CpG island, encompassing CpG sites in both 
Regions A and B. The analysis partly confirmed the previous bisulphite sequencing 
data as it revealed that the majority of clones were unmethylated at CpG sites in the 
14-3-3σ unmethylated tumours and had a low percentage of overall CpG 
methylation. Sequencing analysis of the 14-3-3σ methylated tumours demonstrated 
that they had a clonal pattern of methylation with approximately half of the clones 
displaying mainly methylated CpG sites and half displaying mainly unmethylated 
CpG sites. Therefore, this suggests that in the majority of colorectal tumours, the 
upstream promoter region and the 5’ region of the 14-3-3σ CpG island is both 
methylated and unmethylated. In comparison with the previous bisulphite PCR 
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sequencing, there was no change in methylation across Regions A and B. This may 
be because there is no actual change in the methylation status across the 14-3-3σ 
island, and as mentioned above, the observed ‘hemi-methylation’ is actually due to 
tumour heterogeneity, which is discussed in more detail below. As only six tumours 
were analysed by bisulphite sequencing individual clones, and because the 
percentage of methylated CpG dinucleotides between one of the previously found 
methylated tumours (KR12T) and one of the unmethylated tumours (7645) were 
fairly similar, further analysis is required to confirm these initial findings. 
Nevertheless, the bisulphite sequencing analysis carried out indicated that the 14-3-
3σ unmethylated tumours had a lower percentage of methylated CpG sites compared 
to the methylated tumours, therefore suggesting that their methylation profiles are 
different. The ‘mixed’ clonal methylation pattern observed in the majority of 
colorectal tumours may be a result of intra-tumour heterogeneity, with 14-3-3σ 
methylation status varying between individual tumour cells. Interestingly, in a recent 
report, MLH1 was found to have a heterogeneous pattern of promoter methylation 
within endometrial tumours (Varley et al, 2009). It could also be possible that the 
different alleles of the 14-3-3σ upstream region and CpG island display different 
methylation patterns. To investigate this further, the heterozygosity of a Single 
Nucleotide Polymorphism (SNP) within or in close proximity to the promoter region 
or the CpG island of the gene would need to be analysed. Alternatively, it should also 
be considered that 14-3-3σ may actually be unmethylated in the majority of 
colorectal tumours, in agreement with what was found in the report by Ide et al (Ide 
et al, 2004), and the methylation detected in the tumour samples is due to other 
factors. It may be that there has been incomplete conversion of the tumour DNA 
following bisulphite treatment. Although, this is probably not the case since the 
conversion of each sample is verified by the relevant bisulphite controls and the 
sequence is assessed by eye for complete conversion. The methylation detected could 
also be a result of a combination of PCR bias and the amplification of methylated 14-
3-3σ in other cell types within the tumour sample. All tumour samples are biopsied 
from the proliferative edge of the tumour and assessed by immunohistochemistry 
(prior to use) to ensure that more than 85% of cells are tumour derived. Therefore, 
despite the fact that the majority of cells will be tumour derived, the samples still 
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consist of a heterogeneous cell population. 14-3-3σ methylation has been shown 
previously in peripheral blood lymphocytes (Bhatia et al, 2003; Umbricht et al, 2001) 
and in stroma surrounding epithelium tissue (Lodygin et al, 2003; Umbricht et al, 
2001). Thus, the methylation observed in the colorectal tumours may be from these 
cell types and the higher levels are simply a result of more stromal cells being 
present in the tumour sample for example. In order to control for tissue 
heterogeneity, the tumours could be microdissected. Laser Capture Microdissection 
(LCM) is a technique routinely used to isolate a pure population of cancer cells from 
frozen or embedded tumour sections leaving behind remaining stromal and 
inflammatory cells. The study by Ide et al examined 14-3-3σ methylation in ten 
microdissected colorectal tumours and found that the majority of tumours were 
unmethylated (Ide et al, 2004). The differences observed between this study and the 
results presented in this chapter may be a result of the different sample preparations 
that were used. In hindsight, LCM of the tumour samples prior to 14-3-3σ 
methylation analysis would have provided the purest sample for methylation analysis 
and control for tissue heterogeneity. However, LCM was not available during my 
PhD and there were also insufficient amounts of tumour material available for me to 
use this technique prior to methylation analysis.  
 
Bisulphite PCR sequencing of 14-3-3σ in corresponding normal mucosa samples 
indicated that the upstream promoter region (Region A) was fully methylated in all 
samples. Bisulphite sequencing analysis of 14-3-3σ further downstream in Region B 
revealed that methylation status in this region was similar to the methylation status 
initially found in the colorectal tumours, as it was hemi-methylated in all of the 
normal mucosa samples analysed. 14-3-3σ Region C methylation status in the 
normal mucosa was similar to the tumour samples and was methylated. Again, as 
with the bisulphite PCR sequencing of the colorectal tumours, the observed ‘hemi-
methylation’ in region B could be a result of tissue heterogeneity or PCR/sequencing 
bias. Region A of 14-3-3σ was however found to be methylated in all normal mucosa 
samples, including KR2NM and KR3NM in which Region A was unmethylated in 
the corresponding tumours. Therefore, this suggests that the absence of methylation 
in the upstream promoter region of 14-3-3σ is a tumour-specific event. Tumour-
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specific loss of methylation in the upstream region was not associated with any 
clinicopathological variable, perhaps due to the small number of Region A 14-3-3σ 
unmethylated colorectal tumours analysed (n =10). In order to examine this further, a 
larger dataset of colorectal tumour samples would need to be analysed for Region A 
14-3-3σ methylation.  
 
Similar to the adjacent normal mucosa tissue, Region A of 14-3-3σ was shown to be 
methylated at the majority of CpG sites in nearly all of the clones amplified from 
normal mucosa from an individual free from cancer. In comparison, approximately 
half of the CpG sites were shown to be methylated in skin tissues, indicating that 
skin and colonic epithelium may have different methylation profiles. The mixture of 
methylated and unmethylated CpG sites of 14-3-3σ in the skin tissue could be due to 
tissue heterogeneity or unequal methylation of the two 14-3-3σ alleles (as discussed 
previously with regard to the colorectal tumours). It should be noted however, that 
the methylation profiles from the three skin samples do not display a clonal pattern 
of methylation unlike the colorectal tumours. Instead, the heterogeneity exists at each 
CpG dinucleotide, suggesting that the observed methylation pattern may be the result 
of a separate process in comparison to the colorectal tumours.  
 
From the detailed bisulphite sequencing analysis of 14-3-3σ in both colorectal 
tumours and normal colonic epithelium from a non-colorectal cancer patient, the 
preliminary data suggests that there may be a tumour-specific loss of methylation in 
Region A of 14-3-3σ in all tumours with 10% showing an almost complete loss. 14-
3-3σ methylation analysis in corresponding adjacent normal mucosa samples by 
bisulphite sequencing individual clones, as well as sequencing more tumour samples, 
would support this notion. Furthermore, only one normal colonic mucosa tissue 
sample from a cancer free individual has been sequenced, therefore this also needs to 
be taken into consideration. Follow-up 14-3-3σ methylation analysis in more normal 
colonic tissue samples from cancer free individuals is also needed to support these 
preliminary findings. As with the tumour material, it should also be considered that 
the normal mucosa tissue consists of a heterogeneous cell population. The collection 
and assessment (by immunohistochemistry) of corresponding normal mucosa tissue 
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in the laboratory is well established and it is believed that the majority of cells will 
be epithelial in origin (Prof Malcolm Dunlop & Dr Susan Farrington, personal 
communication). Despite this, a small proportion of lymphocyte cells and stromal 
cells will be present in the tissue samples, therefore these cells may also contribute to 
the methylation of 14-3-3σ observed in the normal mucosa samples. In order to test 
this, LCM could be used to isolate a pure population of epithelial cells from the 
normal mucosa tissues examined in this chapter and subsequently analysed for 14-3-
3σ methylation by bisulphite sequencing. In addition to the heterogeneity of the 
normal tissue, the possibility that contaminating tumour cells are present in the 
normal tissues must also be addressed. All normal mucosa tissue samples are 
biopsied from areas on the opposite side of the colon to the tumour site, so it is 
unlikely that there will be any contaminating tumour cells within the samples. 
However, “tumour-like” cells may be present in the normal mucosa samples as a 
result of field cancerisation. A recent study found that the O6-methylguanine-DNA 
methyltransferase gene (MGMT) was methylated in 50% of normal colon tissues 
with MGMT promoter methylation in adjacent tumours and in 12% of normal colon 
tissues from patients with no evidence of cancer (Shen et al, 2005). Thus, the 14-3-
3σ Region A methylation observed in both the adjacent normal mucosa tissues and 
the normal mucosa tissue from a non-colorectal cancer patient may be a result of a 
field defect. To investigate this further, a larger study would need to be conducted in 
which 14-3-3σ methylation is analysed in colorectal tumours, corresponding adjacent 
normal mucosa tissues and normal mucosa tissues from patients free of cancer. 
Examining normal mucosa tissues from the opposite side of the colon to the tumour 
site may be advantageous with regards to lowering the possibility of analysing 
contaminating tumour cells, however it must also be considered that the methylation 
status of 14-3-3σ may vary in different areas of the colon. As discussed in the 
introduction section, a significantly higher proportion of CIMP tumours are right-
sided (Hawkins et al, 2002). Therefore, it may be that the observed difference in 14-
3-3σ methylation status in the normal colonic tissue is a result of biopsies taken from 
the opposite side of colon to the tumour site. In order to test this, 14-3-3σ 
methylation analysis would need to be carried out on two normal colonic tissue 
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biopsies, one on the opposite side of the tumour site and one on the same side as the 
tumour site.          
 
In summary, I have demonstrated that the majority of colorectal cancer cell lines are 
unmethylated in the upstream promoter region and 5’ region of the 14-3-3σ CpG 
island. In the majority of colorectal tumours, bisulphite sequencing analysis of 
individual clones suggested that the upstream promoter region and 5’ region of the 
14-3-3σ CpG island is both methylated and unmethylated in colorectal tumours with 
a small percentage of tumours being almost completely unmethylated. 14-3-3σ 
methylation was observed in all the corresponding normal mucosa tissues examined 
and in normal mucosa tissue from a non-colorectal cancer patient, therefore 
suggesting that there may be a tumour-specific loss or hypomethylation of 14-3-3σ in 
colorectal tumours. However, as discussed, to fully understand the role of 14-3-3σ 
methylation in colorectal cancer, further investigations, including the methylation 
analysis of larger datasets, the investigation of the effects of tissue heterogeneity, and 
field cancerisation are required.  
 
With the aim to support the preliminary data presented thus far, and the notion that 
14-3-3σ hypomethylation in colorectal cancer may contribute to further downstream 
effects, the relationship between 14-3-3σ expression and methylation status is 





Analysis of 14-3-3σ expression and its 
association with methylation of the gene 




Preliminary findings in chapter 3 demonstrated that 14-3-3σ is umethylated in the 
upstream promoter region (UPR) and 5’ region of the CpG island in the majority of 
colorectal cancer cell lines. In vivo, analysis in the same regions showed that 14-3-3σ 
was differentially methylated in tumour samples, with the majority of tumours 
displaying a clonal pattern of methylation and a small proportion showing low to 
negligible levels of methylation. Analysis of 14-3-3σ methylation in both 
corresponding colonic normal mucosas and colonic normal mucosa tissue from an 
individual free from cancer revealed that the gene was methylated in all samples 
examined, suggesting that there may be a tumour-specific loss of 14-3-3σ 
methylation in colorectal tumours. Furthermore, in comparison to methylated normal 
colon tissue, 14-3-3σ was shown to be both methylated and unmethylated at 
individual CpG sites in skin tissue, which is known to positively express 14-3-3σ 
(Leffers et al, 1993; Oshiro et al, 2005). 
 
Previous reports have shown that in a number of different cancers, aberrant 
methylation of 14-3-3σ is associated with changes in gene expression (Ferguson et 
al, 2000; Mhawech et al, 2005; Suzuki et al, 2000). With this in mind, including the 
preliminary data presented in chapter 3, the hypothesis I wish to test is that 14-3-3σ 
expression levels will be associated with 14-3-3σ methylation status in colorectal 
cancer cell lines, colorectal tumours and in normal colonic tissue. Henceforth in this 
chapter, methylated and unmethylated 14-3-3σ refers to the methylation status in the 
UPR of 14-3-3σ of a given sample determined from the earlier bisulphite PCR 
sequencing data. The association between 14-3-3σ expression and UPR methylation 
status in normal tissues from individuals free from cancer will be investigated based 
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on the bisulphite sequencing analysis from individual clones. The aim of this chapter 
is thus to establish whether the UPR methylation status of 14-3-3σ is associated with 
gene expression in colorectal cancer cell lines, colorectal tumours, matched normal 
mucosa samples and also in colonic mucosa and skin tissues from individuals free 
from cancer. Expression analysis of 14-3-3σ in colorectal cancer cell lines, colorectal 
tumours and in matched normal colonic mucosa was carried out at both the mRNA 
and protein level using a qRT-PCR and Western Blot approach respectively. 
Comparison of 14-3-3σ protein expression in normal colonic mucosa and skin tissues 
was examined by Western blot analysis only. Demethylation of 14-3-3σ in two 
methylated colorectal cancer cell lines by 5-Aza-2’-deoxycytidine treatment was 
optimised and subsequently examined by MSP analysis. Relative levels of 14-3-3σ 
mRNA expression were examined in the colorectal cancer cell lines following 5-
Aza-2’-deoxycytidine treatment to determine whether 14-3-3σ  can be re-expressed 




Figure 4.1: β-Actin RT-PCR from colorectal cancer cell line cDNA samples (+) and 
corresponding negative reverse transcriptase reactions (-) confirming removal of 
gDNA contamination.  
4.2 Methodology 
4.2.1 qRT-PCR analysis 
RNA from colorectal cancer cell lines (including 5-Aza-2’-deoxycytidine treated cell 
lines), normal mucosa tissues and colorectal tumours were DNase treated to remove 
contaminating genomic DNA (gDNA) as described in section 2.6.1. This was 
required as the 14-3-3σ primers and probe were designed within the exon of the gene 
and not on the exon junction (14-3-3σ has only one exon). Therefore, qRT-PCR 
amplification would not distinguish between gDNA and cDNA amplification. 
Following DNase treatment, cDNA synthesis was carried out as described in section 
2.6.2 and the removal of gDNA contamination was verified by amplifying the 
control gene template, β-actin, from cDNA and corresponding negative reverse 
transcriptase reactions as described in section 2.4.3. The β-actin primers were 
designed to amplify a region within a single exon and therefore could detect any 
contaminating gDNA in the negative reverse transcriptase reactions. Each RNA 
sample extracted was tested in this way and cDNA samples with contaminating 
gDNA were discarded. Figure 4.1 shows a β-actin RT-PCR reaction from colorectal 
cancer cell lines. Amplified β-actin products are visible from the positive cDNA 
samples however, they are not present in the negative reverse transcriptase reactions. 
Thus, confirming that the DNase treatment was successful in removing all 
contaminating gDNA from the RNA sample. β-actin RT-PCR reactions from all 
other cDNA samples are illustrated in Appendix B. Negative reverse transcriptase 
reactions were also tested for gDNA contamination alongside cDNA samples during 












Following the verification of gDNA removal, cDNA samples were subjected to qRT-
PCR Taqman analysis as described in section 2.6.3. Relative quantification of 14-3-
3σ mRNA levels was performed using the standard curve method and the target 14-
3-3σ mRNA levels normalised by the endogenous control (β-Actin). All raw data 
and subsequent calculations, including standard curves for each analysis are listed in 
Appendix B. 
 
4.2.2 Western blot analysis 
Cytoplasmic cell extracts from colorectal cancer cell lines, normal mucosa tissues, 
colorectal tumours and skin tissues were examined for 14-3-3σ expression by 
Western blot analysis as described in section 2.6.5.3. Protein loading was assessed by 
probing for β-actin levels and densitometric analysis carried out as described in 
2.6.5.3. 
 
4.2.3 5-Aza-2’-deoxycytidine treatment 
SW480 and Colo320DM colorectal cancer cell lines (14-3-3σ methylated) were 
treated with 5-Aza-2’-deoxycytidine as described in section 2.7.1. Both cell lines 
were treated with 0.1µM to 10µM 5-Aza-2’deoxycytidine over a 4 day period in 
order to test optimal conditions. Control experiments comprised of cells completely 
untreated or treated with vehicle (50% acetic acid). DNA was extracted from treated 
and control cells, bisulphite treated (2.4.2) and examined by MSP analysis to 
determine 14-3-3σ demethylation. 
 
4.2.4 Methylation-specific PCR (MSP) 
14-3-3σ MSP was performed on bisulphite treated DNA extracted from 5-Aza-2’-
deoxycytidine treated colorectal cancer cell lines as described in section 2.4.3 and 
2.4.4 to verify the demethylation of 14-3-3σ following treatment. Products were 
analysed for methylation by gel electrophoresis (2.4.5) and densitometric analysis 
carried out as described in 2.4.3. 
 
 132 
4.2.5 Colorectal cancer cell lines 
RNA and cytoplasmic cell extracts were purified from the following cell lines: 
HCT116, HT29, SW480 & Colo320DM as described in 2.2.3 and 2.6.5.1 
respectively. DNA was extracted from the 5-Aza-2’-deoxycytidine treated cell lines 
SW480 and Colo320DM as described in 2.2.1. 
 
4.2.6 Patient samples 
Matched normal mucosa tissue (NM) and tumour samples (T) from colorectal cancer 
patients were used in this chapter. Three skin tissue samples (Skin A, Skin B and 
Skin C) from individuals free from cancer were also used. Fresh normal colonic 
mucosa from an individual free from disease and cancer (NC) was used for qRT-
PCR analysis, whereas cytoplasmic extract from normal colonic mucosa from an 
individual free from cancer (NC) was used directly from an external source 
(Zyagen). RNA and cytoplasmic extracts were purified from fresh samples as 
described in 2.2.3 and 2.6.5.2 respectively. 
 
4.2.7 Statistical analysis 
Significant differences were examined by performing paired Wilcoxon signed rank 
tests and unpaired non-parametric Mann Whitney tests as described in 2.10.1. The 





4.3.1 14-3-3σ expression analysis in colorectal cancer cell lines 
The work presented in chapter 3 investigated the methylation status of 14-3-3σ in 
nine colorectal cancer cell lines and found that the majority were unmethylated. Only 
two cell lines were methylated: SW480 and Colo320DM. To investigate whether 
there are any associations between 14-3-3σ methylation status and expression, 
mRNA expression and protein levels in the two methylated cell lines SW480 and 
Colo320DM and two unmethylated cell lines HT29 and HCT116 were examined. 
Firstly, qRT-PCR analysis demonstrated that there were high 14-3-3σ mRNA levels 
in the unmethylated cell lines HT29 and HCT116 and only a negligible level of 14-3-
3σ mRNA in the methylated cell lines SW480 and Colo320DM (Figure 4.2). 14-3-
3σ mRNA levels in the unmethylated cell lines was approximately 400-fold higher 
than in the methylated cell lines. Further analysis was carried using Western blot 
analysis to investigate the expression of the 14-3-3σ protein in methylated and 
unmethylated cell lines. Western blot analysis demonstrated that there were high 
levels of 14-3-3σ protein in the two unmethylated colorectal cancer cell lines HT29 
and HCT116 and again only negligible levels of 14-3-3σ protein in the two 
methylated colorectal cancer cell lines SW480 and Colo320DM (Figure 4.3). As only 
two methylated and two unmethylated colorectal cell lines were examined for 14-3-
3σ expression, the sample numbers are too small to test for differences in expression 
levels between the colorectal cancer cell lines. The data does however demonstrate 
that there are lower levels of 14-3-3σ expression in the methylated cell lines 





































































































































































































































Figure 4.3: Detection of cytoplasmic 14-3-3σ protein by Western blot in 
colorectal cancer cell lines: Colo320DM and SW480 (14-3-3σ methylated) 
and HCT116 and HT29 (14-3-3σ unmethylated). β-actin levels were analysed 
to assess protein loading. Film was exposed for 3 minutes for the detection of 




4.3.2 14-3-3σ mRNA expression analysis in vivo 
Expression studies in vitro demonstrated that there were lower levels of 14-3-3σ 
expression in the methylated colorectal cancer cell lines compared to the 
unmethylated colorectal cell lines which expressed high levels of 14-3-3σ. Following 
on from this initial finding, the expression levels of 14-3-3σ at the mRNA level was 
first examined in a set of colorectal tumours and corresponding normal mucosa 
samples. A total of 5 colorectal tumours and matched normal mucosa tissues were 
examined: 3 of the tumours were unmethylated (KR2, KR3 and AM27) and 2 
tumours were methylated (KR10 and KR11). In addition, normal colonic mucosa 
from an individual free from cancer was analysed for comparison. qRT-PCR analysis 
demonstrated higher levels of 14-3-3σ mRNA in two of the 14-3-3σ unmethylated 
tumours (KR2 and KR3) compared to 14-3-3σ mRNA levels in the corresponding 
normal tissues (Figure 4.4). Interestingly, unlike other 14-3-3σ unmethylated tumour 
samples, AM27 displayed low 14-3-3σ mRNA levels and 14-3-3σ mRNA could not 
be detected in the matched normal mucosa tissue. The normal mucosa sample did 
express the endogenous control β-actin, indicating that the lack of 14-3-3σ mRNA 
was not due to low concentration of cDNA in this sample. It is not clear why this 
result was obtained but complete lack of 14-3-3σ in normal tissue suggests that 
another mechanism may be involved in silencing 14-3-3σ expression. When 
combining expression data from all three unmethylated tumours and matched normal 
tissues, it was found that there was no significant difference in 14-3-3σ  mRNA 
levels between the unmethylated tumours and matched normal mucosa tissues (p = 
0.25, paired Wilcoxon signed rank test). These initial findings also demonstrated that 
14-3-3σ mRNA levels in the unmethylated KR2 and KR3 tumours were relatively 
higher compared to methylated tumours KR10 and KR11. In order to test whether 
there is a significant difference in expression between methylated and unmethylated 
tumours, a separate set of tumour samples were examined for 14-3-3σ mRNA 
expression (Figure 4.5). There was an average 3-fold difference in expression 
between the methylated and unmethylated tumours with higher mRNA expression in 
the 14-3-3σ unmethylated tumours (p = 0.03, Mann Whitney test). Therefore, 
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preliminary data suggests that there may be an association in vivo between 14-3-3σ 















































































































































































































































































































































4.3.3 14-3-3σ protein expression analysis in vivo 
Section 4.3.2 demonstrated that there were significantly higher levels of 14-3-3σ 
mRNA in unmethylated colorectal tumours compared to methylated tumours. This 
initial finding and previous analysis carried out in vitro suggests that 14-3-3σ protein 
expression may also be associated with methylation status in colorectal tumours and 
matched normal tissues. To examine this, 14-3-3σ protein levels were first examined 
in 4 colorectal tumours and matched normal tissue samples: 2 unmethylated tumours 
(KR2 and KR3) and 2 methylated tumours (KR1 and KR4) by Western blot analysis. 
Figure 4.6 shows Western blot analysis of 14-3-3σ detection in the tumours and 
matched normal tissues. 14-3-3σ protein is detected at higher levels in the 
unmethylated tumours KR2 and KR3 compared to the matched normal tissue. It 
should however be taken into account that there is unequal protein loading in some 
of these samples and therefore the differences observed may not be so considerable. 
In the methylated tumours there is a decrease in 14-3-3σ protein levels in the tumour 
KR1 compared to matched normal tissue and a small increase in protein levels in the 
tumour KR4 compared to matched normal tissue. Interestingly, when grouping all 
corresponding normal mucosa tissues and tumour samples analysed by Western blot, 
densitometric analysis demonstrated an overall higher level of 14-3-3σ protein in the 
tumour samples compared to the matched normal tissue (Figure 4.7). Secondly, to 
further investigate the relationship between 14-3-3σ methylation status and protein 
expression in colorectal tumours, 14-3-3σ protein levels were examined in 9 
additional colorectal tumour samples: 5 14-3-3σ unmethylated tumours (10811, 
10812, 7007, 7645 and 1924) and 4 14-3-3σ methylated (2109, KR8, KR9 and 
KR10) and one normal mucosa tissue sample from a non-colorectal cancer patient 
(Figure 4.8). Western blot and subsequent densitometric analysis (Figure 4.9), 
demonstrated that 14-3-3σ protein levels were higher in unmethylated tumours 
compared to the majority of methylated tumours and the normal mucosa tissue from 
a non-colorectal cancer patient. However, tumour sample KR8, which is methylated 
in the upstream promoter region of 14-3-3σ has a higher level of 14-3-3σ protein 
expression compared to the other methylated tumours. This anomalous finding may 
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be the result of another mechanism such as gene amplification and is discussed in 
further detail in the discussion section of this chapter. 
 
To further examine the relationship between 14-3-3σ UPR methylation status and 
expression, Western blot analysis was utilised for the analysis of 14-3-3σ protein 
levels in skin tissue compared to normal colonic tissue from colorectal cancer 
patients (Figure 4.10). Western blot and subsequent densitometry analysis (Figure 
4.11) demonstrates that 14-3-3σ protein levels are higher in the three skin tissues 
compared to the normal colonic mucosa tissue. Overall, these initial findings suggest 
that at the protein level, there may be an association between 14-3-3σ methylation 
status and expression in both colorectal tumours, matched normal colonic tissues and 
in skin tissue. A list of the in vitro and in vivo expression data and corresponding 
methylation status of each individual cell line or tissue sample is listed in Table 4.1.                 
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Figure 4.6: 14-3-3σ protein detection by Western blot analysis in 
unmethylated colorectal tumours (KR2 and KR3) and paired normal 
tissues (methylated) from same patient; in methylated colorectal 
tumours (KR1 and KR4) and paired normal tissues (methylated) from 
same patient. HT29 serves as a positive control for 14-3-3σ expression 
and SW480 as a negative control for 14-3-3σ expression. 14-3-3σ 
methylation status is indicated from analysis presented in chapter 3: M = 
methylated U = unmethylated. β actin levels were analysed to assess 





Figure 4.7: Densitometric analysis of 14-3-3σ Western blot (A) upper and 
(B) lower blot from Figure 4.6, in colorectal tumours and matched 
normal tissues. Densitometric intensities of 14-3-3σ bands were normalised 
by β-actin densitometric intensities. Horizontal lines represent mean 
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Figure 4.8: 14-3-3σ protein detection by Western blot analysis in 
colorectal tumours. 14-3-3σ methylated or unmethylated tumours are 
indicated. NC corresponds to normal mucosa tissue from a cancer-free 
individual. High levels of 14-3-3σ protein in methylated KR8 explained in 
text. HT29 (U = unmethylated 14-3-3σ) serves as a positive control for 
14-3-3σ expression. β actin levels were analysed to assess protein 





Figure 4.9: Densitometric analysis of 14-3-3σ Western blot (A) upper and 
(B) lower blot from Figure 4.8, in 14-3-3σ methylated and unmethylated 
colorectal tumours. Densitometric intensities of 14-3-3σ bands were 
normalised by β-actin densitometric intensities. Horizontal lines represent 



























































Figure 4.11: Densitometric analysis of 14-3-3σ Western blot from Figure 
4.10 in normal skin tissues and normal colonic mucosa from colorectal 
cancer patients. Densitometric intensities of 14-3-3σ bands were normalised 
by β-actin densitometric intensities. Horizontal lines represent mean 





























Figure 4.10: 14-3-3σ protein detection by Western blot analysis in 
skin tissue compared to normal colon from colorectal cancer 
patients (NM). SW480 (methylated 14-3-3σ) serves as negative control 
for 14-3-3σ expression. HT29 (unmethylated 14-3-3σ) serves as a 
positive control for 14-3-3σ expression. β actin levels were analysed to 































































































































































Table 4.1: 14-3-3σ expression data and relationship with 14-3-3σ methylation status. 
M = methylated, U = unmethylated, P = partially methylated, methylated and unmethylated 
CpG sites (+) = expression level, (-) = no expression, NC = normal colon from non-
colorectal cancer patient, ND = not determined.  
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4.3.4 Demethylation of 14-3-3σ in vitro by 5-Aza-2’-deoxycytidine 
Initial studies carried out so far suggest that 14-3-3σ UPR methylation may be 
associated with expression in colorectal tumours. More detailed analysis in a larger 
sample set is required to verify this initial finding and determine whether loss of 
methylation in the UPR of 14-3-3σ  may be responsible for overexpression of 14-3-
3σ in colorectal cancer. Experiments demonstrating the re-expression of 14-3-3σ in 
the methylated colorectal cancer cell lines SW480 and Colo320DM following 
demethylation treatment may provide further evidence to support this notion. 
 
In order to establish the optimal concentration of 5-Aza-2’-deoxycytidine for 14-3-
3σ demethylation, dose response experiments (0.1µM to 10µM) for 4 days in both 
cell lines were performed. MSP, which analyses the 5’ region of the 14-3-3σ CpG 
island, and subsequent densitometric analysis, showed that a concentration of 0.5µM 
was optimal for demethylation of 14-3-3σ in SW480 cells over 4 days (Figure 4.12 
(A)) (Table 4.2). Similarly, in the Colo320DM cells, a strong PCR signal and 
densitometric intensity for the 14-3-3σ unmethylated product was observed at 0.5µM 
and 1µM of 5-Aza-2’deoxycytidine (Figure 4.12(B)) (Table 4.3). Hence, a 
concentration of 0.5µM was used for all subsequent experiments in SW480 and 
Colo320DM cells. Interestingly, in Colo320DM cells treated with 5µM of 5-Aza-
2’deoxycytidine there appears to be re-methylation of 14-3-3σ. It is not understood 
why this occurs. However, higher concentrations of 5-Aza-2’-deoxycytidine (5µM 
and 10µM) were often toxic as SW480 and Colo320DM cells sometimes died after 4 
days of treatment. Therefore, the lower concentration of 5-Aza-2’-deoxycytidine was 
considered optimal for cell viability as well as for demethylation of 14-3-3σ and 
expression studies in these cell lines.  
 
Following dose response optimisation, the length of treatment to demethylate 14-3-
3σ was investigated in both cell lines by carrying out time course experiments. 
SW480 and Colo320DM cells were treated at 0.5µM for 4 consecutive days and each 
day the media was replaced with fresh media including fresh 5-Aza-2’-
deoxycytidine. MSP analysis showed that in both SW480 and Colo320DM cells, 14-
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3-3σ was demethylated at day 1, evidenced by the presence of a stronger PCR signal 
and higher densitometric intensity for the unmethylated product in cells treated for 1 
day compared to the signal and densitometric intensity for the unmethylated product 
in control cells (Figure 4.13) (Table 4.4 & 4.5). The signal for the 14-3-3σ 
unmethylated product (in both cell lines) increases with further treatment to day 4 
with a progressively stronger signal and increase in densitometric intensity for the 
unmethylated product. This suggests that 4 days treatment with 0.5µM 5-Aza-2’-
deoxycytidine is optimal in both colorectal cancer cell lines to demethylate 14-3-3σ. 
At longer time points, cells were dying likely due to the toxicity of 5-Aza-2’-
deoxycytidine or high confluency of the flask.   
 
In order to examine whether the demethylation of 14-3-3σ results in re-expression of 
14-3-3σ. 14-3-3σ mRNA levels were measured in SW480 and Colo320DM cells 
following 5-Aza-2’-deoxycytidine treatment by qRT-PCR analysis. The cell lines 
were treated with 0.5µM of 5-Aza-2’-deoxycytidine for 4 consecutive days and 
relative 14-3-3σ mRNA levels were determined for day 4 and compared with 
untreated control day 4 cells. As shown in Figure 4.14 (A), there is no change in 
relative 14-3-3σ mRNA levels in 5-Aza-2’-deoxycytidine treated SW480 cells on 
day 4 compared to untreated control cells. A similar result is observed in 5-Aza-2’-
deoxycytidine treated Colo320DM cells. At day 4 there is also no change in 14-3-3σ 
mRNA levels in 5-Aza-2’-deoxycytidine treated cells compared to untreated control 
cells (Figure 4.14 (B)). Collectively these results demonstrate that even though 
demethylation was achieved in both cell lines on day 4 of 5-aza-2’-deoxycytidine 
treatment, 14-3-3σ was not re-expressed. The explanations for this are examined in 





Figure 4.12: MSP analysis. SW480 (A) and Colo320DM (B) cells were 
treated for 4 days with 5-Aza-2’-deoxycytidine (0.1µM to 10µM) Control cells 
were either completely untreated (0µM control) or untreated with vehicle 50% 
acetic acid (0µMR control). HT29 is shown for unmethylated control and B = 
blank PCR reaction, shown in (A) only. M, methylated PCR product and U, 
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Table 4.2: Densitometric analysis of MSP reactions from SW480 cells 
treated for 4 days with 5-Aza-2’-deoxycytidine (0.1µM to 10µM) Control cells 
were either completely untreated (0 Control) or untreated with vehicle 50% 
acetic acid (0 Control Vehicle). HT29 analysis was carried out for unmethylated 
control. M, methylated PCR product and U, unmethylated PCR product.    
Table 4.3: Densitometric analysis of MSP reactions from Colo320DM cells 
treated for 4 days with 5-Aza-2’-deoxycytidine (0.1µM to 10µM) Control cells 
were untreated with vehicle 50% acetic acid (0 Control Vehicle). M, methylated 





Figure 4.13: MSP analysis. SW480 (A) and Colo320DM (B) cells were 
treated with 5-Aza-2’-deoxycytidine (0.5µM) for 4 days. Control cells were 
untreated for 4 days with vehicle 50% acetic acid (R control). HT29 is shown for 
unmethylated control and B = blank PCR reaction. M, methylated PCR product 







   
Table 4.4: Densitometric analysis of MSP reactions from SW480 cells 
treated with 5-Aza-2’-deoxycytidine (0.5µM) for 4 days. Control cells were 
untreated for 4 days with vehicle 50% acetic acid (Control Vehicle). HT29 
analysis was carried out as a unmethylated control. M, methylated PCR product 
and U, unmethylated PCR product.    
Table 4.5: Densitometric analysis of MSP reactions from Colo320DM cells 
treated with 5-Aza-2’-deoxycytidine (0.5µM) for 4 days. Control cells were 
untreated for 4 days with vehicle 50% acetic acid (Control Vehicle). HT29 
analysis was carried out as a unmethylated control. M, methylated PCR product 
and U, unmethylated PCR product.    
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Figure 4.14: Relative 14-3-3σ mRNA levels in SW480 (A) and Colo320DM 
(B) cells upon treatment with 5-Aza-2’-deoxycytidine (0.5µM) for 4 days 
determined by qRT-PCR. Relative levels were normalized to β-actin 
endogenous control gene mRNA levels. The results are the means of triplicate 






My aim for this chapter was to establish whether 14-3-3σ methylation status is 
associated with expression in colorectal cancer. I analysed comparative expression at 
the mRNA and protein level in a small number of 14-3-3σ methylated and 
unmethylated colorectal cancer cell lines, tumours and corresponding normal tissues. 
I also decided to examine 14-3-3σ protein levels in three separate skin tissues in 
which 14-3-3σ is both methylated and unmethylated at individual CpG sites and 
normal colonic tissue, which has higher levels of methylation with the majority of 
CpG sites methylated. Finally, I analysed the demethylation of 14-3-3σ in vitro by 5-
Aza-2’-deoxycytidine treatment and subsequent 14-3-3σ expression analysis to 
deduce whether demethylation of the gene can result in its re-expression.   
 
14-3-3σ expression analysis in colorectal cancer cell lines by qRT-PCR and Western 
blot analysis demonstrated that there were higher levels of 14-3-3σ expression at 
both the mRNA and protein level in the unmethylated cell lines HT29 and HCT116 
compared to the methylated cell lines SW480 and Colo320DM. More specifically, 
the data showed that the unmethylated cell lines expressed approximately 400-fold 
higher mRNA levels than the methylated cell lines. Therefore, this suggests that 
there could be an association between 14-3-3σ methylation status and expression in 
vitro. However, analysis in a larger sample set of 14-3-3σ methylated and 
unmethylated colorectal cell lines is needed to confirm this. 
 
In human tissues, the majority of 14-3-3σ unmethylated tumours had higher levels of 
expression compared to matched normal mucosa tissues. At the mRNA level, the 
higher levels however, were not significantly different from the expression levels in 
normal tissue possibly due to the small number of samples analysed and the 
anomalous finding in one of the samples. It is therefore unclear whether loss of 14-3-
3σ methylation is associated with higher expression levels in the colorectal tumours 
compared to the matched normal tissues examined. Analysis of a larger number of 
colorectal tumours and matched normal mucosa samples is required in order to fully 
determine whether there is any associated change in 14-3-3σ expression levels. 
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When comparing the expression of 14-3-3σ mRNA in unmethylated tumours with 
methylated tumours, there were significantly higher levels of expression in the 
unmethylated tumours compared to the methylated tumours and western blot analysis 
also showed that there were higher levels of 14-3-3σ protein in the majority of 
unmethylated tumours compared to the methylated tumours. Furthermore, there may 
be an association between the degree of 14-3-3σ methylation and expression in the 
subset of colorectal tumours examined by bisulphite sequencing individual clones. 
Tumours KR2 and KR3 (3.6% and 17.4% methylated CpGs respectively) expressed 
higher levels of 14-3-3σ in comparison to tumours KR4 and KR11 (46.9% and 
45.9% methylated CpGs respectively). Therefore, overall, these preliminary results 
suggest that 14-3-3σ methylation status is associated with 14-3-3σ expression in 
colorectal tumours. Conversely, the tumour sample AM27, which was determined as 
unmethylated in the UPR of 14-3-3σ, did not express higher levels of 14-3-3σ 
compared to other methylated tumours. As discussed previously, this result is 
difficult to explain, but may be due to other mechanisms involved in gene silencing, 
such as a rare control region SNP or other variants. Tumour sample KR8 displayed 
an opposite affect; methylation analysis in chapter 3 deduced that 14-3-3σ was 
methylated in the UPR. However, Western blot analysis showed that the tumour had 
higher levels of 14-3-3σ protein similar to the unmethylated tumours. This 
anomalous finding may be a result of other genetic aberrations in the tumour such as 
Chromosome instability (CIN). Alternatively, these anomalous findings may be due 
to other mechanisms involved in regulating 14-3-3σ expression. These are discussed 
in more detail below.  
 
Comparison of 14-3-3σ protein levels in skin tissue and normal colon tissue using 
Western blot analysis determined that there were higher levels in skin tissue 
compared to normal colon tissue from colorectal patients. Chapter 3 demonstrated 
that the 14-3-3σ UPR was methylated in matched normal mucosa samples and 
normal mucosa from a cancer free individual had a higher percentage methylation 
level compared to the three skin tissues which were examined. Therefore, this 
suggests that in addition to colorectal tumours, 14-3-3σ methylation status and 
expression may also be associated in normal tissues. Indeed, this has been 
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demonstrated in a previous report in which cell type-specific expression of 14-3-3σ 
was found to be regulated by epigenetic mechanisms including 14-3-3σ CpG island 
methylation (Oshiro et al, 2005). In this published study, 14-3-3σ expression analysis 
was examined in skin keratinocytes rather than whole skin tissue. However, 14-3-3σ 
was shown to be expressed in the skin keratinocytes and was associated with low 
levels of percentage CpG methylation in the 14-3-3σ CpG island. In addition to skin 
keratinocytes; oral keratinocytes and airway, prostate and mammary epithelium 
positively express 14-3-3σ and are associated with low levels of CpG island 
methylation. In contrast, 14-3-3σ  expression is absent in non-epithelial tissues such 
as chondrocytes, fibroblasts and lymphocytes and is associated with high levels of 
14-3-3σ CpG island methylation (Oshiro et al, 2005). Further details of this study are 
discussed below.            
 
An important observation from the expression analysis in clinical samples is that 14-
3-3σ is maintained at low levels in normal colonic mucosa tissues and in some 
tumours despite being methylated in the UPR. In addition to the effect of small 
sample numbers, this finding contributed to the overall the analysis of differences in 
expression between methylated and unmethylated samples in vivo. It would be 
expected that normal tissues and tumours which are methylated in the UPR of 14-3-
3σ would express negligible levels of 14-3-3σ or indeed none at all. This lack of 
tight association in vivo may be due to tissue heterogeneity (as discussed in chapter 
3). Cell type heterogeneity in both the tumours and normal tissues could be resolved 
by re-analysing 14-3-3σ expression in microdissected samples. Alternatively, 14-3-
3σ expression could be analysed by immnuohistochemistry. Expression analysis in 
both tumour and matched normal sections would determine which cell types express 
14-3-3σ. During the course of this PhD, I attempted to examine 14-3-3σ expression 
on a number of tumours and matched normal colorectal tissue sections by 
immunohistochemistry. However, due to problems with antibody specificity the 
technique was not fully optimised. One previous study which analysed the 
expression of 14-3-3σ in colorectal tumour sections by immunohistochemistry found 
diffuse immunoreactivity in the cytoplasm of normal epithelial crypts (Ide et al, 
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2004). No staining was observed in surrounding stromal cells. Interestingly, the 
majority of tumours displayed positive expression for 14-3-3σ however, stronger 
staining was observed in the invasion front and to a lesser extent in other areas of the 
tumour (Ide et al, 2004). This study firstly indicates that normal colonic epithelial 
cells in the tissue are probably responsible for the observed 14-3-3σ expression and 
not from other cell types. Secondly, the study also demonstrated that 14-3-3σ was 
expressed in the majority of colorectal tumours examined. The authors believed that 
there was no association between 14-3-3σ methylation status and expression as low 
levels of 14-3-3σ methylation was observed even in microdissected 
immunohistochemically negative areas of the tumour. This is not in complete 
agreement with the preliminary findings presented in this chapter, however it should 
be recognised that this is in comparison to only one other study and therefore further 
analysis is required. It should also be considered that the expression observed in the 
corresponding normal tissues may be due to contaminating tumour cells or field 
cancerisation effects. However, the analysis of 14-3-3σ expression in normal colonic 
mucosa from a patient free from cancer carried out in this chapter suggests that this 
may not be the case since the expression levels in the normal colonic tissues from 
colon cancer patients and the non-colon cancer patient were very similar. Two 
separate studies which examined the level of 14-3-3σ expression in colorectal cancer 
and corresponding normal mucosa tissue (but not 14-3-3σ methylation status) found 
that 14-3-3σ at both the mRNA and protein level was expressed at higher levels in 
colorectal cancer compared to normal tissue (Perathoner et al, 2005; Tanaka et al, 
2004). As with the study by Ide et al, positive staining was observed in the majority 
of colorectal tumours, however immunohistochemical analysis of staining intensity 
and percentage of positively stained tumour cells showed that high levels of 14-3-3σ 
expression occurred in 38.8% of cases (n =121). Furthermore, there was a significant 
correlation of 14-3-3σ expression with tumour differentiation (p =0.001) and tumour 
stage (p =0.003), suggesting that 14-3-3σ may be involved in tumour progression 
(Perathoner et al, 2005). These expression studies are somewhat in agreement with 
the findings in this chapter. The low level of 14-3-3σ expression in the normal 
mucosa and in the majority of colorectal tumours may be the base-line level of 
expression despite 14-3-3σ being methylated in the UPR. An increase in expression 
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from the base-line level is then observed in a small proportion of colorectal tumours, 
and this may be associated with lower levels of methylation at the UPR. Similar 14-
3-3σ expression analysis in a larger dataset of methylated and unmethylated colon 
tumours and corresponding normal tissues would provide further insight. 
 
Since 14-3-3σ expression is observed in methylated normal tissues and colorectal 
tumours, this suggests that mechanisms in addition to, or indeed instead of CpG 
methylation, may be involved in regulating 14-3-3σ expression. A generally held 
view is that methylation in the promoter region of genes is not the only epigenetic 
level of gene expression regulation, as discussed in the introduction of this thesis. 
MBD protein recruitment to the methylated promoter region and subsequent histone 
modifications may also be involved (Jones et al, 1998; Nan et al, 1998). It would be 
interesting to investigate MBD occupancy and the acetylation state of histones H3 
and H4, which are associated with the 14-3-3σ CpG island using Chromatin 
immunoprecipitation (ChIP) assays. Furthermore, H3K9 methylation, chromatin 
structure and downstream effects on transcription factor accessibility at the 14-3-3σ 
promoter region could also be examined. The report by Oshiro et al strongly suggests 
that in cancer, deregulation at the 14-3-3σ promoter  may also be a result of aberrant 
changes in other levels of epigenetic control as well as CpG island methylation 
(Oshiro et al, 2005). The study demonstrated that cell type-specific expression of 14-
3-3σ is associated with DNA methylation, histone modifications and changes in 
chromatin structure at the CpG island region (Oshiro et al, 2005). Indeed, the 5-Aza-
2’-deoxycytidine studies carried out in this chapter support the notion that other 
mechanisms may be involved in regulating 14-3-3σ expression since the 
demethylation of the 14-3-3σ gene following 5-Aza-2’-deoxycytidine treatment did 
not result in re-expression of the gene in either of the methylated cell lines. In 
addition to demethylation, the effects of histone acetylation could be investigated 
further by treating colorectal cancer cell lines with a combination of 5-Aza-2’-
deoxycytidine and the deacetylating agent TSA. Similar experiments in methylated 
prostate cancer cell lines have however shown that 5-Aza-2’-deoxycytidine treatment 
alone, can induce 14-3-3σ mRNA expression, with one cell line displaying an 
approximate 10-fold increase compared to control cells (Mhawech et al, 2005). This, 
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as well as the fact that the experiments conducted here were only carried out once, 
suggests that further optimisation of the technique may be required before exploring 
the effects of the combined treatment mentioned above. In hindsight, it would have 
also been beneficial to have analysed alongside the 14-3-3σ gene, another gene 
which is known to be re-expressed in cell lines following 5-Aza-2’-deoxycytidine 
treatment. This could have acted as a positive control for the experiment, testing the 
specificity of 14-3-3σ re-expression following treatment, and perhaps providing 
further evidence to suggest whether the optimal conditions were established. It 
should also be noted that 5-Aza-2’-deoxycytidine is very toxic to mammalian cells 
(Juttermann et al, 1994) and is non-specific, demethylating many genes which could 
counter the expected effect on 14-3-3σ in the colorectal cancer cells.  
 
Whilst these preliminary results indicate that there is a significant difference in 14-3-
3σ expression in unmethylated tumours and methylated tumours, further expression 
analysis in vivo is required to conclusively determine whether 14-3-3σ methylation is 
associated with expression in colorectal cancer. Furthermore, the findings in this 
chapter and previous studies suggest that other epigenetic mechanisms, including 
CpG methylation may be involved in regulating 14-3-3σ expression, such as histone 
modifications and chromatin re-modelling. Additional studies investigating these 
mechanisms at the 14-3-3σ promoter in colorectal cancer would perhaps provide 
further insight. 
 
The mechanism leading to aberrant methylation of gene promoters in cancer is under 
intensive investigation. It is possible that difference in 14-3-3σ methylation status 
observed in colorectal tumours is not a 14-3-3σ specific effect but in fact related to 
other generalised aberrant methylation phenotypes, such as genome-wide 
demethylation or CIMP. Hence, the specificity of 14-3-3σ hypomethylation in 










The results of experimental work that I presented in chapter 3 suggest that there may 
be a tumour-specific loss of 14-3-3σ UPR methylation in approximately 10% of 
colorectal tumours. Furthermore, I have shown that the loss of methylation or indeed 
hypomethylation of 14-3-3σ  in some colorectal tumours was associated with higher 
levels of 14-3-3σ mRNA expression and increased protein levels compared to the 
methylated tumours. The hypothesis I wish to test in this chapter is that the 
demethylation of 14-3-3σ in colorectal cancer is specific to the 14-3-3σ gene and not 
a result of more general methylation phenomenon. Thus, the aim of this chapter is to 
determine whether loss of methylation in the 14-3-3σ UPR is associated with global 
hypomethylation or the CIMP phenotype (Toyota et al, 1999a). The degree of 5-
methylcytosine content has been quantified by a technique known as Nearest 
Neighbor analysis (Ramsahoye, 2002) in colorectal cancer cell lines and colorectal 
tumours. 14-3-3σ UPR methylated and 14-3-3σ UPR unmethylated cell lines and 
tumours were investigated to determine whether 14-3-3σ hypomethylation is a result 
of genome-wide demethylation or is specific to the gene 14-3-3σ. CIMP analysis in a 
small number of colorectal tumours has also been carried out using MethyLight, a 
Taqman-based methylation technique (Eads et al, 2000). CIMP phenotype for 14-3-
3σ UPR methylated and unmethylated tumours were determined by examining the 
methylation status of 4 CIMP markers (Toyota et al, 1999a), and from this any 





5.2.1 Nearest Neighbor Analysis 
DNA from HT29 and SW480 cell lines and DNA from tumours KR2, KR3, KR10 & 
KR12 were subjected to Nearest Neighbor analysis as described in 2.8.2. The 
technique was carried out with assistance from Dr Bernard Ramsahoye (Cancer 
Research UK, University of Edinburgh) who developed the procedure. Figure 5.1 
illustrates the outline of the procedure in more detail. Briefly, the restriction 
endonuclease MboI(\GATC) was used to cut DNA and [α-32P] dGTP was used to 
end label the DNA using Klenow. Following the digestion of labelled DNA to 
deoxyribonucleotide 3’-monophosphates (dNps), the radio-labelled 5’ α-phosphate 
of the [α-32P] appears as the 3’ phosphate of the nucleotide (X) that was immediately 
5’ to it in the DNA – its nearest neighbor. Therefore, as labelling is template 
dependent, the frequencies of labelled dNps (dCp, dTp, dGp, dAp and 5mdCp) 
reflect the relative amounts of dinucleotides (XpG): dCpG, dTpG, dGpG, dApG and 
5mdCpG at the MboI restriction sites. Radio-labelled dNps were separated, 
visualised and quantified following two-dimensional TLC and subsequent 
phosphorimaging (Ramsahoye, 2002). This technique has been previously used in a 
number of different reports to measure the level of methylated CpG (5mdCpG) 
compared to unmethylated CpG (dCpG) across an entire genome (Meissner et al, 
2005; Ramsahoye et al, 2000; Tollefsbol & Hutchison, 1998). In order to verify the 
efficiency and specificity of the Nearest Neighbor technique, control experiments 
were performed during the optimisation of the technique (Dr Bernie Ramsahoye, 
personal correspondence). Firstly, to test that a global change in CpG methylation 
can be detected using Nearest Neighbor analysis, DNMT3a-/- /DNMT3b-/- early 
passage ES cells prior to and following the expression of a short-hairpin RNAi 
molecule specific for DNMT1, were applied to the technique (Figure 5.2). Wild-type, 
early passage ES cells display CpG methylation levels of approximately 65% 
(Jackson et al, 2004). In comparison, DNMT3a-/- /DNMT3b-/- early passage ES cells 
display overall levels of approximately 35% CpG methylation (Figure 5.2 (A)) and 
following the expression of the DNMT1 short-hairpin RNAi (shRNAi) any residual 
CpG methylation is removed to 2% (Figure 5.2 (B)). Secondly, to further confirm the 
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specificity of the technique, a PCR product, which is known to be unmethylated (as 
only dCTP and not 5mdCTP was included in the dNTP mix) was applied. Figure 5.3 
(A) shows that there is no labelling of the 5mdCp spot, as no 5mdCp is present. The 
same PCR product was also spiked with transfer RNA (tRNA) to ensure that the 
5mdCp spot was not due to the presence of a ribonucleotide (Figure 5.3 (B)). 
Overall, these experiments confirm that Nearest Neighbor analysis can be used to 
specifically and efficiently determine global methylation changes in a given DNA 
sample.   
 
5.2.2 MethyLight Analysis 
Four CIMP markers; hMLH1, CDKN2A (p16), MINT1 and MINT2 were analysed for 
methylation in tumours 1924, 10811, 10812, KR10, 8117, KR3, KR8, 7867, 7329 & 
7007 using MethyLight analysis as described in section 2.8.1. At present there is no 
consensus definition for the CIMP panel, therefore it was decided to use four of the 
five classical CIMP markers (hMLH1, CDKN2A (p16), MINT1, MINT2 and MINT31) 
defined by Issa (Issa, 2004). The choice of these markers to study CIMP in the 
tumours listed above are discussed in the final section of this chapter. MethyLight 
utilises fluorescence-based real time PCR (TaqMan) technology and is a high-
throughput methylation assay, which has a high degree of sensitivity (Eads et al, 
2000). The assay is semi-quantitative and determines the relative frequency of a 
particular pattern of DNA methylation rather than quantifying all methylation 
occurrences of CpG dinucleotides in a genomic DNA sample. The primers and 
fluorescent probes designed for this study overlap potential sites of DNA methylation 
at CpG sites following bisulphite treatment of the DNA. Hence, sequence 
discrimination of the CIMP markers occurs at both the level of PCR amplification 
and at the level of probe hybridisation. For the control reaction (β-actin), neither the 
primers or probe overlie any CpG sites, therefore the PCR reaction is unbiased and 
acts as a control for the amount of bisulphite treated DNA input. The semi-
quantification for each individual CIMP marker was determined relative to the β-
actin control reaction. The percentage methylated reference (PMR – the degree of 
methylation) was calculated by dividing this relative value by the methylation level 
of the CIMP marker in fully methylated CpGenome DNA (which is presumably 
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100% methylated), and multiplied by 100. PMR values for each CIMP marker were 
calculated in each individual tumour. Verification of methylated tumours for each 
CIMP marker and determination of whether the tumour is CIMP positive or negative 
was based on the report by Weisenberger et al (Weisenberger et al, 2006). PMR 
values above 10 for a given sample and locus were considered positive for 
methylation. A sample, which was CIMP positive, was defined if it has ≥3 of the 4 
CIMP markers with positive methylation (PMR >10). If the samples has ≤2 of the 4 
CIMP markers with positive methylation (PMR >10) then it was considered to be 
CIMP negative.  
 
5.2.3 Colorectal cancer cell lines 
DNA was purified from the colorectal cancer cell lines SW480 and HT29 as 
described in 2.2.1. 
 
5.2.4 Patient samples 
DNA was purified from fresh KR colorectal tumour samples as described in 2.2.1. 
Other DNA samples were obtained directly from laboratory stocks. For MethyLight 
analysis purified tumour DNA was subsequently subjected to bisulphite treatment as 




Figure 5.1: Nearest Neighbor analysis MboI is used to cut DNA and [α-32P] dGTP was 
used to end label the DNA at the restriction cut sites using Klenow. Labelled nucleotides (X) 
are marked * and filled in nucleotides are underlined. Radio-labelled 5’ α-phosphate of the 
[α-32P] dGTP appears as the 3’ phosphate of the nucleotide (X) that was immediately 5’ to it 
in the DNA – its ‘nearest neighbor’. Labelled double-stranded DNA was digested to dNps by 
a mixture of exo/endonucleases. Frequencies of labelled dNps (dCp, dTp, dGp, dAp and 
5mdCp) reflect the relative amounts of dinucleotides (XpG): dCpG, dTpG, dGpG, dApG and 
5mdCpG at the MboI restriction sites. Radio-labelled dNps were separated, visualised and 
quantified following two-dimensional thin-layer chromatography (TLC) and subsequent 




Figure 5.2: Control experiment for testing the efficiency of Nearest Neighbor 
analysis: Nearest Neighbor analysis of DNA from DNMT3a-/-/ DNMT3b-/- early 
passage ES cells (A) and following expression of a short-hairpin (sh) RNAi 
molecule specific for DNMT1, (also early passage ES cells) (B). 
Autoradiographs indicate a removal of most residual methylation following 
DNMT1 shRNAi expression. MboI was used to cut the DNA and [α-32P] dGTP and 
klenow were used to end label the DNA. Labelled DNA was digested to dNps by a 
mixture of exo/endonucleases and separated by TLC. Phosphorimaging was 
subsequently used visualise and quantify the labelled dNps. (dNps are indicated, 
origin of application for two-dimensional chromatography (ori). Other spots may be 
indicative of diphosphates or deoxyribose phosphates). 
(A) DNMT3a-/-/ DNMT3b-/- ES cells  
(B) DNMT3a-/-/ DNMT3b-/- ES cells + 
DNMT1 shRNAi   
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Figure 5.3: Control experiment for testing the specificity of Nearest Neighbor 
analysis: Nearest Neighbor analysis of a PCR product (A) and the same PCR 
product spiked with tRNA (B) indicates absence of 5mdCp spot in both 
samples. (dNps are indicated, origin of application for two-dimensional 
chromatography (ori). Other spots may be indicative of diphosphates, deoxyribose 
phosphates or impurities from the dNTP mix). 
 
(A) PCR Product 




5.3.1 Global levels of 5-methylcytosine in colorectal cancer cell 
lines and tumours 
Levels of CpG methylation were first quantified in the two colorectal cancer cell 
lines HT29 and SW480 using Nearest Neighbor analysis. Figure 5.4 shows 
autoradiographs from the two cell lines of labelled dNps following separation by 
two-dimensional TLC. The relative intensities of the spots indicates the frequencies 
of dinucleotide XpG at MboI cut sites. The intensities of the spots were quantified by 
first subtracting the background intensities from dCp and 5mdCp. Percentage 5mdCp 
was calculated from the following equation: 
 
   % 5mdCp  =        
               5mdCp + dCp 
5mdCp 
 
Analysis of the nearest neighbors of 5-methylcytosine at MboI cut sites in the 14-3-
3σ unmethylated cell line HT29 and the 14-3-3σ methylated SW480 colorectal 
cancer cell line demonstrates that 70.8% of CpG sites were methylated in the HT29 
cell line compared to 79.4% of CpG sites in the SW480 cell line (Table 5.1). A 
recent report has estimated a 70 to 80% CpG methylation content in non-malignant 
somatic cells (Yegnasubramanian et al, 2008). Therefore, this suggests that neither of 
the cell lines examined are globally demethylated. Nearest Neighbor analysis was 
then carried out in colorectal tumours KR2 and KR3 (14-3-3σ UPR unmethylated) 
and KR10 and KR12 (14-3-3σ UPR methylated). Autoradiographs of labelled dNps 
following separation by two-dimensional TLC from the four colorectal tumours are 
shown in Figure 5.5. Nearest neighbors of 5-methylcytosine at MboI cut sites were 
quantified as described previously. 80.4% and 63% of CpG sites were methylated in 
the 14-3-3σ unmethylated tumours KR2 and KR3 respectively (Table 5.1). 71.2% 
and 68% of CpG sites were methylated in the 14-3-3σ methylated tumours KR10 and 
KR12 respectively (Table 5.1). As a reduction in global levels of CpG methylation 
was detected in both the 14-3-3σ methylated and unmethylated tumours, this 
suggests that a reduction in global levels of methylation may be independent of 14-3-
3σ demethylation in the tumours examined. Percentage levels of 5-methylcytosine 
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for the individual colorectal cancer cell lines and tumours are illustrated in Figure 
5.6. Overall, these studies suggest that in the samples examined, there is no 
relationship between global methylation levels and the specific methylation status of 
14-3-3σ itself.  
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Figure 5.4: Autoradiographs of labeled dNps after separation by two-dimensional 
TLC from colorectal cancer cell lines SW480 (14-3-3σ UPR methylated) and HT29 
(14-3-3σ UPR unmethylated). dNPs are indicated in one autoradiograph. An arrow in the 




Figure 5.5: Autoradiographs of labeled dNps after separation by two-dimensional 
TLC from colorectal tumours. KR2 and KR3 (14-3-3σ UPR unmethylated), KR10 and 
KR12 (14-3-3σ UPR methylated). dNps are indicated in one autoradiograph, an arrows 
indicates position of 5mdCp in subsequent autoradiographs.   
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Table 5.1: Phosphorimaging quantification of intensities of spots (dNps) and 
subsequent calculation of percentage 5mdCp, which reflects the percentage of 
5mdCpG in colorectal cancer cell lines and colorectal tumours. 
Figure 5.6: Percentage CpG methylation in colorectal cancer cell lines and 
colorectal tumours. Methylation status of 14-3-3σ UPR is indicated for each sample.  
HT29 SW480 2T 3T 10T 12T
Background 1615.5 676.1 13722.1 7397.3 14860.1 10484.3
dCp 81670.6 7830.6 37149.7 45232.6 60154.2 46860.9
5mdCp 195703 28248 109834.9 71748.2 126725.3 90037.3
dCp - Background 80055.1 7154.5 23427.6 37835.3 45294.1 36376.6
5mdCp - Background 194087.5 27571.9 96112.8 64350.9 111865.2 79553
total C 274142.6 34726.4 119540.4 102186.2 157159.3 115929.6
% 5mdCp 70.8 79.4 80.4 63.0 71.2 68.6
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5.3.2 CIMP analysis in colorectal tumours 
MethyLight, a Taqman based real time PCR assay was used to assay for the 
presence of CIMP in 5 14-3-3σ UPR unmethylated colorectal tumours and 5 14-3-3σ 
UPR methylated tumours. The CIMP marker panel consisted of MLH1, CDKN2A, 
MINT1, and MINT2. MethyLight analysis of MLH1 methylation status in the 10 
tumours showed that only one tumour sample (KR3) was positive for methylation of 
MLH1 with a PMR value >10 (Table 5.2) (Figure 5.7). The PMR value was 
markedly above the PMR cut-off value and therefore is a strong positive result for 
methylation. Furthermore, previous bisulphite sequencing analysis of MLH1 
methylation (data not shown), has demonstrated that the tumour sample KR3 is fully 
methylated in the promoter region and the majority of other tumour samples 
(including KR8, which was examined in this chapter for MLH1 methylation) is 
unmethylated, thus supporting the validity of the MethyLight assay. Interestingly, the 
PMR value for tumour sample KR3 was higher than the CpGenome DNA sample, 
which is presumably fully methylated. KR3 and KR10 also displayed higher PMR 
values than the CpGenome DNA sample for the CIMP markers CDKN2A and 
MINT1. This has previously been described in a number of reports (Friedrich et al, 
2004; Siegmund & Laird, 2002), and is thought to be a result of fluctuations in the 
real time PCR measurements or due to incomplete methylation of the DNA reference 
sample (CpGenome DNA). Alternatively, this finding may also be a result of a high 
copy number variation of the gene locus of interest. MethyLight analysis of tumours 
for CDKN2A methylation demonstrated that two tumours KR3 and KR10 were 
positive for methylation with PMR values above the cut-off value therefore 
indicating positive methylation (Table 5.3) (Figure 5.8). Analysis of methylation of 
the MINT1 locus in the tumours showed that 4/10 were positive for methylation 
(Table 5.4) (Figure 5.9). KR3 and KR10 demonstrated high PMR values. It should be 
noted however, that there were high levels of variability for tumour KR10 thus the 
PMR value may not be as high as is illustrated in Figure 5.9. Variability of the 
MethyLight assay has been previously reported and it is thought that this may be a 
result of stochastic PCR amplification which can occur at low template concentration 
(Eads et al, 2000). Tumours KR8 and 7329 displayed lower PMR values 
respectively, with tumour sample 7329 only just being above the PMR cut-off value 
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of 10. Finally, MethyLight analysis of the MINT2 locus for methylation in the 
tumours demonstrated that 5/10 tumours were positive for methylation with a PMR 
>10. Table 5.5 and Figure 5.10 show that the tumour samples KR3, KR10, 1924, 
10811 and 7007 were positive for MINT2 methylation with high PMR values.  
 
Following the analysis of the four individual CIMP markers for methylation in the 
colorectal tumours, the CIMP phenotype was determined for each sample. Table 5.6 
summarises the results from the MethyLight analysis and the CIMP status for each 
tumour. 2/10 tumours were CIMP positive: KR3 and KR10. KR3 displayed positive 
methylation for all four of the CIMP markers. KR10 displayed positive methylation 
for CDKN2A, MINT1 and MINT2 CIMP markers. All other tumours analysed were 
CIMP negative with either one or no CIMP markers positive for methylation. For the 
two CIMP positive tumours, KR3 is a 14-3-3σ UPR unmethylated tumour and KR10 
is a 14-3-3σ UPR methylated tumour. Therefore, this study suggests there is no 
relationship between 14-3-3σ UPR methylation status and CIMP in the colorectal 


















Figure 5.7: MethyLight analysis of MLH1 methylation status in colorectal 
tumours. The results are the means of duplicate results ± standard errors. CpG 
(100%) = fully methylated CpGenome DNA.  
Table 5.2: MethyLight analysis of MLH1 methylation status in colorectal 
tumours. Tumours with positive MLH1 methylation (PMR > 10) are highlighted. CpG 
















Table 5.3: MethyLight analysis of CDKN2A methylation status in colorectal 
tumours. Tumours with positive CDKN2A methylation (PMR > 10) are highlighted. 
CpG (100%) = fully methylated CpGenome DNA.  
Figure 5.8: MethyLight analysis of CDKN2A methylation status in colorectal 
tumours. The results are the means of duplicate results ± standard errors. CpG 
















Table 5.4: MethyLight analysis of MINT1 methylation status in colorectal 
tumours. Tumours with positive MINT1 methylation (PMR > 10) are highlighted. 
CpG (100%) = fully methylated CpGenome DNA.  
Figure 5.9: MethyLight analysis of MINT1 methylation status in colorectal 
tumours. The results are the means of duplicate results ± standard errors. CpG 















   
Figure 5.10: MethyLight analysis of MINT2 methylation status in colorectal 
tumours. The results are the means of duplicate results ± standard errors. CpG 
(100%) = fully methylated CpGenome DNA. Blue dashed line indicates PMR cut-off 
value.  
Table 5.5: MethyLight analysis of MINT2 methylation status in colorectal 
tumours. Tumours with positive MINT2 methylation (PMR > 10) are highlighted. 
















    NEGATIVE 
10811 
 
Unmethylated     NEGATIVE 
10812 
 
Unmethylated     NEGATIVE 
KR3 
 
Unmethylated     POSITIVE 
7007 
 
Unmethylated     NEGATIVE 
KR10 
 
Methylated     POSITIVE 
8117 
 
Methylated     NEGATIVE 
KR8 
 
Methylated     NEGATIVE 
7867 
 
Methylated     NEGATIVE 
7329 
 
Methylated     NEGATIVE 
Table 5.6: MethyLight analysis of four CIMP markers MLH1, CDKN2A, MINT1 and 
MINT2 determines CIMP phenotype in colorectal tumours. 14-3-3σ UPR methylation 
status is indicated for each tumour. Positive methylation of CIMP markers is indicated by 
filled red box. CIMP positive tumours = ≥3 markers methylated. CIMP negative tumours = ≤2 




My aim for this chapter was to investigate the specificity of 14-3-3σ UPR 
hypomethylation in colorectal cancer. The percentage of methylated CpG levels were 
determined in 14-3-3σ UPR methylated and unmethylated colorectal cancer cell lines 
and tumours to examine whether there is relationship between 14-3-3σ 
hypomethylation and global levels of DNA methylation in colorectal cancer. The 
CIMP phenotype (Toyota et al, 1999a) was also investigated in a number of 14-3-3σ 
UPR methylated and unmethylated colorectal tumours to deduce any associations 
between CIMP and 14-3-3σ methylation status. 
 
Nearest Neighbor analysis (Ramsahoye, 2002) suggested that there was no 
relationship between 14-3-3σ UPR methylation status and global levels of CpG 
methylation in the colorectal cancer cell lines or tumours studied. Further studies are 
however required to confirm these initial findings due to the small sample numbers. 
A previous study estimated that 70-80% of CpGs are methylated in non-malignant 
mammalian cells (Yegnasubramanian et al, 2008), thus suggesting that two of the 
four tumour samples examined by the Nearest Neighbor technique were globally 
hypomethylated (KR3T: 63%, KR12T: 68.6%). It should be noted that the technique 
utilised to measure methylated CpG content in the Yegnasubramanian et al study was 
different to the technique carried out in this thesis, therefore direct comparisons 
cannot be made. However, the data presented in this chapter shows that one 
potentially globally hypomethylated tumour was unmethylated in the UPR of 14-3-
3σ (KR3T) and the other globally hypomethylated tumour was methylated (KR12T). 
Therefore, these preliminary findings suggest that 14-3-3σ hypomethylation in 
colorectal cancer may be a specific event and not due to the explanation that it is part 
of global methylation status as an epiphenomenon. 
 
MethyLight analysis (Eads et al, 2000) was undertaken to determine the methylation 
status of CIMP markers MLH1, CDKN2A, MINT1 and MINT2 (Toyota et al, 
1999b) in a number of colorectal tumours which I had defined with respect to 14-3-
3σ methylation status. 2/10 (20%) colorectal tumours were determined as CIMP 
 
 181 
positive, a similar frequency to previous reports (Weisenberger et al, 2006). One of 
the CIMP positive tumours was unmethylated at the 14-3-3σ UPR and the other 
tumour was methylated at the 14-3-3σ UPR. This suggested that there may be no 
relationship between 14-3-3σ methylation status and CIMP. However, CIMP 
analysis in a larger dataset is required in order to draw any firm conclusions and 
determine whether 14-3-3σ hypomethylation is independent of the CIMP phenotype 
in colorectal carcinomas. 
 
The observations made here in colorectal cancer are in line with the results of Sato et 
al who proposed that 14-3-3σ hypomethylation and its associated overexpression in 
pancreatic cancer is gene-specific rather than a random result of genome-wide 
hypomethylation (Sato et al, 2003). Genome-wide effects have however been shown 
to activate the Melanoma Antigen 1 (MAGE-1) gene, indicating that genome-wide 
hypomethylation may be responsible for the activation of genes specifically involved 
in cancer (De Smet et al, 1996). This study used a similar approach to measure global 
levels of methylation, although only one tumour cell line was examined and no fresh 
tumour material was investigated. As previously discussed, colorectal cancer cell 
lines are highly selected for and therefore may not be wholly representative of the 
epigenetic architecture of colorectal tumours. Indeed, several studies have found that 
cancer cell lines generally have higher levels of CpG island hypermethylation and 
lower levels of 5-methylcytosine DNA content compared to primary tissue (Paz et al, 
2003; Suter et al, 2003). The proportion of CpG dinucleotides that were methylated 
in colorectal cancer cell lines examined in this chapter were higher (HT29 70.8%, 
SW480 79.4%) relative to some of the tumour samples and compared to a previous 
report, which determined genome-wide hypomethylation levels in colorectal cancer 
cell lines by measuring LINE-1 methylation (Estecio et al, 2007). An average 
proportion of 46% CpG methylation (n = 10) was observed compared to the mean 
proportion of 75.1% presented in this chapter. The dissimilarities observed are 
probably due to the different techniques that were used and the difference in sample 
sizes. LINE-1 methylation is often measured to estimate the genome-wide 
demethylation level as it has been shown to correlate with global DNA methylation 
levels (Weisenberger et al, 2005; Yang et al, 2004). Nearest Neighbor analysis 
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utilised in this chapter on the other hand, measures the level of methylation of a 
specifically methylated CpG dinucleotide in a given DNA sample. Therefore, the 
levels of methylation in a DNA sample can be quantified directly.  
 
As mentioned previously, there are some discrepancies associated with CIMP 
analysis (Ogino et al, 2007; Toyota et al, 1999a; Yamashita et al, 2003). Firstly, 
whether it is actually a distinct phenotype and secondly if CIMP is a distinct 
phenotype, which methylated genes should be used to define it. Currently, there is no 
consensus definition for the CIMP panel in colorectal cancer. As this is the case, it 
was decided to investigate CIMP in a number of 14-3-3σ methylated and 
unmethylated colorectal tumours using a select number of markers first described by 
Jean-Pierre Issa (Issa, 2004). These markers have been previously shown to correlate 
with CIMP (Goel et al, 2007; Samowitz et al, 2005; Toyota et al, 1999b). A recent 
large-scale study however, showed that the MINT1, MINT2 and MINT31 loci were 
non-specific for BRAF mutated CIMP tumours, and therefore it was concluded that 
these markers may not be useful for CIMP analysis (Weisenberger et al, 2006). The 
authors of this study proposed a ‘robust new marker panel’ consisting of RUNX3, 
CACNA1G, IGF2, NEUROG1, and SOCS1 (Weisenberger et al, 2006). Another 
study tested the validity of these new proposed markers and that the found levels of 
specificity of each individual marker varied slightly compared to the report by 
Weisenberger et al. This study suggested that RUNX3 followed by CACNA1G, 
IGF2, MLH1, NEUROG1, CRABP1, SOCS1 and CDKN2A were the best individual 
markers to evaluate CIMP status (Ogino et al, 2007). MINT1, MINT2 and MINT31 
were not examined in this study, however this was not because they were deemed 
inappropriate for the assessment of CIMP. MLH1 and CDKN2A were found to have 
98% and 80% specificity respectively in this study (Ogino et al, 2007). The 
specificity of these two CIMP markers may also be reflected in the data presented in 
this chapter since fewer colorectal tumours were positively methylated for MLH1 
and CDKN2A compared to the other CIMP markers MINT1 and MINT2. 
Interestingly, the two tumours determined as CIMP positive (KR3 and KR10) were 
the only tumours positive for CDKN2A methylation. In addition, only KR3 tumour 
was positive for MLH1 methylation and KR10, even though the tumour was not 
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positive for MLH1 methylation, had the next largest PMR value of 4.13. Moreover, 
KR3 had been previously determined as fully methylated in the MLH1 promoter 
region by bisulphite sequencing, further establishing the high specificity of this 
specific CIMP marker. The dissimilarities observed between each published CIMP 
study are likely a result of differences in size and source of samples and differences 
in PCR conditions and primer design, which will affect the specificity and sensitivity 
of a particular marker. CIMP analysis is not absolute; therefore, methylation analysis 
of the other genes mentioned above, in addition to the ones examined in this thesis 
would improve the current study providing further insight into the CIMP status of 
14-3-3σ methylated and unmethylated tumours. Another factor to consider when 
carrying out CIMP analysis is the cut-off value used to assess the different levels of 
CIMP. In this chapter, CIMP high was defined when 3 or more markers were 
methylated and CIMP low was defined when less than 3 markers were methylated. 
The threshold values for CIMP differ between various reports. A recent population-
based study defined three subgroups of methylation in colorectal tumours; No-CIMP 
(tumours with no methylation), CIMP-Low (tumours with 1 -3 loci methylated) and 
CIMP-High (tumours with 4 or 5 loci methylated) (Barault et al, 2008). The report 
found that individuals with CIMP-High and CIMP-Low MSS tumours had a 
significantly worse outcome than those with no-CIMP MSS tumours, demonstrating 
that higher levels of methylation were associated with poorer survival. Hence, this 
emphasised the importance of identifying the CIMP-Low group as well as CIMP-
High, which is often not carried out in other studies (Barault et al, 2008). Finally, 
another limitation of this study was the small number of tumour samples that were 
examined. Even though there was no observed association between 14-3-3σ 
methylation status and CIMP in the colorectal tumours examined, as only two 
tumours were determined as CIMP positive, the finding that one tumour was 14-3-3σ 
methylated and one was 14-3-3σ unmethylated could be just a coincidence. 
However, these findings do suggest that CIMP and 14-3-3σ methylation status are 
not tightly related. Analysis of a larger dataset would provide more evidence to 
determine whether there is an actual relationship between 14-3-3σ methylation status 
and CIMP. In addition, with the analysis of a larger dataset, clinicopathological and 




In summary, the work I have presented in this chapter suggests that 14-3-3σ 
hypomethylation may be specific in colorectal cancer and not a result of the genome-
wide demethylation that is often associated with colorectal tumours. In addition, I 
have demonstrated from the analysis of four CIMP markers, that 2/10 tumours were 
CIMP-High. One of these tumours was 14-3-3σ UPR methylated and the other 14-3-
3σ UPR unmethylated, suggesting that it is unlikely that 14-3-3σ methylation is 
tightly linked to CIMP. The following chapter (chapter 6), investigates the potential 
functional consequences of gene specific 14-3-3σ hypomethylation in colorectal 
cancer and examines whether associated overexpression of 14-3-3σ can contribute to 
carcinogenesis or tumour progression. 









So far, I have shown that 14-3-3σ is unmethylated in the UPR and 5’ CpG island 
region of 14-3-3σ in the majority of colorectal cancer cell lines. In contrast to this, 
bisulphite sequencing showed that fresh colorectal tumours displayed varying 
degrees of methylation, with a small percentage displaying almost unmethylated 
UPR and 5’ CpG island regions. As all matched normal mucosa samples and normal 
mucosa from a cancer free individual were found to be almost fully methylated in the 
14-3-3σ UPR, this suggests that there may be tumour-specific loss of 14-3-3σ 
methylation in colorectal cancer. Furthermore, I have shown that in the majority of 
colorectal tumours, loss of 14-3-3σ methylation is associated with higher expression 
levels when compared with methylated tumours. The aim of this chapter is to test the 
hypothesis that an increase in 14-3-3σ expression will have an effect on downstream 
events relevant to tumour initiation and/or progression, including apoptosis, 
proliferation, and cell cycle control. In this chapter, cell lines SW480 (14-3-3σ 
methylated) and HCT116 (14-3-3σ unmethylated) were transfected with a 14-3-3σ 
GFP-tagged construct (14-3-3-σGFP-C1) and the empty control construct (GFP-C1). 
Annexin V apoptosis assays were performed on DNA damaged 14-3-3σ 
overexpressing cells and compared to empty vector control transfected cells to 
determine whether 14-3-3σ overexpression results in a delay in the apoptotic signal. 
Proliferation levels were also measured in methylated cells overexpressing the 14-3-
3σ and empty vector control cells using an MTT-based assay in order to establish 
whether overexpression of 14-3-3σ affects proliferation. In addition, cell cycle 
analysis was carried out on methylated cells overexpressing 14-3-3σ and control 
cells to determine whether increased 14-3-3σ expression has an effect on the cell 
cycle. Finally, it is hypothesised that 14-3-3σ methylation and p53 mutations are 
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mutually exclusive occurring events in colorectal cancer since both proteins play a 
pivotal role in maintaining genomic stability. Therefore, previously published data 
on the p53 status in colorectal cancer cell lines and 14-3-3σ methylation data from 
chapter 3 were used to investigate whether there are any associations between p53 
status and 14-3-3σ methylation. In addition, to investigate any associations in vivo, 
tumour p53 status was analysed by immunohistochemistry and Western blot analysis 
in 14-3-3σ methylated and 14-3-3σ unmethylated colorectal carcinomas. 
                        
6.2 Methodology 
6.2.1 Transfection of colorectal cancer cell lines 
Approximately 2 x 105 cells were plated in 2ml media, into 6-well dishes on day 1 
for transfections prior to apoptosis assays and FACS analysis. Cells were plated at a 
density of 5000 in 50µl media, into 96-well plates on day 1 for transfections prior to 
proliferation assays. The initial cell number for the proliferation assays was 
determined by carrying out titration assays (Appendix C). On day 2, transfections of 
SW480 or HCT116 (for apoptosis assays only) cells with the 14-3-3σGFP-C1 and 
empty control pEGFP-C1 constructs were carried out as described in section 2.7.2. 
Transfections of the two constructs were set up in triplicate in 6-well or 96-well 
plates depending on the subsequent functional assay that was carried out. As 
transient transfections were performed, overexpression of the constructs were 
initially verified by Western blot analysis (Figure 6.1). For all transfections, 
fluorescence microscopy was used to confirm transfection was successful at 24 hours 
by visualising GFP-positive cells (Appendix C), and to calculate transfection 
efficiencies prior to proliferation assays. For the proliferation assay experiments, 
fluorescence microscopy and Western blot analysis were both used to confirm 
expression of 14-3-3σGFP-C1 and GFP-C1 constructs for each day over a 4-day 
period (Appendix C and Figure 6.1 (C) respectively).  
 
6.2.2 Apoptosis assays 
Transfected cells were UV-C exposed or unexposed as a control on day 3 as outlined 
in section 2.7.3. Cells were harvested for apoptosis assays on day 4. Apoptosis assays 
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were performed by annexin V staining on the transfected SW480 and HCT116 cells 
as described in section 2.7.3. Apoptotic cells were calculated as a percentage of 200 
randomly selected GFP-positive cells. 
 
6.2.3 Proliferation assays 
On day 3, MTT-based proliferation assays were performed on transfected SW480 
cells as described in section 2.7.4. Transfection efficiencies were calculated prior to 
the proliferation assays by counting 200 randomly selected cells in triplicate, in one 
field of view using fluorescence microscopy. The average transfection efficiency was 
calculated for each independent experiment conducted, for each construct (Appendix 
C). Proliferation was measured every 24 hours for 4 days in total and was corrected 
accordingly depending on the transfection efficiency. 
    
6.2.4 Western blot analysis 
Cytoplasmic extracts from 14-3-3σ methylated and 14-3-3σ unmethylated colorectal 
tumours were purified as outlined in 2.6.5.2 and examined for the expression of 
stable mutant p53 by Western blot analysis as described in section 2.6.5.3. 
Cytoplasmic extracts were purified from colorectal cancer cell line HT29 as 
described in 2.6.5.1 and used as a control for Western blot analysis of p53. Protein 
loading was assessed by probing for β-actin levels. 
 
6.2.5 Immunohistochemistry 
KR tumour sections were embedded and sectioned as described in 2.9.1. Other 
tumour samples were obtained directly as sections. 14-3-3σ methylated and 14-3-3σ 
unmethylated colorectal tumours were analysed for the expression of stable mutant 
p53 by immunohistochemistry as described in section 2.9.2. 
 
6.2.6 Statistical analysis 
Unpaired T- tests, Two-way ANOVA and Fishers exact tests were used as 




6.3.1 Analysis of UV-C induced apoptosis in 14-3-3σGFP-C1 
overexpressing colorectal cancer cell lines 
In line with the report by Samuel et al, which demonstrated that 14-3-3σ delays the 
apoptotic signal in cancer cells by sequestering Bax protein, I hypothesised that an 
increase in 14-3-3σ expression will result in a reduced level of apoptosis in 
colorectal cancer cells. SW480 (14-3-3σ methylated) and HCT116 (14-3-3σ 
unmethylated) cells were transiently transfected with 14-3-3σGFP-C1 construct and 
empty control GFP-C1 construct. Figure 6.1 shows the expression levels of 14-3-3σ 
protein in SW480 and HCT116 transfected cells. Without transfections, SW480 cells 
do not express any basal levels of 14-3-3σ, whereas HCT116 cells express high basal 
levels. 24 hours following transfections, cells were either left unexposed (control) to 
assess basal levels of apoptosis following transfections, or UV-C exposed to induce 
apoptosis. The next day, the cells were harvested and stained for annexin V. From 
previous work in the laboratory and from a previously published report (Stark & 
Dunlop, 2005), I decided that a time of 24 hours post UV-C exposure would be 
optimal for measuring apoptosis. Apoptosis was also measured 48 hours after UV-C 
treatment and the majority of cells were found to be apoptotic (data not shown), 
therefore a time of 24 hours was taken for assay of the level of apoptosis. Percentage 
of GFP-positive cells that stained positive for annexin V in the unexposed and UV-C 
exposed cells were determined from three independent experiments.  
 
Apoptosis assays firstly demonstrated that in unexposed SW480 cells overexpressing 
14-3-3σGFP-C1 and GFP-C1 approximately 11% of cells were apoptotic, indicating 
this as a basal level of apoptosis for this cell line following transfection (Figure 6.2 
(A)). Notably, overexpression of 14-3-3σ in itself had no effect on apoptosis. 
However, in UV-C exposed SW480 cells, apoptosis levels were increased and cells 
overexpressing 14-3-3σGFP-C1 were found to have a significantly lower percentage 
of apoptotic cells (~14%) compared to cells overexpressing the control construct 
GFP-C1 (~28%) (p =0.001, unpaired T- test) (Figure 6.2 (A)).  
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In unexposed HCT116 cells, the levels of apoptosis were approximately 9%. Similar 
to the unexposed SW480 cells, 14-3-3σ overexpression had no effect on apoptosis in 
the HCT116 cells. However, in UV-C exposed HCT116 cells, the percentage of 
apoptotic cells increased compared to unexposed HCT116 overexpressing cells. 
HCT116 cells overexpressing 14-3-3σGFP-C1 did show a lower level of apoptosis 
(~21%) compared to HCT116 cells expressing the control construct (~28%). 
Although, this just failed to reach significance (p =0.06, unpaired T- test) (Figure 6.2 
(B)). It seems likely that this finding in HCT116 cells overexpressing 14-3-3σGFP-
C1 and control GFP-C1 is different compared to the significant changes observed in 
SW480 overexpressing cells because of the high levels of endogenous 14-3-3σ 
expression in the HCT116 cells. SW480 14-3-3σ expression levels as demonstrated 
in chapter 4 are very low. Overall, these results demonstrate that increasing the levels 
of 14-3-3σ in the SW480 colorectal cancer cell line, results in a lower UV-C induced 




Figure 6.1: Western blot analysis of transient transfections of SW480 (14-3-3σ 
methylated) cells (A) and HCT116 cells (14-3-3σ unmethylated) 24 hours post 
transfections (B). SW480 transfected cells showing expression of 14-3-3σGFP-C1 
over the 4-day period (C). Differing ratios of construct:transfection reagent were initially 
tested for the SW480 14-3-3σGFP-C1 transfections. A transfection ratio of 1:3 was chosen 
for all transfections in both cell lines. Arrow indicates endogenous levels of 14-3-3σ protein 
in HCT116 transfected cells. Presence of white line on membrane (B) for GFP is due to a 
mark from adhesive tape. GFP is shown to demonstrate presence of GFP tag. Rabbit 
polyclonal anti-GFP was used to probe for GFP in Western blots (A) and (B), mouse 
monoclonal anti-GFP was used to probe for GFP in Western blot (C) separately from 14-3-
3σ and actin. HT29 and HCT116 act as positive controls for 14-3-3σ expression. β-actin 
levels were measured to assess protein loading.  









Figure 6.2: Percentage apoptosis in (A) SW480 (14-3-3σ methylated) and (B) 
HCT116 (14-3-3σ unmethylated) cells transfected with 14-3-3σGFP-C1 or control 
empty construct GFP-C1 after 24 hours without UV-C exposure or with UV-C 
exposure. Cells were left 24 hours after transfection then unexposed or exposed to UV-
C. For unexposed and UV-C exposed cells standard error bars ± are shown from three 
separate experiments. p-values are indicated.   
(B) 
SW480 (14-3-3σ methylated) 
HCT116 (14-3-3σ unmethylated) 
* p =0.001 
* p =0.06 
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6.3.2 Analysis of proliferation in 14-3-3σGFP-C1 overexpressing
 SW480 cell line 
Previous in vivo data has suggested that 14-3-3σ expression may be associated with 
increase proliferation in colorectal tumour cells (Ide et al, 2004). To investigate this 
further, proliferation assays on SW480 cells overexpressing 14-3-3σGFP-C1 and 
control empty construct GFP-C1 were carried out to determine if increased 
expression of 14-3-3σ results in an increase in proliferation. An MTT-based assay 
was performed to measure the number of viable cells in proliferation. As transient 
transfections were performed, the transfection efficiency for each construct was 
calculated using fluorescence microscopy before each proliferation assay was 
conducted. The 14-3-3σGFP-C1 construct tended to have on average a 10% lower 
transfection efficiency compared to the empty GFP-C1 construct (Appendix C). 
Proliferation was measured over 4 days and was corrected by the transfection 
efficiencies for each construct. Fluorescence microscopy (Appendix C) and Western 
blot analysis (Figure 6.1 (C)) confirmed that both 14-3-3σGFP-C1 and control 
construct GFP-C1 were expressed over the 4-day period.  
 
Figure 6.3 shows that proliferation is higher in SW480 transfected cells on day 1 
compared to day 2, which is likely due to the effects of experimental intervention. 
The standard error bars for both cell types overexpressing 14-3-3σGFP-C1 and GFP-
C1 at day 1 are very high further suggesting that this may be due technical artefacts. 
Following 2 days of culture, proliferation does however increase each day in the 
SW480 transfected cells. Furthermore, the 14-3-3σGFP-C1 overexpressing cells 
show an increased trend for proliferation after days 2, 3 and 4 compared to control 
GFP-C1 overexpressing cells. This increase is not significantly different at days 2 
and 3, although at day 4 there is a significant increase in proliferation in the 14-3-
3σGFP-C1 overexpressing cells compared to the GFP-C1 control cells (p <0.01, 
Two-way ANOVA). Overall, the preliminary data demonstrates that there is a trend 
for an increase in proliferation in 14-3-3σ overexpressing cells compared to control 
cells, however, in the 14-3-3σ overexpressing cells, a significant increase in 
proliferation is not reached until day 4.   
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Figure 6.3: Proliferation of SW480 cells transfected with 14-3-3σGFP-C1 or control 
empty construct GFP-C1 over a 4 day period. Cell proliferation was determined by an 
MTT-based assay. Standard error bars ± are shown from triplicate results carried out on 
three separate occasions. At day 4 there was a significant difference in proliferation 
between 14-3-3σGFP-C1 and control GFP-C1 overexpressing cells as indicated *p 
<0.01.  










































6.3.3 Analysis of cell cycle in 14-3-3σGFP-C1 overexpressing
 SW480 cell line 
As 14-3-3σ plays a principal role in regulating the cell cycle, I decided next to 
investigate the effects of 14-3-3σ overexpression on the cell cycle in the SW480 cell 
line. The cell cycle was analysed in 14-3-3σGFP-C1 overexpressing cells and 
compared with empty control GFP-C1 overexpressing cells. To ensure only 14-3-
3σGFP-C1 and GFP-C1 cells were assayed, GFP-positive cells from the 14-3-
3σGFP-C1 and GFP-C1 transfections were first sorted by FACS analysis. Sorted 
GFP-positive cells were then stained with propidium iodide and flow cytometry was 
used for cell cycle analysis on GFP-positive sorted cells from three separate 
transfections. Using proprietary software, dead cells and doublets were removed 
from the cell cycle data by plotting FL2-Area against FL2-Width. Cell cycle analysis 
was then carried out by plotting the number of cells against FL2-Area. To calculate 
the percentage of cells in each stage of the cell cycle, I used the Watson (Pragmatic) 
model to fit the data (Watson et al, 1987). The Watson model fits the S-phase exactly 
by making no assumptions about the shape of the S-Phase distribution. Figure 6.4 
shows the cell cycle analysis results from the three transfections of SW480 cells for 
both the 14-3-3σGFP-C1 and GFP-C1 constructs. In all experiments, cells were 
FACS sorted on GFP expression. The average results, including standard deviations 
from the cell cycle analysis data from the three separate transfections, are shown in 
Table 6.1. The cell cycle analysis indicated that 56.78% of GFP-C1 control cells 
were present in G0/G1, 33.94% were in S-phase and 7.04% were present in G2/M 
phase. In 14-3-3σGFP-C1 cells, the percentage of cells in G0/G1 was significantly 
lower (40.32 ± 4.21%) (p =0.01, unpaired T- test) and the percentage of cells in the 
S- phase was significantly higher (49.10 ± 3.47%) (p =0.0079, unpaired T- test). In 
the G2/M phase the percentage of cells was very similar to GFP-C1 control cells 
(6.56 ± 1.05%). These results demonstrate that there was a decrease in the number of 
cells in G0/G1 and an accumulation of cells in the S-phase in 14-3-3σ overexpressing 
cells compared to control cells. This may additionally indicate the role of 14-3-3σ 
expression in cell growth. Alternatively, the increasing trend could indicate an S-
phase arrest and therefore increased 14-3-3σ protein levels in the SW480 cell line 
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could be causing an induction of the G1/S DNA damage checkpoint. Further analysis 
is required to differentiate between these possibilities. This will be discussed in more 
detail in section 6.4. 



















































































































































































































































































14-3-3S1 44.94 45.73 5.48
14-3-3S2 36.71 52.67 6.61
14-3-3S3 39.32 48.89 7.58
Average 40.32 49.10 6.56
St Dev 4.21 3.47 1.05
GFP1 61.81 29.39 6.06
GFP2 57.33 35.36 5.82
GFP3 51.21 37.08 9.25
Average 56.78 33.94 7.04
St Dev 5.32 4.04 1.91
 
Table 6.1: Summary of cell cycle analysis data of 14-3-3σGFPC1 (14-3-
3S) overexpressing cells and GFP-C1 (GFP) overexpressing cells. 
Average values and standard deviations (St Dev) are shown. There was a 
significant difference in the percentage of cells in G0/G1 (p =0.01) and in the 
percentage of cells in S-phase (p =0.0079) between 14-3-3σGFP-C1 and 
control GFP-C1 overexpressing cells.  
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6.3.4 Analysis of 14-3-3σ methylation and p53 mutations 
The previous sections of this chapter have shown that 14-3-3σ overexpression may 
have functional effects on apoptosis and potentially cell growth in colorectal cancer 
cell lines, although further experimentation is required to determine the exact effect. 
p53 is a major player in the response to DNA damage and has been shown to trans-
activate 14-3-3σ expression (Hermeking et al, 1997). 14-3-3σ methylation and p53 
mutational status in colorectal cancer cell lines and in vivo were next investigated to 
assess whether there is a relationship between 14-3-3σ methylation and p53 status. 
 
The association between 14-3-3σ methylation and p53 status was first examined in 
colorectal cancer cell lines. p53 status was obtained from the International Agency 
for Research on Cancer (IARC) TP53 mutation database (http://www-p53.iarc.fr), 
unless otherwise stated. Table 6.2 lists the cell lines with corresponding 14-3-3σ 
methylation status (as determined in chapter 3 of this thesis) and p53 status. From the 
nine cell lines examined there does not appear to be an obvious relationship between 
14-3-3σ methylation and p53 status. Both 14-3-3σ methylated cell lines (SW480 and 
Colo320DM) are p53 mutated and 4/6 14-3-3σ unmethylated cell lines also have p53 
mutation. The number of cell lines is too low to conduct a meaningful statistical 
analysis. However, this does indicate that in vitro 14-3-3σ methylation and p53 
mutations are not mutually exclusive.  
 
Next, immunohistochemistry and Western blots were utilised to determine p53 
stabilised protein levels in 14-3-3σ methylated and unmethylated colorectal tumours. 
The same tumour samples were analysed by each technique apart from tumours 
1736, AM27 and AM31, which were not available for immunohistochemistry 
analysis. Therefore, a total of 16 tumours were examined for p53 stabilised levels by 
immunohistochemistry and 19 by Western blot analysis. Immunohistochemistry 
demonstrated that 6/16 colorectal tumours were likely to have p53 mutations due to 
the presence of positive staining in the nuclei of tumour cells (Figure 6.5 (A)). Other 
tumours displayed heterogeneous p53 staining with varying intensities and locations 
(Figure 6.5 (B)), and some tumours were negative for p53 staining. Detailed scoring 
of intensity and location of p53 staining for each tumour section are listed in Table 
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6.3. Western blot analysis verified that 5/19 colorectal tumours had increased 
stabilised p53 levels indicating a possible mutation (Figure 6.6). In general, the 
Western blot data agreed with the immunohistochemistry data apart from two 
tumours 5123 and 7219 which were positive for p53 stabilised protein by 
immunohistochemistry analysis and were negative by Western blot analysis. 
 
Combining all available results from the immunohistochemistry and Western blot 
analysis, the data suggests that there is no overall relationship between 14-3-3σ 
methylation and p53 stabilised protein levels (Table 6.4). In the scenario that 
tumours 5123 and 7219 show increased stabilised p53 levels and are likely to be 
mutated, then 33% (3/9) 14-3-3σ unmethylated colorectal tumours appear to have a 
p53 mutation while 50% (5/10) 14-3-3σ methylated colorectal tumours have a p53 
mutation (p =0.6499, Fishers exact test) (Table 6.5). If tumours 5123 and 7219 are 
not included, then it is clear there is no relationship between 14-3-3σ methylation 
and p53 status. These results indicate that similar to the in vitro data, 14-3-3σ 
methylation does not occur less frequently in tumours that potentially carry a p53 
mutation. It is accepted that there are small numbers of unmethylated tumours and so 
statistical power is limited. Nonetheless, my data supports the notion that there is no 
absolute relationship between 14-3-3σ methylation and p53 status in either colorectal 
cancer cell lines (where most are unmethylated for 14-3-3σ) or in colorectal tumours 














SW480 Methylated Low Mut 
Colo320DM Methylated Low Mut 
HCT116 Unmethylated High WT 
HRT18 Unmethylated ND Mut (Din et al, 2004) 
Caco-2 Unmethylated ND Mut 
SW48 Unmethylated ND Unknown 
LoVo Unmethylated ND WT 
SW620 Unmethylated ND Mut 
HT29 Unmethylated High Mut 
 
 
Table 6.2: p53 status in relation to 14-3-3σ methylation status and 14-3-3σ 
protein levels in colorectal cancer cell lines. WT = wild-type p53, mut = 
mutated p53, ND = not determined in this thesis. p53 status was obtained from 
the International Agency for Research on Cancer (IARC) TP53 mutation database 





Figure 6.5: p53 immunohistochemistry at x40 magnifications. Positive 
staining in colorectal tumour 7329 (14-3-3σ methylated) (A) and heterogeneous 
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Methylated 1-2 75  YES 
7478 
 
Methylated 2-3 100  YES 
7219 
 
Methylated 3 100  YES 
7329 Methylated 2-3 75  
 
YES 
Table 6.3: p53 immunohistochemistry analysis of 14-3-3σ unmethylated colorectal 
tumours and 14-3-3σ methylated colorectal tumours. Intensity of staining is scored 1-3 
depending on strength, 1 = light staining, 3 = strong staining (0 = negative staining). 
Percentage coverage of positively stained nuclei in epithelial cells within cancerous crypts is 
scored 0-100%. Tumour sections with strong positive staining in the majority of nuclei across 
the cancerous crypts were assumed p53 mutated.     
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Figure 6.6: p53 Western blot analysis of 14-3-3σ unmethylated and 14-3-3σ 
methylated colorectal tumours as indicated. Tumours overexpressing p53 were 
assumed p53 mutated. HT29 is shown as a positive control for p53 mutation. β- actin 
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(Western blot analysis only carried out) 
 Table 6.4: p53 status analysis by indicative increase in stabilised p53 protein levels, 
using immunohistochemistry and Western blot analysis in 14-3-3σ unmethylated and 















Table 6.5: Summary of p53 status analysis by indicative increase in 
stabilised p53 protein levels, and 14-3-3σ methylation status in colorectal 




In this chapter, I set out with the aim to investigate the functional consequences of 
the tumour-specific overexpression of 14-3-3σ. The analysis of effects on apoptosis, 
proliferation and the cell cycle were undertaken. Functional assays suggest that 14-3-
3σ overexpression may affect apoptosis, cell growth and the cell cycle of cancer cells 
in vitro. I have demonstrated from carrying out Annexin V apoptosis assays that 14-
3-3σ overexpression delayed the UV-C induced apoptotic response in the colorectal 
cancer cell line SW480, but not in the HCT116 colorectal cancer cell line, which is 
probably due to the different endogenous levels of 14-3-3σ in the two cell lines. 
Overall, these results suggest that 14-3-3σ overexpression in colorectal tumours may 
protect cancer cells from apoptosis. An MTT-based proliferation assay demonstrated 
an increasing trend in proliferation levels in 14-3-3σ overexpressing SW480 cells 
compared to SW480 control cells, with a significant increase on day 4. This suggests 
that continued overexpression of 14-3-3σ might further result in a significant 
increase in proliferation in the cancer cells. Thus, together, the apoptosis and 
proliferation data indicate that increased 14-3-3σ levels in cancer cells may 
contribute to deregulation of the control of cell growth. Cell cycle analysis of SW480 
cells overexpressing 14-3-3σ showed that there was a decrease in cells presented in 
G0/G1, accompanied with an increase in the number of cells presented in S-phase 
compared to GFP-C1 control cells. Preliminary data therefore suggests that 14-3-3σ 
overexpression may promote the accumulation of cells in S-phase. However, it must 
also be considered an accumulation of cells in the S-phase could indicate an S-phase 
block and thus increased expression of 14-3-3σ may in fact result in a DNA damage 
induced cell cycle response. Further experimental work is required to clarify the 
relationship between these initial findings. 
 
Analysis of increased levels of stabilised p53 protein was carried out in a number of 
14-3-3σ methylated and unmethylated colorectal tumours using 
immunohistochemistry and Western blot. It is generally assumed that an increased 
level of stabilised p53 protein is indicative of a p53 mutation. As other changes in 
p53 related proteins can also have an effect on stabilised p53 levels these results 
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were only an indication of p53 mutation status, and sequencing of the gene to screen 
for mutations would be needed to confirm its actual status. It was hypothesised that 
14-3-3σ methylation and p53 mutations may be mutually exclusive occurring events 
in colorectal cancer as both proteins play a pivotal role in maintaining genomic 
stability. However, my findings showed that there was no relationship between 
increased expression of stabilised p53 protein and 14-3-3σ methylation status in 
colorectal cancer cell lines or in tumours. These results therefore might suggest that 
14-3-3σ methylation and p53 mutations occur independently from each other.  
 
A previously published report by Samuel et al demonstrated that a lack of 14-3-3σ in 
colorectal cancer cell lines sensitises them to chemotherapy induced apoptosis, 
therefore suggesting a preventative role of 14-3-3σ in apoptosis (Samuel et al, 2001). 
My results agree with this initial finding, with the demonstration that 14-3-3σ 
overexpression protected SW480 cells from UV-C induced apoptosis. Samuel et al 
also found that mechanistically, 14-3-3σ suppresses apoptosis through binding and 
sequestering the pro-apoptotic Bax protein. In DNA damaged HCT116 cells, Bax 
protein was present at high levels in the cytosol fraction. However, in DNA damaged 
14-3-3σ negative HCT116 cells, there was a marked decline of Bax protein in the 
cytosol (Samuel et al, 2001). It would therefore be interesting to investigate the 
binding of 14-3-3σ to Bax and the subcellular localisation of Bax in 14-3-3σ 
overexpressing SW480 cells, which could be examined by co-immunoprecipitation 
analysis and Western blot analysis respectively. It would be expected that in the 14-
3-3σ overexpressing cells, the 14-3-3σ protein would be bound to the Bax protein 
and furthermore Bax would be localised mainly in the cytosol compared to other 
subcellular compartments, and at a higher level compared to Bax levels in the cytosol 
from control SW480 cells. This would verify whether the overexpression of 14-3-3σ 
and associated delay in apoptosis in colorectal tumour cells is functioning through 
the same mechanism. The apoptosis results presented in this chapter could also be 
examined using other techniques besides annexin V assays, such as TUNEL 
immunofluorescence assays. A decrease in pro-caspase-3 levels is characteristic of 
apoptosis as the protein is cleaved due to the induction of apoptosis. Thus, analysis 
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of pro-caspase-3 by Western blot could also be used to analyse apoptosis levels in 
the 14-3-3σ overexpressing cells. 
 
The proliferation assays demonstrated that 14-3-3σ overexpression might have a 
positive effect on SW480 cell growth. A more striking effect may have been 
observed in 14-3-3σGFP-C1 stably transfected cells as the transfections carried out 
here were only transient, with the efficiency of the 14-3-3σGFP-C1 construct being 
on average less that 50%. Throughout this PhD, I attempted to develop stably 
transfected 14-3-3σGFP-C1 and GFP-C1 cell lines however they were unsuccessful. 
Nevertheless, these initial findings do suggest that extended 14-3-3σ overexpression 
in colorectal tumour cells may induce proliferation. On day 4, the difference in 
proliferation between the 14-3-3σ overexpressing cells and control cells increased 
significantly as proliferation levels began to plateau in the control cells, whereas 
proliferation in the 14-3-3σ overexpressing cells continued to increase. It would be 
interesting to extend the proliferation assay further to see if proliferation continues to 
increase in the 14-3-3σ overexpressing cells. The proliferation data agrees with 
previously published reports in which 14-3-3σ expression in colorectal and gastric 
cancers was found to be associated with increased cell proliferation (Ide et al, 2004; 
Tanaka et al, 2004). In colorectal cancer, it was found from Ki-67 labelling and 
cyclin B1 staining of colorectal tumour sections that there was a higher proliferative 
activity at the invasion front in 14-3-3σ positive carcinomas compared to 14-3-3σ 
negative carcinomas (Ide et al, 2004). Ki-67 labelling also demonstrated that there 
was a significantly positive correlation between 14-3-3σ overexpression and 
proliferation (p= 0.001) in gastric carcinomas but no significant correlation in 
colorectal cancer (Tanaka et al, 2004). The proliferation results presented in this 
chapter were obtained from an in vitro assay. To investigate whether these results 
translate in vivo, the association between 14-3-3σ overexpression and proliferation 
by Ki-67 labelling in colorectal tumour sections or qRT-PCR analysis of 
proliferating cell nuclear antigen (PCNA) expression could be carried out. The 
underlying mechanisms which are responsible the increase in cell proliferation as a 
result of altered levels of 14-3-3σ remain to be elucidated. Given 14-3-3σs important 
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role in cell cycle regulation (Hermeking et al, 1997) and translational control during 
mitotsis (Wilker et al, 2007), it is likely that aberrant expression of 14-3-3σ directly 
affects these two processes, which subsequently contributes to altered cell growth. 
Further investigations in vitro using SW480 14-3-3σ stably overexpressing cells may 
provide some added insight. 
 
Initial studies carried out on the cell cycle in 14-3-3σ overexpressing cells appeared 
to agree with the proliferation data since the cell cycle analysis suggested that there 
was an accumulation of cells in the S-phase. This could indicate that an increase in 
DNA synthesis is occurring. To investigate this further, the incorporation of BrdU in 
the 14-3-3σ overexpressing cells by immunofluorescent staining could be carried 
out. Accumulation of cells in the S-phase may also indicate an S-phase arrest. 14-3-
3σ has been previously shown to associate with G1 specific CDK proteins such as 
CDK2 and CDK4 (Laronga et al, 2000). Therefore, 14-3-3σ induced S-phase arrest 
may function through these or other related CDK proteins. Many studies have 
reported the impairment of G2/M arrest following DNA damage in 14-3-3σ negative 
cells. Fewer studies have investigated the effects of 14-3-3σ overexpression on the 
cell cycle. However, the report by Hermeking et al demonstrated that by infecting 
HCT116 cells with a 14-3-3σ expressing adenoviral vector, ectopic expression of 14-
3-3σ in colorectal cancer cells disrupts G2/M progression and blocks proliferation in 
colon cancer cells (Hermeking et al, 1997). They showed, using a combination of 
Fluorescent in situ hybridisation (FISH) and flow cytometry, that exogenous 
expression of 14-3-3σ caused an increase in the number of cells with a DNA content 
of 4N, and hence were arrested at the G2/M checkpoint (similar to the response 
observed in DNA damaged HCT116 cells). Further adenoviral transfection caused 
the cells to re-enter S-phase, where they synthesised DNA without dividing, leading 
to the production of cells with a DNA content of more than 4N (Hermeking et al, 
1997). Interestingly, this block in mitosis is similar to what was observed in the 
studies by Wilker et al, in which loss of 14-3-3σ expression in cancer cells resulted 
in an impaired mitotic exit (Wilker et al, 2007). As with the Wilker et al studies, a 
block in cytokinesis was observed from the overexpression of 14-3-3σ. However, 
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time lapse microscopy showed that following this block, half of the 14-3-3σ 
overexpressing cells re-fused forming one cell with a single nucleus and half of the 
cells underwent apoptosis (Hermeking et al, 1997). As binucleate cells were 
generated from the knock-down of 14-3-3σ (Wilker et al, 2007), this suggests that 
14-3-3σ overexpressing cells may undergo an earlier failure in cytokinesis. 
Nevertheless, in reflection with the data I have presented in this thesis, the study by 
Hermeking et al suggests that the accumulation of the 14-3-3σ overexpressing 
SW480 cells in the S-phase may in fact be a result of an uncoordinated arrest rather 
than a change in the replicative state of the cells. Furthermore, the block in 
proliferation observed in the 14-3-3σ overexpressing colon cancer cells (Hermeking 
et al, 1997) is in contrast to the proliferation data presented in this chapter. 
Investigative experiments in the SW480 14-3-3σGFP-C1 cells, similar to the ones 
carried out in the Hermeking et al, would perhaps clarify whether there is a growth 
arrest at the S-phase or an increase in the replicative state of the cells. 
 
Previous reports, which have investigated the association between 14-3-3σ 
methylation and p53 status in different cancers have been inconsistent. Some studies 
have found an association and have suggested that 14-3-3σ methylation and p53 
mutations are mutually exclusive occurring events in cancer cells, as loss of genomic 
stability only requires the inactivation of p53 or 14-3-3σ (Gasco et al, 2002a). Given 
that the data presented in chapter 3 has indicated that it may be a loss of 14-3-3σ 
methylation rather than gain of methylation which is tumour-specific in colorectal 
cancer, this hypothesis is perhaps inaccurate. Since 14-3-3σ is normally methylated 
in the colonic epithelium, loss of 14-3-3σ methylation and p53 mutations would 
perhaps be less likely to occur. Indeed, in this chapter methylation of 14-3-3σ was 
found at a higher frequency in p53 mutated cancers, although due to the small 
numbers of colorectal tumours examined the statistical power was limited. It was 
however concluded that there was no absolute relationship between 14-3-3σ 
methylation and p53 status in the colorectal cancer cell lines or tumours examined. 
Similar studies have investigated the association between p53 status and 14-3-3σ 
expression levels in colorectal cancer. p53 mutations have been shown to reduce 14-
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3-3σ expression and affect stable G2 /M arrest in DNA damaged cells (Hermeking et 
al, 1997). However, the effects of p53 mutation status on 14-3-3σ expression in the 
absence of DNA damage are not known. Previous studies have demonstrated that 
there is no association between 14-3-3σ protein expression and p53 status in 
colorectal cancer and gastric cancer (Ide et al, 2004; Tanaka et al, 2004). 
Furthermore, data in chapter 4 demonstrated that 14-3-3σ is expressed at high levels 
in both wild-type and p53 mutated 14-3-3σ unmethylated colorectal cancer cell lines 
and fresh tumours. These results therefore suggest that 14-3-3σ overexpression 
occurs irrespective of the p53 status. 
 
In summary, the work I have presented in this chapter adds to and puts into context 
previously published data since loss of 14-3-3σ methylation may be the key 
molecular event in colorectal cancer. The data presented demonstrates that 
overexpression of 14-3-3σ may contribute to carcinogenesis or tumour progression 
in colorectal cancer through suppressing apoptosis and affecting cell growth. In 
addition, I have shown that there was no absolute association between either 14-3-3σ 
expression or methylation status and p53 mutation status. Further studies are required 
to fully understand the downstream effects of 14-3-3σ overexpression in colorectal 













The work I have presented in this thesis has focused on investigating the methylation 
status of 14-3-3σ, its relationship to gene expression and function in colorectal 
cancer, and the role it may play in initiation or progression of the disease. I studied 
the methylation status of the 14-3-3σ gene in colorectal cancer cell lines and fresh 
colorectal tumours along with matched normal mucosa samples, as well as normal 
mucosa and skin from cancer-free individuals. Previous to this work, 14-3-3σ 
methylation analysis had only been carried out in colorectal cancer cell lines and in a 
very small number of colorectal tumour samples (Ide et al, 2004; Suzuki et al, 2000). 
Furthermore, the results presented in this thesis are the first to study the methylation 
status of 14-3-3σ in normal colonic mucosa and show the tumour specificity of 
aberrant 14-3-3σ methylation in colorectal cancer. Using bisulphite sequencing of 
the upstream promoter region and 5’ region of the 14-3-3σ CpG island, I show that 
normal colorectal mucosa tissue is essentially fully methylated at CpG sites; whereas 
colorectal tumours displayed an admixture of both methylated and unmethylated 
sequences in the upstream and 5’ CpG regions. My initial data suggested that the 
degree of 14-3-3σ methylation might vary between individual tumours, since PCR 
bisulphite sequencing identified approximately 10% of tumours, which appeared to 
have a low degree of methylation in the upstream promoter region of 14-3-3σ. As 
14-3-3σ is fully methylated in normal colorectal mucosa, these results suggested that 
loss of methylation is specific to colorectal cancer and that this phenomenon occurs 
in a minority of tumours, in contrast to previous work which suggested that 
hypermethylation was rare in the majority of colorectal tumours (Ide et al, 2004).   
 
The remainder of the thesis investigated the specificity of 14-3-3σ methylation in 
colorectal cancer and the functional effects of 14-3-3σ hypomethylation, including 
any associated changes in expression levels. In chapter 4, 14-3-3σ expression 
analysis in vitro using cell lines, suggested that there may be an association between 
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14-3-3σ methylation status and expression. In fresh human samples however, this 
association was not so evident. There was no significant difference in expression 
levels between 14-3-3σ unmethylated tumours and corresponding methylated normal 
tissue; indicating that loss of 14-3-3σ methylation in colorectal tumours may not be 
associated with changes in 14-3-3σ expression in colorectal cancer. However, when 
14-3-3σ protein levels were examined in fully methylated normal colonic tissue and 
skin tissue, which has lower levels of methylation; there were higher levels of 14-3-
3σ protein expression in the skin tissue samples compared to normal colonic tissue. 
In addition, when 14-3-3σ expression was analysed in a selection of tumour samples, 
there was a significant difference in expression between 14-3-3σ methylated and 
unmethylated tumours. As discussed in chapter 3, the effect of 14-3-3σ methylation 
in colorectal cancer may be reduced as a result of tumour heterogeneity. LCM was 
not carried out; therefore, the colorectal tumours samples which were examined did 
not exclusively consist of cancer cells. Other cell types such as infiltrating 
lymphocytes and stromal cells would have also been present, which may have 
contributed to the observed 14-3-3σ methylation and expression data presented in 
this thesis. Another explanation is that other epigenetic mechanisms may be involved 
in regulating 14-3-3σ expression in colorectal cancer. The 5-Aza-2’-deoxycytidine 
experiments carried out in cell lines in the final section of chapter 4 added further 
evidence to support this, since demethylation of 14-3-3σ in vitro did not result in re-
expression of the gene.  
 
In chapter 5, using Nearest Neighbor analysis (Ramsahoye, 2002) and MethyLight 
(Eads et al, 2000), loss of 14-3-3σ methylation in colorectal cancer appeared to not 
be an epiphenomenon as part of a more general methylation defect. I recognise 
however, that the small sample numbers limited these studies and analysis of a larger 
sample is required before any firm conclusions can be drawn. In addition, with 
regards to the CIMP analysis that was carried out, a panel consisting of only four 
CIMP markers were selected to determine whether colorectal tumours were CIMP 
positive or negative. As discussed, there is no consensus definition for the CIMP 
panel, therefore I decided to use four of the five classical CIMP markers (hMLH1, 
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CDKN2A, MINT1, MINT2 and MINT31) defined by Jean Pierre Issa (Issa, 2004). 
The analysis of other additional CIMP markers, which have more recently been 
tested for their validity (Ogino et al, 2007; Weisenberger et al, 2006), would improve 
the analyses carried out and perhaps further support the conclusions drawn from this 
data. Nevertheless, the studies that I undertook suggest that it is unlikely that there is 
a strong relationship between 14-3-3σ methylation status and either a generalised 
methylation phenotype or the CIMP phenotype. 
 
In chapter 6, I presented data demonstrating that overexpression of 14-3-3σ in vitro 
results in a delay in the apoptotic signal, an increase in cell proliferation and a 
change in cell cycle progression. The functional studies suggested that 14-3-3σ 
overexpression might contribute to carcinogenesis or tumour progression through 
altering cell growth. Clearly, these are preliminary observations and future studies 
are required to investigate the underlying mechanisms involved in these processes, 
and to clarify whether 14-3-3σ overexpression due to tumour-specific methylation 
changes plays a significant role in colorectal cancer development. 
 
In comparison with previously published data, the work presented in this thesis 
suggests another cancer-type in which overexpression of 14-3-3σ is associated with 
14-3-3σ CpG demethylation (Iacobuzio-Donahue et al, 2003; Sato et al, 2003). 
Normal pancreatic tissue was previously found to be largely or completely 
methylated, while the majority of pancreatic cell lines, and a high proportion of 
pancreatic carcinomas were completely unmethylated (Sato et al, 2003). Due to the 
reasons discussed in chapter 3, the proportion of colorectal tumours with low levels 
of 14-3-3σ CpG methylation identified in this thesis may be underrepresented; 
namely, the percentage of colorectal tumours with completely unmethylated 
upstream and 5’ CpG island regions might be higher than the 10% which was found 
in this current study. Therefore, it could be that 14-3-3σ demethylation in colorectal 
cancer is more frequent than was suggested by my work. This would in some way 
agree with the report from Ide et al, in which the majority of colorectal tumours 
(9/10) displayed a low  percentage of 14-3-3σ methylation (<15% methylated CpG 
sites) (Ide et al, 2004). Furthermore, previous reports examining 14-3-3σ expression 
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in colorectal cancer have shown that 14-3-3σ is overexpressed in a high percentage 
of colorectal carcinomas (23/30; 76.7%) (Tanaka et al, 2004) and (6/8; 75%) 
(Perathoner et al, 2005) respectively, compared to matched normal tissue. Thus, 
given that 14-3-3σ CpG methylation has been shown to be associated with 
expression, both in normal cell types (Oshiro et al, 2005) and in different cancers 
(Ferguson et al, 2000; Lodygin et al, 2004); this would add further evidence to 
suggest that the frequency of 14-3-3σ demethylation in colorectal cancer may indeed 
be higher than was observed in this thesis. In contrast to this, a recent study 
examined 14-3-3σ promoter methylation in human melanocytes and melanoma (Liu 
et al, 2009). The study demonstrated that 14-3-3σ was heavily methylated both in 
normal melanocyte cells and in 100% (20/20) melanoma tumour samples, which 
resulted in silencing of 14-3-3σ gene expression. Therefore, in this case, 
demethylation and associated changes in expression of 14-3-3σ were found to be a 
rare event in melanoma (Liu et al, 2009). As mentioned previously, in order to 
accurately assess the degree of 14-3-3σ methylation in colorectal carcinomas in 
comparison with normal tissue, further work examining 14-3-3σ methylation status 
in a series of microdissected colorectal tumours, matched normal tissues, and normal 
colonic tissue from cancer-free individuals would be helpful.  
 
If I were given the opportunity to continue this research, I would further examine the 
relationship between 14-3-3σ CpG island methylation and tissue-specific expression. 
In silico analysis of human 14-3-3σ expression, using online Affymetrix datasets: 
GNF SymAtlas V 1.2.4 (http://symatlas.gnf.org) (Su et al, 2002) demonstrates that 
14-3-3σ has a tissue-specific expression profile (Appendix D). Tissues expressing 
high levels of 14-3-3σ expression (at least 10-fold above the median) are bronchial 
epithelial cells, prostate, lung, tongue, skin and tonsil. Whole blood, uterus, pancreas, 
thymus, thyroid and trachea all express medium levels of 14-3-3σ (3-fold above the 
median). Whether 14-3-3σ CpG methylation is involved in regulating normal tissue-
specific expression of 14-3-3σ  in vivo remains an unanswered question, despite the 
work I present here. However, the preliminary studies presented in chapter 4, which 
compared protein expression of 14-3-3σ in the normal colon and skin tissue, at least 
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provide a suggestion that there might be an association between methylation in the 
upstream promoter region and 5’ region of the 14-3-3σ CpG island and tissue-
specific expression. Furthermore, a previously published paper has demonstrated that 
cell type-specific expression of 14-3-3σ is associated with epigenetic modifications 
including 14-3-3σ CpG island methylation (Oshiro et al, 2005). The authors 
concluded that 14-3-3σ CpG island methylation does partly play a role in its tissue-
specific regulation. Similar studies to those carried out in the Oshiro et al report, in a 
number of microdissected normal tissues (including the analysis of other epigenetic 
mechanisms such as, histone acetylation/methylation and chromatin structure), 
would perhaps provide further support to the previously drawn conclusions. In 
addition to examining the regulatory features within the 14-3-3σ promoter region, it 
would also be interesting to whether there were any other regulatory regions 
associated with 14-3-3σ . These might include miRNA target sequences; enhancer 
sequences; or CCCTC-binding factor (CTCF) binding sites, which could indicate any 
insulator elements that are associated with 14-3-3σ. The analysis of other regulatory 
regions would require a huge undertaking, however, they may play a significant role 
in regulating 14-3-3σ tissue-specific expression and perhaps even be involved in 14-
3-3σ dysregulation associated with carcinogenesis (Ferguson et al, 2000; Lodygin et 
al, 2004).         
 
Following on from this, one of my other aims would be to establish whether 14-3-3σ 
methylation is causally involved in downregulating 14-3-3σ expression. The analysis 
of 14-3-3σ re-expression following 5-Aza-2’-deoxycytidine treatment is one 
approach which can be used to investigate whether there is any causal relationship. 
This was carried out in chapter 4, however, due to a number of possible factors, 
which were discussed, 14-3-3σ re-expression was not achieved. Another approach 
would be to subclone the 14-3-3σ promoter region into a luciferase reporter plasmid 
and carry out in vitro expression assays. The 14-3-3σ promoter region could be 
methylated in vitro using SssI methylase and the suppressive effect of the methylated 
promoter region determined by comparing its activity, once transfected into a 
colorectal cancer cell line, with that of an unmethylated 14-3-3σ promoter construct. 
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If there were a reduced promoter activity in cells transfected with the methylated 
construct, then this would strongly suggest that CpG methylation at the promoter 
region of 14-3-3σ could act as a repressor of 14-3-3σ expression in colorectal cancer.   
 
Lastly, another of my aims would be to focus on investigating the complexity of 14-
3-3σ tissue-specific function. It is not fully understood why in some cancers 14-3-3σ 
is silenced suggesting that 14-3-3σ is acting as a tumour suppressor, and 
overexpressed in others, which would imply that 14-3-3σ is tumour promoting. 
Indeed, the observation that most colorectal cancer cell lines are unmethylated and 
express high levels of 14-3-3σ protein product, whilst most fresh tumour tissues 
appear not to is interesting. One explanation is that the loss of methylation in vitro is 
a consequence of the generation of cell lines, in which there is selection pressure for 
particular clones. However, the data presented in this thesis and previously published 
studies have indicated that increased levels of 14-3-3σ (Hermeking et al, 1997; 
Samuel et al, 2001), in addition to the inactivation of 14-3-3σ (Ferguson et al, 2000; 
Wilker et al, 2007) results in changes in apoptosis and cell cycle progression, both of 
which may contribute to cancer development. From these findings, a model could be 
proposed in which ‘too much’ or ‘too little’ of 14-3-3σ is detrimental to normal 
cellular function. It remains unclear however, why 14-3-3σ appears to have different 
functions in different tumour types. As discussed in the introduction of this thesis, 
14-3-3σ acts as a ‘chaperone molecule’, functioning through modifying the actions 
of other proteins, and has no activity of its own (Mhawech, 2005). Various screening 
approaches have identified a number of potential 14-3-3 interacting proteins, 
demonstrating that via its binding partners, 14-3-3σ could perhaps modify the 
function of many different biological pathways (Meek et al, 2004; Pozuelo Rubio et 
al, 2004). Therefore, one might speculate that it may be that the role of 14-3-3σ in 
cancer is actually determined by the binding partners that are available for 
interaction. The availability of these binding partners could vary in different tissues 
and at different times, or even between normal and neoplastic cells. Hence, this may 
be why 14-3-3σ appears to have such a diverse function in different tumour types. It 
would be interesting to identify and compare 14-3-3σs binding partners in different 
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cancers and perhaps during different stages of the cell cycle. Techniques such as, co-
immunoprecipitation, yeast two-hybrid assays or tandem affinity purification (TAP) 
tagging (which would allow in vivo capture) could be used to carry out these studies. 
Candidate 14-3-3σ binding proteins, such as the proteins involved in cell-cycle 
control (p53, CDC2-cyclinB1, Cdk2) (Chan et al, 1999; Hermeking et al, 1997; 
Laronga et al, 2000) or apoptosis (Bax) (Samuel et al, 2001) could be analysed. 
Alternatively, a library-based approach could be performed, which may co-
incidentally identify novel 14-3-3σ binding partners. These studies could be valuable 
in elucidating 14-3-3σs exact role in cancer and the underlying mechanisms which 
are involved. 
 
In conclusion, the work presented in this thesis provides further insight into the 
complexities of 14-3-3σ methylation and its relevance to colorectal cancer. 
Previously published data and the results presented in this thesis suggest that aberrant 
methylation and associated changes in expression of 14-3-3σ may contribute to 
colorectal carcinogenesis. However, extensive studies to follow up the observations 
that I have made here, such as those outlined above, would be required to fully 
determine the clinical relevance of 14-3-3σ methylation in colorectal cancer. With 
this further understanding, 14-3-3σ methylation could perhaps be considered a 
therapeutic drug target or as a marker for cancer detection or prognosis, at least in a 
subset of cases. 
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